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1. Summary 
 
1.1 Summary 
 
Colorectal cancer (CRC) is one of the most common cancer types worldwide. In 
recent years chemokines and miRNAs were found to be deregulated in CRC and 
some members were used as diagnostic- and prognostic markers. Chemokines are 
small secretory molecules involved in pro- and anti-tumour directed processes. 
MiRNAs are small non-coding RNA molecules which post-transcriptionally regulate 
gene expression thereby influencing oncogenic or tumour-suppressive effects 
dependent on the set of targeted genes. 
Therefore, the present thesis aimed to analyze functional interactions between 
miRNAs and chemokine CCL20 and to characterize their interactions and expression 
profiles in CRC tissues. Target prediction tools were used to identify miRNAs, 
potentially regulating CCL20 expression. The predicted interactions were validated 
using luciferase assays and site directed mutagenesis. Functional interactions 
between specific miRNAs and the mRNA of their target gene CCL20 were tested in 
CRC cells by transfection of miRNA mimics and subsequent quantification of CCL20 
expression on mRNA and protein level. CCL20 expression was also analyzed on 
mRNA and protein level in CRC tissue samples. In addition, miRNA expression was 
analyzed using qRT-PCR. Furthermore, localization of CCL20 and miRNA 
expression was investigated using immunohistochemistry and in situ hybridization, 
respectively. The results have shown that CCL20 gene expression is regulated by 
miR-21 in 3 of 4 CRC cell lines whereas miR-145 showed no interaction with CCL20 
gene expression. Nevertheless, miR-21 expression and CCL20 mRNA and protein 
expression were demonstrated to be significantly up-regulated in CRC tissues in 
relation to corresponding normal colorectal tissues. However, CCL20 and miR-21 
were observed to be predominantly expressed in mesenchymal elements in the 
tumour microenvironment, where miR-21 expression is restricted to tumour-
associated fibroblasts while CCL20 is mainly expressed in infiltrating immune cells. 
In summary, the results of this thesis demonstrated a functional interaction between 
miR-21 and CCL20 in CRC cells. However, investigating miR-21 and CCL20 
expressions in CRC tissues revealed that the two molecules were predominantly 
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expressed in different cell types in the microenvironment of CRC tumours which 
indicates that miR-21 and CCL20 may not directly interact in CRC tissues. Therefore, 
a therapeutic application of miR-21 mediated CCL20 down-regulation would have to 
be applied in CCL20 expressing cells in the microenvironment of CRC tissues. 
 
 
1.2 Zusammenfassung 
 
Das kolorektale Karzinom (CRC) ist eine der häufigsten Krebsarten weltweit. In den 
letzten Jahren wurde erforscht, dass Chemokine und miRNAs im CRC dereguliert 
sind, wobei verschiedene Mitglieder dieser Molekülgruppen als diagnostische- und 
prognostische Marker untersucht wurden. Chemokine sind kleine, sekretorische 
Moleküle, die an pro- und anti-Tumor assoziierten Prozessen beteiligt sind. MiRNAs 
sind kleine nicht-kodierende RNA Moleküle, die die Genexpression post-
transkriptionell regulieren und dabei in Abhängigkeit ihrer Zielgene eine onkogene 
oder Tumor supprimierende Wirkung entfalten. 
Daher war es das Ziel dieser Arbeit, funktionelle Interaktionen zwischen spezifisch 
ausgewählten miRNAs und dem Chemokin CCL20 zu untersuchen und die 
Interaktionen und Expressionsprofile in CRC Gewebeproben zu charakterisieren. 
MiRNAs, die potentiell die Expression von CCL20 regulieren, wurden mit online 
verfügbaren Vorhersageprogrammen analysiert und die Interaktionen mittels 
Luciferase Assays und zielgerichteter Mutation validiert. Die funktionellen 
Interaktionen zwischen den so identifizierten miRNAs mit ihrem Zielgen CCL20, 
wurden in CRC Zellen durch Transfektion von miRNA-Mimics mit anschließender 
Expressionsanalyse von CCL20 auf mRNA und Proteinebene untersucht. Im 
nächsten Schritt wurde die Expression von CCL20 in CRC Gewebeproben auf mRNA 
und Proteinebene in Relation zu normalem, kolorekektalen Gewebe analysiert. Die 
Expression der miRNAs wurde ebenfalls mit qRT-PCR untersucht. Die Lokalisation 
der Expressionen von CCL20 und den entsprechenden miRNAs wurde durch 
Immunhistochemie und In-situ-Hybridisierung dargestellt. Die Ergebnisse zeigten, 
dass miR-21 die Expression des CCL20 Gens in 3 von 4 CRC Zelllinien reguliert 
während miR-145 keine regulatorische Funktion aufwies. Im CRC Gewebe wurde die 
Expression von miR-21 und CCL20 signifikant erhöht detektiert. Allerdings zeigte 
sich, dass CCL20 und miR-21 überwiegend in mesenchymalen Bereichen des 
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Tumor-Microenvironments exprimiert werden, wobei die miR-21 Expression vor allem 
in Tumor assoziierten Fibroblasten und die CCL20 Expression überwiegend in 
infiltrierenden Immunzellen stattfindet. 
Zusammenfassend zeigten die Untersuchungen dieser Arbeit, dass miR-21 die 
CCL20 Expression in CRC Zellen reguliert. Expressionsuntersuchungen im Gewebe 
von CRC Patienten zeigten hierbei, dass miR-21 und CCL20 signifikant erhöht 
exprimiert werden. Allerdings findet ihre Expression vorwiegend im Tumor-
Microenvironment statt und dort in jeweils unterschiedlichen Zelltypen. Dies zeigt, 
dass mutmaßlich keine direkte Interaktion zwischen miR-21 und CCL20 in CRC 
Gewebe stattfindet. Eine therapeutische Anwendung von miR-21 vermittelter CCL20 
Regulation sollte daher in CCL20-exprimierenden Zellen im Tumor-Microenvironment 
von CRC Gewebe stattfinden. 
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2. Introduction 
 
2.1 Cancer 
 
2.1.1 Cancer – a general approach 
 
In 2008, globally 12.7 million new cancer cases were diagnosed resulting in 7.6 
million cancer deaths [Ferlay et al., 2008]. There are three distinct varieties of cancer 
which comprise leukaemia’s and lymphomas, defined as cancers of the blood and 
blood-forming tissue, carcinomas, which are cancers of the epithelial cells and 
sarcomas, which are cancers of the mesodermal cells.  
The most prevalent intersexual cancer types are solid tumours of the lung, 
colon/rectum and stomach. In females breast cancer is most prevalent and in males 
prostate cancer dominates the sex specific cancers [Jemal et al., 2011]. 
It is well documented that the incidence of cancer increases progressively with age in 
humans as well as in animals [Anisimov et al., 2009; Parkin et al., 2001; Balducci et 
al., 2005]. Thus, aging is associated with a number of events at the molecular, 
cellular and physiological level that influence carcinogenesis and cancer growth 
[Anisimov et al., 2009]. To explain the association of cancer and age, one simple 
explanation presumes that the high prevalence of cancer in older individuals may 
simply reflect a more prolonged exposure to carcinogens [Peto et al., 1985]. 
However, to list all recent arguments against this hypothesis would be beyond the 
scope of this thesis. To date, reputable scientific sources propose that age-related 
progressive changes in the internal milieu of the organism like proliferative 
senescence and many other changes may provide an increasingly favourable 
environment for the induction of new neoplasia as well as for the growth of latent 
malignant cells [Campisi, 2005; Anisimov, 2003]. Moreover, the combined effects of 
cumulative mutational load, increased epigenetic gene silencing, telomere 
dysfunction and altered stromal cell milieu may boost the development of age-related 
cancer [DePinho, 2000; Anisimov et al., 2009]. In addition to the major risk factor 
age, other risk factors for the development of cancer comprise heavy consumption of 
tobacco, alcohol, red meat and obesity. Thus, our diet can influence the risk of 
cancer. For example a diet which is high in fat like red meat has been linked to 
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increased risk of breast and colon cancer. Numerous environmental factors like 
industrial waste or cigarette smoke are also known to increase the risk of developing 
cancer. Thus, some chemicals such as asbestos may cause lung cancer and 
mesothelioma. Also several viruses can cause cancer, such as papillomavirus which 
causes cervical cancer in women or hepatitis B virus which can cause liver cancer. 
Moreover, inflammatory diseases like ulcerative colitis are known to cause colon 
cancer. Another risk factor for cancer is the exposure to radiation [Anand et al., 
2008]. These risk factors can result in acquired genetic mutations and therefore 
contribute to the development of neoplasias which may be caused by the 
accumulation of several mutations [Mucci et al., 2001; Hahn et al., 2002]. The 
accumulation of mutations along with signals from the microenvironment may result 
in neoplastic changes which are characterized by cells that exhibit unregulated 
growth linked with the capability to invade the surrounding tissue and to spread to 
distant organs. To achieve such alterations, crucial cellular mechanisms need to be 
altered including the amplification of proliferative signalling, bypassing growth 
suppressors, avoiding cell death, gaining replicative immortality, increasing 
angiogenesis and achieving invasive properties [Hanahan et al., 2011]. The spread 
of tumour cells to distant organs leads to the formation of secondary tumours called 
metastases [Poste et al., 1980]. The alterations in genetics and behaviour of 
cancerous cells are also associated with a decrease in the differentiation state 
compared to neighbouring normal cells. 
All these visible alterations in cancerous tissue and cancer cells as well as the 
incidence of secondary tumours are used by pathologists to determine the 
progression state of the cancer [American Joint Committee on Cancer, 2002; 
Wittekind et al., 2010]. Such categorization is generally used as a basis to apply 
suitable therapies and to predict the prognosis for the patients outcome. 
 
 
2.1.2 Colorectal cancer (bowel cancer) 
 
The development of colorectal cancer is viewed as a slow process which may 
progress over many years [Kozuka et al, 1975]. The most common preliminary stage 
of colorectal carcinomas (CRC) is the polyp. A special type of polyp designated 
adenomatous polyp (adenoma) is most susceptible to progress into a neoplastic 
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stage. However, only less than 10 % of adenomas become cancerous [Levine et al., 
2006]. 
The progression of normal colorectal mucosa to colorectal cancer appears via the 
accumulation of genetic mutations in a multistep process (Figure 1) [Fearon et al., 
1990]. The mutational landscape of CRC is complex and the alterations leading to 
CRC can occur in 20 different cancer-associated genes [Beerenwinkel et al., 2007]. 
Thus, one path compasses the inactivation of tumour-suppressor genes by mutation. 
For example, one pathway involved in CRC development which is often activated by 
mutations, is the Wnt-pathway [Morin et al., 1997]. The most common mutation 
leading to constitutive activation of this pathway is a mutation in the tumour-
suppressor gene APC which regulates the oncoprotein β-catenin an activator of the 
Wnt-pathway [Korinek et al., 1997]. Another frequently affected pathway is the p53 
pathway which is involved in cell cycle arrest, apoptosis and restriction of 
angiogenesis [Vazquez et al., 2008]. Inactivation of p53 is frequently found at the 
intersection from adenoma to carcinoma [Baker et al., 1990]. Finally, the TGF-β 
pathway is often deregulated by the mutation of tumour-suppressor genes. In a high 
number of CRCs the kinase domain of the TGFBR2 receptor is inactivated by 
mutations [Markowitz et al., 1995] but also mutations in downstream targets (e.g. 
SMAD4) are found [Takagi et al., 1996]. In addition to the inactivation of tumour-
suppressor genes, the activation of oncogenic pathways is frequently involved in 
CRC development. Such activations often take place because of mutations in the 
RAS or BRAF genes which are activators of the MAPK pathway [Bos et al., 1987; 
Oliveira et al., 2007]. These two genes are also involved in DNA methylation 
processes [Nagasaka et al., 2008]. Another oncogenic pathway is the 
phosphatidylinositol 3-kinase (PI3K) pathway where the catalytic subunit PI3KCA 
frequently exhibits mutations as well as other regulators (like PTEN) in this cascade 
[Berg et al., 2010]. Therefore, some pathways and regulators are frequently affected 
in CRC and show effects associated with chromosomal instability (RAS and p53) or 
DNA methylation (RAS and BRAF). Such alterations can also have an impact on the 
expression of microRNAs (miRNA) which have an influence on cancer pathology 
including CRC [Lujambio et al., 2008]. 
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Figure 1 Development of CRC. 
The progression from normal colorectal cells to cancerous and metastatic cells is linked to the 
accumulation of certain mutations. (Adapted from Davies et al., 2005) 
 
MiRNAs are a relatively new group of molecules whose defective regulation has an 
impact on CRC development, progression and metastasis [Slaby et al., 2009; de 
Krijger et al., 2011]. 
Mutations in these pathways are associated with different hereditary diseases 
associated with an increased risk of developing CRC, e.g. familial adenomatous 
polyposis, Gardner's and Turcot syndromes and hereditary nonpolyposis colon 
cancer. However, only 5 % of CRCs are due to these syndromes [Ivanovich et al., 
1999]. Beyond these hereditary risk factors also acquired factors have an impact on 
the risk for developing CRC. As described above for the general risk of developing 
neoplasias also acquired CRC risk factors comprise diets rich in fat or red meat, 
cigarette smoking, pelvic irradiation or inflammatory bowel disease [Lin, 2009]. 
According to histological tumour features distinct colorectal tumour types can be 
distinguished (Table 1). The most common (~96 %) colorectal tumour type is the 
adenocarcinoma which develops from the glandular in colonic tissue [Stewart et al., 
2006]. 
 
Tumour Type ICD-O Code 
Adenocarcinoma 8140/3 
Mucinous adenocarcinoma 8480/3 
Signet-ring cell carcinoma 8490/3 
Small cell carcinoma 8041/3 
Squamous cell carcinoma 8070/3 
Adenosquamous carcinoma 8560/3 
Medullary carcinoma 8510/3 
Undifferentiated carcinoma 8020/3 
Table 1 Colorectal Tumour Types and ICD-O Codes (Adapted from Hamilton et al., 2000) 
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The progression state of colorectal cancer is primarily staged by two different 
systems. The older and simpler system is the Dukes Classification which classifies 
colorectal cancer into three classes (Table 2) [Dukes, 1932]. The second, newer and 
presently most common system for CRC staging is the TNM 
(tumour/node/metastases) system edited by the American Joint Committee on 
Cancer (AJCC) which uses different classes and their combinations (Table 2) 
[Wittekind et al., 2010]. 
 
Stage  Dukes stage 
T stage: primary tumour 
TX Primary tumour can not be assessed  
T0 No evidence of primary tumour  
Tis Carcinoma in situ: intraepithelial or 
invasion of lamina propria 
 
T1 Tumour invades submucosa A 
T2 Tumour invades muscularis propria A 
T3 Tumour invades through muscularis 
propria into subserosa or into non-
peritonealised pericolic or perirectal tissue 
B 
T4 Tumour directly invades other organs or 
structures and/or perforates visceral 
peritoneum 
B 
N stage: regional lymph nodes 
NX Regional lymph nodes cannot be 
assessed 
 
N0 No regional lymph node metastasis  
N1 Metastasis in one to three regional lymph 
nodes 
C (any T stage) 
N2 Metastasis in four or more regional lymph 
nodes 
C (any T stage) 
M stage: distant metastasis 
MX Distant metastasis cannot be assessed  
M0 No distant metastasis  
M1 Distant metastasis  
Stage grouping 
Stage 0 Tis N0 M0  
Stage I T1 N0 M0 
T2 N0 M0 
 
Stage II T3 N0 M0 
T4 N0 M0 
 
Stage III Any T N1 M0 
Any T N2 M0 
 
Stage IV Any T Any N M1  
Table 2 Staging of colorectal cancer. 
(Adapted from Treanor, 2007) 
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In addition, tumours can be graded according to the degree of differentiation based 
on a system from the WHO. Low grade carcinomas (G1 and G2) are well 
differentiated tumours whereas high grade carcinomas (G3 and G4) are low 
differentiated types. 
 
 
2.2 Chemokines 
 
2.2.1 Chemokines - a general approach 
 
Chemokines are chemotactic cytokines which belong to a group of small secretory 
signal molecules. Commonly, chemokines have a length of 70-125 amino acid 
residues and a molecular weight of 8-14 kDa. According to their structural and 
functional characteristics they belong to a family of inflammatory and chemotactic 
active cytokines [Zlotnik et al., 2000]. Due to their secretion from the cell, chemokines 
control the migration of different cell types including lymphocytes, monocytes, 
neutrophils and fibroblasts and play a role in maturation and development of immune 
cells [Rossi et al., 2000]. Chemokines and their receptors are involved in a wide 
variety of biological processes such as angiogenesis, morphogenesis, autoimmunity 
and wound healing and also play a role in tumour cell growth and development of 
metastasis [Rossi et al., 2000]. Interestingly, the chemokine-chemokine receptor 
network was also shown to be involved in Human immunodeficiency virus (HIV)-
infection and appear to take part in the process of HIV-resistance [Suresh et al., 
2006]. 
Chemokines interact with specific chemokine receptors on the surface of their target 
cells. These receptors belong to a group of 7-transmembrane G-protein coupled 
receptors. The interaction of chemokines with their receptors activates an intracellular 
signal cascade which plays a role in the binding and extravasation of lymphocytes 
from the blood vessels into the corresponding tissues in physiologic and inflammatory 
processes [Locati et al., 2005]. Since many chemokines can interact with different 
chemokine receptors and most chemokine receptors bind different chemokines, the 
chemokine network is relatively complex (Figure 2). In addition, different cell types 
can produce and sustain different chemokine receptor sets and produce several 
chemokines [Mantovani, 1999]. According to the number and adjustment of the 
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characteristic cysteine residues at the amino-terminus, chemokines are subdivided 
into four subgroups (CC, CXC, CX3C and XC). The CC, CXC and CX3C group each 
contain four cysteine residues in the amino-terminal region whereas the XC group 
only contains two cysteines. In the CC-chemokine group the first two cysteines are 
directly neighboured whereas in the CXC-chemokine group the two cysteines are 
interspersed by any amino acid and in the CX3C-chemokine group these cysteines 
are interspersed by three arbitrary amino acids [Zlotnik et al., 2000]. According to a 
chemokine nomenclature reform the name of a chemokine consists of the name of 
the subgroup followed by L for ligand and consecutive numbers for the corresponding 
chemokine (e.g. CCL20) [International Union of Immunological Societies/World 
Health Organization Subcommittee on chemokine nomenclature, 2001]. Most of the 
human CXC-chemokine genes are coded on chromosome 4 whereas many CC-
chemokine genes are predominantly found on chromosome 17 (Figure 2) [Zlotnik et 
al., 2000]. 
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Figure 2 Human chemokines with their chromosomal location and their corresponding 
chemokine receptors. 
Red labelled chemokines are inflammatory/inducible; green labelled chemokines are homeostatic; 
yellow labelled chemokines are both. (Adapted from Locati et al., 2005) 
 
Furthermore, CXC-chemokines are classified according to the existence or absence 
of a characteristic motif of three amino acids (glutamic acid, leucin, arginin) referred 
to as the ELR-motif [Strieter et al., 1995]. CXC-chemokines which contain this ELR-
motif are designated to induce angiogenesis whereas chemokines without this motif 
are angiostatic [Belperio et al., 2000]. In addition, CXC-chemokines containing the 
ELR-motif attract neutrophils by chemoattraction whereas CXC-chemokines without 
this motif attract lymphocytes [Luster, 1998]. Further subdivision of chemokines is 
achieved by their physiological characteristics into inflammatory and homeostatic 
chemokines. Homeostatic chemokines are constitutively expressed in certain tissues 
and are responsible for the infiltration of leukocytes into organs and thus being 
involved in activation, differentiation and maturation of leukocytes [Schaerli et al., 
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2005]. Moreover, homeostatic chemokines play a role in angiogenesis and stem cell 
biology and have a direct proliferatory effect on cells. Contrarily, the main task of 
inflammatory chemokines is the recruitment of effector leukocytes to the site of 
inflammation [Moser et al., 2004]. Nevertheless, some chemokines appear to be 
involved in both inflammatory and homeostatic effects. Therefore, these chemokines 
cannot be categorized unambiguously as belonging to one of the two groups (Figure 
2). 
 
 
2.2.2 Chemokines and cancer 
 
The potential to chemotactically attract immune- and tumour-cells made chemokines 
interesting targets for investigations on the development and progression of cancer. 
In recent years chemokines were therefore reported to play a role in different 
processes associated with cancer. CXCL1, CXCL2 and CXCL3 were shown to 
directly promote growth and tumourigenicity of melanoma cell lines [Balentien et al., 
1991; Owen et al., 1997]. Furthermore, mutations in the corresponding receptor 
CXCR2 which renders this receptor constitutively active, are also capable of inducing 
oncogenic transformation [Burger et al., 1999]. In addition to these direct effects 
chemokines are also involved in angiogenesis of tumours. Thereby, CXCL8 
enhances angiogenesis by interaction with CXCR2 [Gabellini et al., 1999] whereas 
CXCL4 [Yang et al., 2011b], CXCL9 [Addison et al., 2000] and CXCL10 [Sato et al., 
2007] inhibit angiogenesis via CXCR3 signalling. Also in metastatic processes 
chemokines appear to play a role. CXCL8 is involved in increased matrix 
metalloproteinase expression in different cancers and thereby enhances 
invasiveness and metastatic potential [Watanabe et al., 2002; Inoue et al., 2000]. 
However, even in organ specificity of metastasis chemokines are involved. In this 
respect, the best investigated systems are the CXCL12-CXCR4 and CCL21/CCR7 
pathways which guide CXCR4 and CCR7 positive cancer cells to organs expressing 
high amounts of CXCL12 and CCL21 [Müller et al., 2001]. As chemokines are key 
factors in leukocyte recruitment, these features also play a role in cancer. Thus, 
CCL2 was found to be the main attractor of macrophages in different cancers 
[Arenberg et al., 2000; Ueno et al., 2000]. In recent years, macrophage infiltration 
was shown to be associated with cancer progression, thereby affecting angiogenesis, 
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immunosuppression and metastasis [Sica, 2010]. The chemokines CCL3 [Maric et 
al., 1999], CCL5 [Lavergne et al., 2004] and XCL1 [Huang et al., 2004] were shown 
to attract effector T-cells as well as natural killer cells and thereby mediating anti-
tumour effects. On the other hand, certain chemokines can attract regulatory T-cells 
which seem to be associated with decreased anti-tumour immunity [Maruyama et al., 
2010; Shields et al., 2010]. Therefore, the subset of attracted T-lymphocytes is critical 
for pro- or anti-tumoural chemokine function. A third group of attracted lymphocytes 
are dendritic cells. Different chemokines were reported to mediate recruitment of 
immature dendritic cells to the tumour site. However, it is not clear if the accumulation 
of dendritic cells is pro- or contra-tumourigenic. Recent investigations propose 
dendritic cells to mediate tumour-induced immune tolerance [Janikashvili et al., 
2011.]. 
As chemokines play such different roles in processes associated with cancer, 
chemokines are a potential starting point for cancer therapy. Some chemokine 
antagonists were already identified and were used in pre-clinical trials [Ishida et al., 
2006]. 
 
 
2.2.3 CCL20 - a general approach 
 
The chemokine CCL20 is also formerly known as liver and activation-regulated 
chemokine (LARC), macrophage inflammatory protein 3alpha (MIP-3α) or exodus-1 
[Bacon et al., 2002]. CCL20 was first described in 1997 as a 96 amino acid residue 
long precursor and 70 amino acid residue long mature protein. It is a chemotactic 
cytokine of the group of CC-chemokines and is coded by a gene located on 
chromosome 2 locus q36.3 [Hieshima et al., 1997]. In contrast to most other 
chemokines consisting of three exons and two introns CCL20 contains four exons 
and three introns [Nelson et al., 2001]. Thus, CCL20 shows a relatively low sequence 
homology to other CC chemokines [Yoshie et al., 1997]. Expression of CCL20 was 
found in different mucosal-associated lymphoid tissues like liver, lung, peripheral 
lymph nodes, thymus, tonsils, colon and appendix [Schutyser et al., 2000]. Therefore, 
one important function of the CCL20 pathway seems to constitute an appropriate 
immunity in intestinal mucosal tissues [Kunkel et al., 2003]. In addition CCL20 is also 
expressed by immune cells like B-cells, dendritic cells, granulocytes, macrophages or 
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T-cells. The G-protein coupled CC-chemokine receptor CCR6 is the sole receptor for 
CCL20 and is not targeted by any other chemokine. Expression of CCR6 was mainly 
found in the appendix, fetal liver, lymph node and spleen tissue and in these tissues 
also in lymphocytes (T cells and B cells) and dendritic cells but not in monocytes 
[Baba et al., 1997]. 
CCL20 expression can be initiated by different factors or pathogens such as dsRNA, 
lipopolysaccharide or bacterial endotoxins [Schutyser et al., 2000]. In addition, 
CCL20 expression is also induced by pro-inflammatory cytokines including interleukin 
1beta (IL-1β), tumour necrosis factor-alpha (TNF-α), or IL-17 [Kawashiri et al., 2009]. 
The regulatory role of CCL20 appears to be mediated in part through signalling via 
MAPK pathway(s) [Scapini et al., 2002] or the NF-κB pathway [Fujiie et al., 2001]. In 
contrast anti-inflammatory cytokines like IL-10 cause decreased expression of CCL20 
[Rossi et al., 1997].  
According to these activation pathways it was described that CCL20 can act as an 
inflammatory as well as a homeostatic chemokine due to the cellular conditions 
[Mantovani, 1999]. In immune responses CCL20 is proposed to be responsible for 
the attraction of cells specialized in antigen presentation and activation of the 
adaptive immune system. CCL20 is therefore involved in the attraction of CCR6 
positive immature Langerhans cells, other immature dendritic cells and their 
precursors to locations of putative antigen invasion [Charbonnier et al., 1999; Iwasaki 
et al., 2000]. Upon maturation of these cells the expression of CCR6 and the 
chemotactic activity of CCL20 decrease [Charbonnier et al., 1999]. CCL20 seems to 
be involved in the enrichment of immature dendritic cells to the scene of infection 
[Dieu et al., 1998]. Additionally, memory B-lymphocytes in contrast to naive B-
lymphocytes exhibit chemotactic movement towards CCL20 [Liao et al., 2002] and 
subsets of memory/effector T-lymphocytes are responsive to CCL20 rather by 
intracellular signalling than induction of chemotaxis [Liao et al., 1999]. Thereby the 
CCL20-CCR6 axis appears to be involved in the arrest of memory/effector T-cells on 
endothelial cells activated by TNF-α during the early phase of immune response 
[Fitzhugh et al., 2000]. In addition to these inflammatory associated functions of 
CCL20 the constitutive expression in mucosal tissue proposes a role for CCL20 in 
the general immune surveillance of the mucosa under normal conditions [Izadpanah 
et al., 2001]. This multifarious attraction of leukocytes enables the CCL20-CCR6 axis 
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to be involved in activation of the immune system as well as in immune tolerance 
[Comerford et al., 2010]. 
According to this dual function the expression and defective regulation of CCL20 has 
been reported to be involved in different human diseases like rheumatoid arthritis 
[Hirota et al., 2007] or inflammatory bowel disease [Kaser et al., 2004]. In rheumatoid 
arthritis CCL20 attracts memory T cells whereas in inflammatory bowel disease over-
expressed CCL20 increases accumulation of both memory T cells and immature T 
cells [Kaser et al., 2004]. 
 
 
2.2.4 CCL20 and cancer 
 
The expression of the pro-inflammatory chemokine CCL20 and its receptor CCR6 
has been described in different types of cancer including pancreatic cancer [Rubie et 
al., 2010; Kleeff et al:, 1999], non-small-cell lung carcinoma [Kirshberg et al., 2011], 
breast [Bell et al., 1999], hepatocellular carcinoma (HCC) [Rubie et al., 2006a], CRC 
[McLean et al., 2011] and colorectal liver metastases (CRLM) [Rubie et al., 2006b; 
Rubie et al., 2006c]. 
Regulation of basal CCL20 in the CRC cell line Caco-2 is mediated by Sp1 whereas 
ESE-1 is required for basal and cytokine induced CCL20 expression in this cell line 
[Kwon et al., 2003]. Even in the colon tumour cell line CT26 the expression of CCL20 
is regulated by the Toll-like receptor pathway and promotes tumour immune escape 
[Wang et al., 2008]. Another study that analyzed the role of the CCL20 receptor 
CCR6 in intestinal epithelial cells and CRC cells reported that CCR6 mediates ERK-
1/2, SAPK/JNK, and Akt signaling resulting in proliferation and migration of CRC cells 
[Brand et al., 2006]. However, the role of CCL20 in tumour associated effects is 
discussed contradictorily. In experiments with the HCC cell line Huh7 stimulation with 
CCL20 resulted in increased growth via the p44/42 MAPK pathway [Fujii et al., 2004] 
and in a rodent tumour cell line CCL20 increased tumour growth and decreased anti-
tumour immunity even though immature dendritic cells are attracted [Bonnotte et al., 
2004]. It was shown that the attracted immature dendritic cells do not mature in the 
tumour which is a putative mechanism for tumour immune escape [Bell et al., 1999]. 
In addition, CCL20 increased adhesion to collagen and advanced growth in vitro and 
enhances invasion and tumour growth in vivo in a mouse xenograft model [Beider et 
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al., 2009]. In another mouse model of CRC the expression of CCL20 was found in 
tumour-associated macrophages and in turn promoted tumour growth by the 
recruitment of CCR6 positive regulatory T-cells [Liu et al., 2011a]. In human 
pancreatic cancer over-expression of CCL20 was present in pancreatic cancer cells 
as well as in tumour-infiltrating macrophages and promotes tumour growth and 
invasiveness in a autocrine or paracrine way [Kleeff et al., 1999]. Additionally, a high 
expression of CCL20 in HCC patients after resection was linked to poor prognosis 
[Ding et al., 2011]. Conversely in a mouse model decreased tumour growth was 
found upon intratumoural injection of CCL20 expressing adenovirus [Fushimi et al., 
2000]. However CCL20 expression alone was not sufficient to induce anti-tumour 
reactions in B16 tumours [Crittenden et al., 2003; Furumoto et al., 2004]. 
 
 
2.3 MicroRNAs (miRNA) 
 
2.3.1 MicroRNAs - general approach 
 
The miRNA family comprises a class of small, non-coding RNAs in a range of 21-25 
nucleotides which play an important role in post-transcriptional gene regulation 
[Bartel, 2004]. The negative regulation of post-transcriptional expression conducted 
by miRNAs is mediated either by inhibition of translation or degradation of the target 
mRNA [Kim, 2005]. The fact that miRNAs are endogenously expressed as imperfect 
stem loop structures distinguishes miRNAs from siRNAs which are generated from 
long, double stranded RNA (dsRNA) molecules [Zeng et al., 2003]. The first miRNA 
discovered, lin-4, is complementary to parts of the 3’UTR of lin-14 mRNA and thereby 
regulating lin-14 expression in Caenorhapditis elegans (C. elegans) which is involved 
in timing of embryonic development [Lee et al., 1993]. Since their discovery miRNAs 
were described as an abundant class of gene regulatory elements in many different 
organisms including worms [Ambros, 2003], flies [Ambros, 2003], plants [Reinhart et 
al., 2002] and mammals [Lagos-Quintana et al., 2002]. In this respect, miRNAs play a 
role in the regulation of a wide variety of cellular processes involved in development 
[Agrawal et al., 2009], differentiation [Tarantino et al., 2010], proliferation [Pogue et 
al., 2010] and apoptosis [Ge et al., 2011]. In order to accomplish these multifaceted 
functions, miRNAs are expressed in distinct patterns in different tissue types. If these 
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patterns become defective, the aberrant expression of miRNAs can cause or 
contribute to diseases [Geekiyanage et al., 2011] as well as to cancer development 
and progression [Chang et al., 2011b]. Efforts to predict the number of miRNA genes 
in humans estimated that there are >1000 different miRNAs [Berezikov, 2011]. 
Therefore miRNAs are the most prevalent group of regulatory molecules. As every 
miRNA can regulate the expression of multiple target genes and miRNAs can 
cooperatively regulate one gene [Krek et al., 2005] it was assumed that miRNAs take 
part in the post-transcriptional regulation of approximately 30 % of human genes 
[Lewis et al., 2005]. 
 
 
2.3.2 MicroRNA biogenesis 
 
MiRNA genes are spread in clusters over the genome but most frequently found in 
introns of protein coding genes or intergenic regions [Kim et al., 2007; Borchert et al., 
2006]. Therefore miRNAs which reside in introns are expressed with the according 
gene whereas miRNAs in intergenic regions have their own promoters. 
The miRNA genes are transcribed either by polymerase II or polymerase III 
according to the location of the gene [Borchert et al., 2006; Lee et al., 2004]. MiRNAs 
transcribed by polymerase II result in several kilobases (kb) long primary-miRNAs 
(pri-miRNAs) which are capped and poly-adenylated and contain a stem loop (Figure 
3) [Lee et al., 2004]. Such pri-miRNAs can be mono- or poly-cistronic and are 
processed by the microprocessor complex consisting of the RNAse III type protein 
Drosha and the protein DiGeorge syndrome critical region gene 8 (DGCR8) to 
smaller ~65-75 nucleotide long hairpin-structured molecules which are designated 
precursor-miRNAs (pre-miRNAs) [Han et al., 2004]. In addition to this common 
pathway there is a less common one in which pre-miRNAs are created by direct 
splicing from intronic structures called mirtrons. These mirtrons are independent from 
the Drosha/DGCR8 microprocessor complex but in turn have special splicing sites 
and are therefore dependent on the functional splicing machinery and debranching 
enzymes [Okamura et al., 2007]. However, not all miRNAs coded in introns undergo 
this processing pathway and it is not terminally clarified whether pre-miRNAs created 
from mirtrons enter the normal downstream miRNA processing machinery or if they 
are processed in a separate pathway [Sibley et al., 2012]. Following the nuclear 
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processing steps the pre-miRNAs are exported to the cytoplasm in an energy 
consuming Ran-GTP dependent step mediated by Exportin 5 which is part of the 
nuclear transport receptor family (karyopherins) [Katahira et al., 2011]. In the 
cytoplasm the pre-miRNAs are cleaved ~22 nucleotides distant from the 5’ end of the 
pre-miRNA by the Dicer complex consisting of the cytoplasmic RNAse III type protein 
Dicer, human immunodeficiency virus transactivating response RNA binding protein 
(TRBP) and PKR activator (PACT) [Kok et al., 2007] in order to create 
miRNA:miRNA* duplexes [Park et al., 2011]. After cleavage by Dicer the 
miRNA:miRNA* duplexes are loaded to Ago proteins. To date, four Ago proteins (Ago 
1-4) are known in humans, but the sets of miRNAs that bind to each of them 
obviously overlap among all Ago proteins [Su et al., 2009]. The Ago proteins are a 
central part of the RNA induced silencing complex (RISC) [Yoda et al., 2010]. After 
incorporation to the RISC complex the dsRNA is unwound and only one strand 
(designated as the guide strand) remains in the complex whereas the other strand is 
degraded. Thus, the thermodynamic features of the 5’ end of both strands are 
responsible for strand selection [Khvorova et al., 2003]. However, the mechanism of 
strand loading and selection is not completely understood as in some rare cases both 
strands produce functional miRNAs [Yang et al., 2011a]. Once loading and assembly 
of the RISC complex is completed, the regulatory events are mediated. 
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Figure 3 Overview of the biogenesis of miRNAs. 
MiRNAs are primarily transcribed as pri-miRNAs in the nucleus and further processed by 
Drosha/DGCR8 to pre-miRNAs. Besides this pathway pre-miRNAs can also be generated by splicing 
from mirtrons. The pre-miRNAs are exported to the cytoplasm by Exportin 5. In the cytoplasm the pre-
miRNAs are processed by the Dicer-complex which results in miRNA-duplexes and the strand with the 
weaker 5’ base pairing is incorporated into the RISC complex. (Adapted from Filipowicz et al., 2008) 
 
 
2.3.3 MicroRNA regulatory interactions 
 
The guide strand incorporated into the RISC complex is the key element for the 
recognition of the target mRNAs [Parker et al., 2006]. Recognition is mediated by 
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complementarity between the miRNA and parts of the 3’UTR of the target mRNA. 
Some rare cases also reported that miRNA target sites are present in the open 
reading frame (ORF) or 5’UTR of target mRNAs [Moretti et al., 2010]. The degree of 
complementarity between the miRNAs and their target sequences is considered as a 
predictor for the respective regulatory mechanism. Complete or nearly complete 
complementarity labels the target mRNA for proteolytic degradation whereas a lower 
degree of complementarity labels the mRNA for processes resulting in decreased 
translation or mRNA destabilization [Bartel, 2009]. Nevertheless, there are some 
exceptions in which low complementarity also leads to degradation of the target 
mRNA [Bagga et al., 2005]. In both cases target recognition is mediated by perfect 
base pairing between the “seed” sequence, present at position 2-8 at the 5’ end of 
the miRNA and the target mRNA. Another interaction which possibly takes part in 
target recognition is 3’ end pairing of the miRNA which is primarily important for 
miRNAs with weaker “seed” interaction. This effect is referred to as “compensatory 3’ 
end binding” [Brennecke et al., 2005]. In addition to “seed” complementarity as the 
most common mechanism there are some functional miRNAs reported which do not 
have such a “seed” interaction. 
In most cases miRNAs are only partially complementary to their target sequences. To 
date, various mechanisms are discussed by which miRNAs possibly or actually 
mediate the repression of target mRNA translation (Figure 4) [Fabian et al., 2010; 
Filipowicz et al., 2008]. There are different steps in which the translation can be 
blocked by miRNAs. The first step is translation initiation. Competition of AGO 2, 
which contains certain homology to the binding site of the initiation factor eIF4E, with 
eIF4E for cap binding [Kiriakidou et al., 2007] or interruption of the association of 
active 80S ribosomes by the RISC-complex [Chendrimada et al., 2007] can lead to 
blockage of initiation. Also mechanisms at post-initiation steps like poly(A) tail 
shortening and decapping of the target mRNA which leads to mRNA degradation 
[Behm-Ansmant et al., 2006], retarded translation speed and subsequent ribosome 
drop-off [Petersen et al., 2006] or degradation of synthesized protein during 
translation [Nottrott et al., 2006] can contribute to translational repression. 
It was shown that miRNA-mediated translationally repressed mRNAs are directed to 
P-bodies by the RISC-complex where they are either stored or degraded [Liu et al., 
2005]. 
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Figure 4 Possible mechanisms for miRNA mediated post-transcriptional target gene 
repression. 
The translation of mRNAs can be blocked at different stages. The initiation can be blocked by 
inhibition of 5’ cap recognition or ribosome assembly. Post-initiation the translation can be blocked by 
deadenylation, decapping or retardation of translation speed which results in ribosome drop-off. At last 
it was proposed that the RISC complex is directly involved in degradation of the nascent protein. 
(Adapted from Filipowicz et al., 2008) 
 
 
2.3.4 MicroRNAs in cancer 
 
The process of carcinogenesis is characterized by altered regulation of gene 
expression. Thus, special interest is focused on altered expression of tumour-
suppressor genes and oncogenes which normally are involved in many cellular 
processes such as development, proliferation, differentiation, metabolism or 
apoptosis. As miRNAs are involved in post-transcriptional regulation of gene 
expression, they were proposed to have an impact on tumour-associated gene 
expression. 
In recent years, a wide variety of interactions between miRNAs and cancer 
associated genes were found. The first interaction of miRNAs with cancer was shown 
in B-cell chronic lymphocytic leukemia where the loss of the 13q14 locus is 
responsible for the decreased expression of miR-15a and miR-16-1 [Calin et al., 
2002]. Hence miRNAs can also act as tumour-suppressor genes (tumour-suppressor 
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miRs) or oncogenes (oncomiRs) [Cowland et al., 2007] by interacting with protein 
coding oncogenes or tumour-suppressor genes. This is in line with the investigations 
that miRNA signatures can also be used as markers of cancer [Fabbri, 2010] and the 
expression patterns of miRNAs can actually be applied for the determination of 
different cancer types and tissue origin of tumours [Su et al., 2001]. 
Altered regulation of miRNAs and reduced global miRNA expression evolved as a 
characteristic of cancer [Davalos et al., 2010]. Along the global down-regulation of 
miRNAs, also up-regulated expression of distinct miRNAs is found to be associated 
with tumour development [Li et al., 2012b]. As all tissue types have their specific 
miRNA expression patterns [Liang et al., 2007a] it is not surprising that miRNAs are 
misregulated in cancer. When normal cells are transformed into malignant cells they 
experience changes with respect to their phenotype and their state of differentiation 
which distinguishes them from normal cells and endows them with characteristic 
capabilities [Hanahan et al., 2011.]. The dysregulation of miRNA expression patterns 
can therefore be causative or a consequence of these processes. 
Reasons for the altered expression of miRNAs in different kinds of cancer can be 
diverse. A wide variety of miRNA genes are coded in fragile genomic regions and/or 
in regions associated with distinct kinds of cancer [Calin et al., 2004]. Therefore, 
genomic instability can be one cause of increased or decreased miRNA expression 
associated with cancer [Braude et al., 2006]. However, alterations in miRNA 
expression can also occur when parts of the miRNA processing machinery or its 
regulators are deficient [Kumar et al., 2007]. Thus, a defect of the proteins Drosha, 
DICER1 or Exportin 5 was shown to be associated with global down-regulation of 
miRNAs in cancer [Thomson et al., 2006; Kumar et al., 2009; Melo et al., 2010]. 
Apart from mutational/genomic changes also epigenetic changes like histone 
modifications or DNA methylation patterns have an impact on the expression levels 
of miRNAs in diverse cancer types [Sampath et al., 2012; Saito et al., 2006]. In 
selected cancer types it was shown that several miRNA transcription units are 
located in CpG islands which are major targets of DNA methylation processes 
[Suzuki et al., 2011]. In addition to the mechanisms described above, polymorphisms 
in the sequence of mature miRNAs or pre-miRNAs can also have an impact on 
miRNA expression [Jazdzewski et al., 2008]. However, this is rather rare due to the 
shortness of miRNA sequences. 
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Apart from an altered miRNA gene expression profile, failure in miRNA function can 
also lead to altered gene expression. Thus, polymorphisms in miRNA binding sites of 
target genes can have an impact on miRNA mediated regulation in cancer [Schetter 
et al., 2011]. 
In recent years miRNAs aberrantly expressed in different cancer types were related 
to certain classical oncogenic and tumour-suppressor pathways. A miRNA known to 
act as an oncomiR is miR-155 which is over-expressed in different cancer types and 
regulates among others the tumour suppressor gene SOCS1 [Volinia et al., 2006; 
Jiang et al., 2010]. Also the miR-17 cluster (containing miR-17-5p, miR-18a, miR-
19a, miR-20a, miR-19b-1 and miR-92) is up-regulated in several cancer types, 
[Volinia et al., 2006] where it appears to be activated by Myc, targeting the 
expression of PTEN [Olive et al., 2009] and E2F1 [O'Donnell et al., 2005] and also 
decreasing TGF-β signalling [Dews et al., 2010]. Similarly, miR-21 plays a role as an 
oncomiR and is up-regulated in a wide variety of cancer types including stomach, 
prostate, pancreas, lung, colon and breast [Vicinus et al., 2012; Volinia et al., 2006]. 
Thereby miR-21 is activated by RAS through AP-1 and represses the expression of 
PDCD4 [Talotta et al., 2009.]. 
In contrast, miRNAs can also act as tumour suppressor miRNAs. Known tumour 
suppressor miRNAs are miR-15a and miR-16-1 whose down-regulation is coupled to 
loss of 13q14 in different cancers [Calin et al., 2002; Dong et al., 2001]. These 
miRNAs down-regulate BCL-2, CCND1 and WNT3A which are involved in 
tumourigenic processes [Bonci et al., 2008]. Another miRNA with tumour suppressor 
activity is let-7 which regulates the oncogene RAS, E2F2 and CCND2 [Johnson et 
al., 2005; Dong et al., 2010]. At last, miR-143 and miR-145 are predominantly down-
regulated in cancer of the colon and breast [Slaby et al., 2007] where their down-
regulation is involved in altered expression of the KRAS and EGFR receptors [Chen 
et al., 2009; Cho et al., 2011]. 
Thus, the small selection of miRNAs incorporated upstream or downstream of 
oncogenic and tumour-suppressor pathways show their potential role in these 
tumourigenic pathways. However, as miRNAs can regulate a wide variety of target 
genes and as to date not all targets of a distinct miRNA are identified, it cannot 
reliably be predicted if a miRNA acts pro- or contra-tumourigenic. 
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2.3.5 MicroRNAs in colorectal cancer 
 
The first study related to altered regulation of miRNAs in CRC was published in 2003 
[Michael et al., 2003]. Subsequently, several high throughput profiling studies on 
miRNAs expression patterns in CRC identified more than 100 miRNAs with altered 
gene expression. The miRNAs miR-20, miR-21, miR-31 and miR-99b were 
consistently up-regulated whereas expressions of miR-143, miR-145 and miR-192 
were found to be decreased [Bandrés et al., 2006; Volinia et al., 2006; Slaby et al., 
2007; Schetter et al., 2008; Chen et al., 2009]. Thereby, miR-31 showed increased 
expression in higher stages and miR-21 was correlated to metastasis and tumour 
stage [Slaby et al., 2007]. Down-regulation of miRNAs in CRC can be caused by 
epigenetic silencing as 47 miRNAs of 37 primary transcription units were potential 
targets of these mechanisms [Suzuki et al., 2011]. Another mechanism contributing 
to altered miRNA expression in CRC is the p53 pathway which is frequently mutated 
in CRC [Scott et al., 1991]. MiRNA profiling in CRC cell lines identified p53 putative 
binding sites present in ~45 % of miRNA promoter regions [Xi et al., 2006b]. Direct 
targets activated by p53 in CRC are the miRNAs miR-34a [Chang et al., 2007], miR-
192 and miR-215 [Georges et al., 2008] which play a role in cell cycle arrest and 
other cancer relevant processes. 
Certain miRNAs deregulated in CRC were shown to target pathways often altered in 
CRC (Figure 5). MiRNA-143, which is frequently down-regulated in CRC was shown 
to regulate KRAS and therefore decreased miR-143 expression was shown to 
promote growth in CRC cells [Chen et al., 2009]. The regularly up-regulated miRNA-
135 targets APC, a member of the Wnt/β-catenin pathway, whose expression is often 
altered in initial steps of CRC [Nagel et al., 2008]. In the PI3K pathway miR-126 
decreases p85-beta whereas the up-regulated miR-21 regulates PDCD4, an inhibitor 
of the PI3K pathway [Guo et al., 2008; Asangani et al., 2008]. 
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Figure 5 Overview of miRNAs involved in central pathways in CRC. 
The presented miRNAs influence key pathways of CRC carcinogenesis like Wnt/β- catenin, PI3K, p53 
or KRAS signalling. (Adapted and modified from Faber et al., 2009) 
 
It is known that the dysregulation pattern of miRNAs is characteristic for different 
cancer types and the origin of various tumours. Therefore, distinct investigations on 
miRNA dysregulation patterns are presently conducted for the diagnosis of CRCs. 
Thus, the expression of certain miRNAs was found to be altered in plasma (miR-17-
3p, miR-92, miR-95, miR-135b and miR-222) or stool samples (miR-21 and miR-
106a) of CRC patients compared to normal controls [Ng et al., 2009; Link et al., 
2010]. Therefore, miRNAs can possibly serve as a non-invasive diagnostic tool of 
CRC. The expression levels of miR-21 [Schetter et al., 2008], miR-200c [Xi et al., 
2006a], miR-106a [Díaz et al., 2008] and miR-215 [Karaayvaz et al., 2011] were 
correlated with prognosis of survival. To date, preliminary studies were conducted 
with respect to the application of miRNAs in therapeutics. Thereby, local or systemic 
administration of miR-145 led to reduced proliferation in a mouse xenograft model of 
CRC [Ibrahim et al., 2011]. 
 
 
2.4 Aims of this study 
 
In various cancer entities chemokines were reported to be deregulated and reported 
to be associated with tumour development and progression [Wang et al., 2009b]. 
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Thereby CCL20 was identified as a chemokine which may play a role in cancer 
associated processes. Similarly, various miRNAs were reported to be deregulated in 
colorectal carcinoma [Dong et al., 2011]. As recently both groups of molecules 
gained importance with respect to cancer development and progression, the aim of 
the present thesis was to identify and characterize a functional link between certain 
miRNAs and the chemokine CCL20 with a special interest in CRC. 
As no information on miRNAs interacting with CCL20 was known at the starting point 
of this thesis, computational prediction of interactions together with experimental 
validation of functionality were applied. Therefore, it was aimed to investigate the 
regulatory correlation between the identified miRNAs and CCL20 by transfecting 
CRC cells with the specific miRNAs. In addition, it was scheduled to analyze the 
expression profiles of CCL20 and the respective miRNAs in tissue samples from 
patients with CRC in order to detect expression alterations compared to normal non-
affected tissues and to identify potential correlations between miRNA expression and 
CCL20 mRNA and/or protein expression. To further characterize the role of the 
identified miRNAs and CCL20 with respect to CRC pathology and progression it was 
intended to localize the expression patterns of these molecules by 
immunhistochemistry (CCL20) and in situ hybridization (miRNAs). 
The results obtained from the present study aimed to identify miRNAs which may 
have the potential to regulate the expression of CCL20, thereby shedding light on the 
role of miRNA-chemokine interactions and impact on CRC pathogenesis. 
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3. Material and Methods 
 
3.1 Material 
 
3.1.1 Instrumentation 
 
Instrumentation Manufacturer 
Analysis scale Sartorius 
Autoclave, VARIOKLAV® Thermo Fisher Scientific 
Centrifuge, AvantiTM J-20 XP Centrifuge Beckman CoulterTM 
Centrifuge, Biofuge primo Hereaus Holding GmbH 
Centrifuge, Centrifuge 5417R Eppendorf 
Centrifuge, Centrifuge 5810R Eppendorf 
Exthaust hood Köttermann GmbH 
Homogenizer Ultra-Turrax ®T8 IKA® -Werke GmbH Co. KG 
Incubator (37 °C; 5,0 % CO2) NuncTM RS Biotech 
Incubator shaker, INNOVA® 44 New Brunswick Scientific 
Laminar flow, s@feflow 1.2 NuncTM 
Luminometer, Lumat LB9501 Berthold Technologies GmbH & Co.KG 
Multipipette® Plus Eppendorf 
PCR-Cycler,  
Gene Amp® PCR System2700 
Applied Biosystems 
pH-meter WTW GmbH 
Photometer, Biophotometer Eppendorf 
Photometer, Microplate Absorptions-
Reader ELx800 
BioTek Instruments 
Pipettes (10/20/200/1000µl) Eppendorf 
Pipetting aid, Accu-Jet® Pro VWR International GmbH 
Sequence Detection System, 7900HT 
ABI PRISM 
Applied Biosystems 
Shaker, Unimax 2010 Heidolph Instruments GmbH & Co.KG 
Thermomixer compact Eppendorf 
Ultrasonic bath, RK100 Bandelin-Sonorex 
Vortex 2x3 UniEquip Laborgerätebau und 
Vertriebspartner GmbH 
Water bath, WB22 Labortechnik Medingen 
Tweezers Carl Roth GmbH + Co KG 
Humidity chamber Thermo Fisher Scientific 
Millipore water dispenser Arium® 611 Sartorius 
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Instrumentation Manufacturer 
Neubauer counting chamber Bender & Hobein 
Microscope Olympus 
Microtome Leica Microsystems 
Waterbath Kunz Instruments 
Heating cabinet HIR12 (for 
hybridization) 
Grant Boekel 
 
 
3.1.2 Consumables 
 
Product Manufacturer 
Cell culture multiwell plates, 
CELLSTAR® (6 und 24 well) 
Greiner Bio-One GmbH 
Centrifuge tubes (50 ml) Greiner Bio-One GmbH 
Centrifuge tubes, SuperClear™  
(14 ml) 
VWR International GmbH 
Culture flask, CELLSTAR® (25 cm2) Greiner Bio-One GmbH 
Cuvette, UVette® Eppendorf 
Disponsable cell scraper Greiner Bio-One GmbH 
Disponsable Weighing pan, Rotilabo® Carl Roth GmbH + Co. KG 
ELISA-plates, Immuno 96 Microwell™ 
Solid Plates 
NuncTM 
MicroAmp® 96-Well Optical Adhesive 
Film 
Applied Biosystems 
MicroAmp® Optical 96-Well Reaction 
Plate 
Applied Biosystems 
Microtest-plates, Rotilabo® Carl Roth GmbH + Co. KG 
Optical adhesive film for ELISA-plates NuncTM 
Parafilm M, Laboratory Film American National Can 
PCR-tubes, 0.2 ml VWR International GmbH 
Petri dish, 8.5 cm Greiner Bio-One GmbH 
Pipette tips (0.1-100/200/1000 µl) Greiner Bio-One GmbH 
Pipettes, Serologic 
Rotilabo® Pipettes (1/2/5/10/25 ml) 
Carl Roth GmbH + Co. KG 
Polypropylen tubes, round bottom (12 
ml) 
Greiner Bio-One GmbH 
Polystyrol tubes, round bottom Greiner Bio-One GmbH 
Reaction tubes (1.5/2 ml) Eppendorf 
Ritips® professional, non-sterile 
(500 µl/2.5 ml /5 ml) 
Ritter GmbH 
Weighing paper Carl Roth GmbH + Co. KG 
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Product Manufacturer 
Coblin jar Carl Roth GmbH + Co. KG 
Staining insert Carl Roth GmbH + Co. KG 
Microscopic slides Superfrost® / Plus Carl Roth GmbH + Co. KG 
Coverglasses Carl Roth GmbH + Co. KG 
Fixogum Marabu 
 
 
3.1.3 Chemicals and Biochemicals 
 
Product Manufacturer 
Absolute ethanol VWR 
Albumin Fraktion V, Protease-frei Carl Roth GmbH + Co. KG 
Complete, Proteaseinhibitor cocktail 
tablets 
Roche 
DharmaFECT®1, Transfection Reagent Thermo Scientific 
Dimethylsulfoxid (DMSO) Carl Roth GmbH + Co. KG 
Dinatriumhydrogenphosphat (Na2HPO4) Carl Roth GmbH + Co. KG 
DPBS GIBCO® (InvitrogenTM) 
EDTA (Dinatriumsalz Dihydrat) Carl Roth GmbH + Co. KG 
Ethanol 99 % denatured Zentrales Chemikalienlager Saarbrücken 
Foetal Bovine Serum Gold PAA Laboratories GmbH 
HPLC-H2O ROTISOLV® HPLC Gradient 
Grade 
Carl Roth GmbH + Co. KG 
Kanamycin Sigma-Aldrich® 
LipofectamineTM 2000 Reagent InvitrogenTM 
N, N-Dimethylformamide (DMF) Sigma-Aldrich® 
NP-40 Alternative 100 % Calbiochem® 
Pen/Strep, Penicillin Streptomycin GIBCO® (InvitrogenTM) 
PMSF AppliChem GmbH 
Sodium chloride (NaCl) Merck 
Sodium deoxycholate (DOCA) Carl Roth GmbH + Co. KG 
Sodium dihydrogen phosphate 
(NaH2PO4) 
Carl Roth GmbH + Co. KG 
Sodium fluoride (NaF) Carl Roth GmbH + Co. KG 
Sodium hydroxide (NaOH) Sigma-Aldrich® 
Sodium orthovanadate (Na3VO4) Sigma-Aldrich® 
ß-Mercaptoethanol Merck 
Sulphuric acid H2SO4, reinst 98 % Zentrales Chemikalienlager Saarbrücken 
TaqMan® Universal Master Mix II Applied Biosystems 
Tris Ultra Qualität 
(Tris–(hydroxylmethyl-) aminomethan) 
Carl Roth GmbH + Co. KG 
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Product Manufacturer 
TrypsinEDTA (10x) InvitrogenTM 
Tween®-20 Carl Roth GmbH + Co. KG 
Potassium chloride (KCl) Carl Roth GmbH + Co. KG 
Hydrochloric acid Riedel-de Haën® 
Xylene Carl Roth GmbH + Co. KG 
SSC solution 20 x Ambion® 
NBT/BCIP Ready-to-Use Tablets Roche Applied Science 
Sheep serum Santa Cruz Biotechnology Inc. 
Nuclear Fast Red Sigma-Aldrich® 
RNaseZap® Ambion® 
Levamisole hydrochloride Sigma-Aldrich® 
Eukitt® quick-hardening mounting 
medium 
Sigma-Aldrich® 
HiPerFect® Transfection reagent Qiagen 
DEPC AppliChem GmbH 
Aquatex Merck KGaA 
Mayers Hämalaun AppliChem GmbH 
Hydrogen peroxide (H2O2) VWR 
Antibody diluent DAKO 
Target Retrieval Solution DAKO 
 
 
3.1.4 Applied Kits 
 
Product Manufacturer 
BCATM Protein Assay Kit  Thermo Fisher Scientific 
Dual-Luciferase® Reporter Assay 
System 
Promega Corporation 
DuoSet® ELISA, human MIP-3α/CCL20 R&D Systems® 
GenEluteTM HP Plasmid Maxiprep Kit Sigma-Aldrich® 
High Capacity cDNA Reverse 
Transcription Kit 
Applied Biosystems 
mirVanaTM miRNA Isolation Kit Ambion® 
RNeasy® Mini Kit QIAGEN 
Substrate Reagent Pack R&D Systems® 
TaqMan® MicroRNA Reverse  
Transcription Kit 
Applied Biosystems 
VECTASTAIN® Elite ABC Kit (Goat IgG) Vector Laboratories 
DIG Wash and Block Buffer Set Roche Applied Science 
miRCURY LNA™ microRNA ISH 
Optimization Kit (FFPE) 
Exiqon 
QuikChange® II XL Site-Directed 
Mutagenesis Kit 
Agilent Technologies 
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3.1.5 Enzymes 
 
Product Manufacturer 
MultiScribeTM Reverse Transkriptase, 50 
U/µl (part of High Capacity cDNA 
Reverse Transcription Kit) 
Applied Biosystems  
RNAse–Inhibitor (Part of TaqMan® 
MicroRNA Reverse Transcription Kit)  
Applied Biosystems 
Proteinase K buffer and reagent (part of 
the miRCURY LNA™ microRNA ISH 
Optimization Kit (FFPE) 
Exiqon 
 
 
3.1.6 Probes and nucleic acids 
 
All TaqMan® Gene Expression Assays, TaqMan® MicroRNA Assays and Pre-miR™ 
miRNA Precursor were purchased from Ambion® Life Technologies (Darmstadt, 
Germany). 
TaqMan® Gene expressions assays: 
B2m – Gene Expression Assay 
CCL20 – Gene Expression Assay 
TWF1 – Gene Expression Assay 
TaqMan® microRNA assays: 
hsa-miR-21 MicroRNA Assay  
hsa-miR-145 MicroRNA ssay 
RNU48 MicroRNA Assay 
 
Pre-miR™ miRNA Precursors: 
hsa-miR-21 Pre-miRTM miRNA Precursor 
hsa-miR-145 Pre-miRTM miRNA Precursor 
hsa-miR-1 Pre-miRTM miRNA Precursor (Positive control) 
Negative Control # 1 Pre-miRTM miRNA Precursor (Negative control) 
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All miRCURY LNA™ microRNA Detection Probes for in situ hybridization (ISH) were 
purchased from Exiqon (Vedbaek, Denmark). 
 
hsa-miR-21 miRCURY LNA™ Detection probe, 5`-DIG and 3`-DIG 
labeled 
hsa-miR-145 miRCURY LNA™ Detection probe, 5`-DIG and 3`-DIG 
labeled 
U6 hsa/mmu/rno Control, miRCURY LNA™ detection probe, 5`-DIG and 
3`DIG labeled 
scramble-miR Control, miRCURY LNA™ detection probe, 5`-DIG and 
3`DIG labeled 
 
For the site-directed mutagenesis of the miR-21 target site the following primer were 
applied and purchased from Thermo Scientific (Waltham, MA, USA): 
Forward Primer: 
5'-CTGTGTTTAGCTATTTAATACTAATTTTCCGTGAGCTATTTTGGTTTAGTGCAAAGTATAAAA-3' Primer sequence 
   |||||||||||||||||||||||||||||| | |||||||||||||||||||||||||||||| 
3’-GACACAAATCGATAAATTATGATTAAAAGGTATTCGATAAAACCAAATCACGTTTCATATTTT-5’ CCL20 3’UTR 
Reverse Primer: 
5’-TTTTATACTTTGCACTAAACCAAAATAGCTCACGGAAAATTAGTATTAAATAGCTAAACACAG-3’Primer sequence 
   |||||||||||||||||||||||||||||| | |||||||||||||||||||||||||||||| 
3’-AAAATATGAAACGTGATTTGGTTTTATCGAATACCTTTTAATCATAATTTATCGATTTGTGTC-5’CCL20 3’UTR 
 
 
3.1.7 Culture media, Buffers and Solutions 
 
3.1.7.1 Culture media for bacteria- und human cell lines 
 
DMEM + GlutaMAXTM   GIBCO® (InvitrogenTM) 
MEM + GlutaMAXTM   GIBCO® (InvitrogenTM) 
McCoy’ s 5A + GlutaMAXTM  GIBCO® (InvitrogenTM) 
Leibovitzs L-15, GlutaMAX™  GIBCO® (InvitrogenTM) 
OPTI- MEM® I + GlutaMAXTM  GIBCO® (InvitrogenTM) 
LB Broth     Sigma-Aldrich® 
LB Agar     Sigma-Aldrich® 
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3.1.7.2 Buffers and Solutions 
 
(1) Saturation buffer (ELISA): 
  Tris-(hydroxymethyl)-aminomethan  12.1 g 
  Adjust pH with HCl to a value of 7.5 
  BSA            5 g 
  Fill up with dd H2O to a final volume of 500 ml 
 
(2) Stock CompleteTM  
25 x CompleteTM Protease Inhibitor Cocktail 1 tablet 
  Dissolve in 2 ml of dd H2O 
 
(3) Sodium fluoride (200 mM): 
  NaF      840 mg 
  Dissolve in 100 ml dd H2O and autoclave the solution 
 
(4) PMSF (100 mM): 
  PMSF      87.1 g 
  Isopropanol     5 ml 
 
(5) RIPA Lysis Buffer: 
  0.5 M Tris-HCl pH 7.4    10 ml 
  100 % NP-40 Alternative     1 ml 
  2.5 % DOCA     10 ml 
  1.5 M NaCl     10 ml 
  100 mM EDTA pH 7.4     1 ml 
  dd H2O     58 ml 
On the day of the experiment add: 
  200 mM NaF       5 µl 
  200 mM Na3VO4      5 µl 
  25 x Stock CompleteTM   80 µl 
  Directly before use add 10 µl PMSF (100 mM) 
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(6) TE Buffer: 
  0.121 g Tris-HCl (10 mM) 
  0.029 g EDTA (1 mM) 
  Dissolve in 100 ml dd H2O and adjust pH to 8.0 
 
(7) 0.5 M Tris-HCl: 
  12.11 g Tris-HCl 
  Dissolve in 100 ml H2O dest. 
  Adjust pH to 7.4 
  Fill up with dd H2O to a final volume of 200 ml 
 
(8) Washing buffer for ELISA 0.01 M PBS + 0.1 % Tween: 
  0.01 M Na2HPO4 x 2H2O    3.5598 g 
  0.01 M NaH2PO4 x 2H2O    3.1202 g 
  0.15 M NaCl      17.529 g 
  Adjust pH to 7.4 with NaOH 
Add 1 ml of Tween20 and fill up with dd H2O to a final volume of 2000 
ml 
 
(9) 10x PBS for ISH: 
  10.9 g Na2HPO4 
  3.2 g NaH2PO4 
  90 g NaCl 
  Dissolve in 1000 ml H2O and autoclave 
 
(10) PBS-T for ISH: 
  1000 ml 1x PBS 
  1 ml Tween®-20 
  autoclave 
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(11) KTBT buffer for ISH: 
  7.9 g Tris-HCl 
  8.7 g NaCl 
  0.75 g KCl 
  Dissolve in 1000 ml DEPC H2O 
 
(12) 1 M Tris-HCl pH 7.4: 
121.1 g Tris-HCl 
Dissolve in DEPC H2O, adjust pH to 7.4 with HCl and fill to final volume 
of 1000 ml 
 
(13) 10 mM Tris-HCl pH 7.5: 
0.121 g Tris-HCl 
Dissolve in DEPC H2O, adjust pH to 7.5 with HCl and fill to final volume 
of 100 ml 
 
(14) 0.5 M EDTA: 
186.1 g EDTA 
Dissolve in DEPC H2O, adjust pH to 8.0 with NaOH and fill to a final 
volume of 1000 ml 
 
(15) 5 M NaCl: 
146.1 g NaCl 
Dissolve in 500 ml DEPC H2O 
 
(16) Proteinase K buffer: 
  5 ml of 1 M Tris-HCl (pH 7.4) 
  2 ml of 0.5 M EDTA 
  0.2 ml of 5 M NaCl 
  Adjust with DEPC H2O to a final volume of 1000 ml and autoclave 
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(17) DEPC H2O: 
  1000 ml dd H2O 
  1 ml DEPC 
  Mix for 6 h on a magnetic stirrer and then autoclave 
 
 
3.1.8 Antibodies 
 
Product  Manufacturer 
Capture Antibody, mouse anti-human 
MIP-3α/CCL20 (part of DuoSet® ELISA) 
R&D Systems® 
Detection Antibody, biotinylated goat 
anti-human MIP-3α/CCL20 (part of 
DuoSet® ELISA) 
R&D Systems® 
Standard, recombinant human MIP-
3α/CCL20 (part of DuoSet® ELISA) 
R&D Systems® 
IHC/ICC antibody: goat anti-human 
CCL20/MIP-3α (AF360) 
R&D Systems® 
biotinylated anti-goat secondary 
antibody (part of VECTASTAIN® Elite 
ABC Kit (Goat IgG) 
Vector Laboratories 
Anti-Digoxigenin-AP, Fab fragments 
from sheep 
Roche Applied Science 
 
 
3.1.9 Cell lines 
 
The cell line Caco-2 (ATCC number: HTB-37): 
The cell line Caco-2 is a human CRC cell line which was isolated and characterized 
from a primary colon adenocarcinoma by J. Fogh in the year 1974 [Fogh et al., 1975]. 
Caco-2 cells are immortally and adherent growing cells. Under normal growth 
conditions these cells become differentiated and polarized which results in a 
morphological, physiological and functional similarity to enterocytes of the human 
small intestine [Pinto M et al., 1983]. 
 
The cell line HT29 (ATCC number HTB-38): 
The cell line HT29 was isolated from a primary tumour of a colorectal 
adenocarcinoma by J. Fogh in the year 1964 [Fogh et al., 1975]. These cells are 
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immortally and adherent growing cells which attain morphological characteristics of 
absorptive epithelial cells growing in a polarized monolayer under specific growth 
conditions [Le Bivic et al., 1988]. 
 
The cell line SW480 (ATCC number: CCL-228): 
The cell line SW480 was isolated from a primary adenocarcinoma and characterized 
by A. Leibovitz [Leibovitz et al., 1976]. SW480 cells are hyperdiploid and grow as 
small clusters of epithelial cells and bipolar cells. 
 
The cell line SW620 (ATCC number: CCL-227): 
The cell line SW620 was isolated from lymph nodes of recurring colorectal 
adenocarcinoma and characterized by A. Leibovitz [Leibovitz et al., 1976]. SW 620 
cells are hyperdiploid, highly dedifferentiated and grow as a mixture of spherical cells 
and bipolar cells. 
 
The cell line 293T (ATCC number: CRL-11268): 
The cell line 293T, a kidney epithelial cell line, is a variant of the cell line HEK-293 
(Human Embryonic Kidney) which was primarily transformed with fractions of 
Adenovirus 5 DNA [Graham et al., 1977]. 293T cells in addition express the SV40 
large T-antigen which allows these cells to replicate episomal plasmids containing the 
SV40 origin of replication. The 293T cell line is widely used for reporter expression 
assays [DuBridge et al., 1987]. 
 
 
3.1.10 Patient material 
 
All tissue samples applied in the present thesis were surgically resected and stored 
at the Department of General, Visceral, Vascular and Paediatric Surgery of the 
University of the Saarland. The study was permitted by the local ethics committee of 
the Ärztekammer des Saarlandes and informed written agreement for tissue 
procurement was obtained from all patients. Fourty-six patients with colorectal 
adenocarcinoma were included in the present work. For all patients corresponding 
non-affected normal colorectal tissue was available. The clinical data and patient 
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characteristics were obtained from a prospective database and were summarized in 
Table 3. 
 
Characteristic CRC (n=46) 
Localization of primary tumour  
    Colon 23 
    Rectum 23 
Gender  
    Male 28 
    Female 18 
Age at surgery (yr)  
    Median 68.3 
    Range 44-88 
Tumour (T)-stage of primary 
tumour 
 
    T1 8 
    T2 12 
    T3 16 
    T4 10 
Lymph node status  
    Positive 26 
    Negative 20 
Clinical stage of primary tumour  
    I 16 
    II 7 
    III 17 
    IV 6 
Grade  
    G1 4 
    G2 19 
    G3 21 
    G4 2 
Table 3 Clinical features of CRC patients 
 
 
3.1.11 Vectors 
 
3.1.11.1 Reporter construct containing the 3’UTR of CCL20 
 
The miTarget™ microRNA 3'UTR target clones in mammalian expression vector 
pEZX-MT01 (GeneCopoeiaTM; Rockville, MD, USA) containing two luciferase reporter 
genes allows the identification of miRNA-targets and the functional validation of 
predicted targets by detection of regulatory interactions. In the present thesis a 
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construct from GeneCopoeiaTM was chosen which contains the 3’UTR of CCL20. In 
the reporter vector the 3’UTR of CCL20 is arranged directly downstream of the 
Firefly–luciferase gene (hLuc) (Figure 6). Therefore a hybrid-mRNA of the coding 
region of the firefly-luciferase and the 3’UTR of CCL20 is transcribed and the 
interaction of miRNAs with the 3’UTR of CCL20 can be measured by firefly-luciferase 
activity. The reporter vector contains another luciferase gene coding for Renilla-
luciferase (hRLuc) whose expression is independent from the investigated target 
sequence and served for the normalization for general expression and transfection 
differences. In addition the vector contains a Kanamycin/Neomycin resistance gene 
required for cloning of the vector. 
 
 
Figure 6 Luciferase Reporter Vector 
The reporter vector contains two luciferase genes. The firefly luciferase gene is fused to the 3’UTR of 
CCL20. Furthermore, the vector contains a pUC origin and a Kanamycin/Neomycin resistance gene 
for amplification. hLuc = Firefly luciferase gene; hRLuc = Renilla luciferase gene, pA = poly Adenin 
signal; Sv40 and CMV = promoter sequences; pUC Ori = origin of replication; Kan/Neomycin = 
Resistence genes; 3’UTR CCL20 = untranslated region of CCL20 gene 
 
 
3.1.11.2 Reporter construct containing a mutated 3’UTR of CCL20 
 
In order to demonstrate that the interaction of miRNAs with the 3’UTR of CCL20 is 
specific the 3’UTR of CCL20 in the expression vector was mutated at the binding site 
of the according miRNA (Figure 7). 
 
Material and Methods 40 
 
Figure 7 Luciferase Reporter Vector with mutated 3’UTR of CCL20 
Two nucleotides in the predicted target site of miR-21 were mutated in the 3’UTR of CCL20. hLuc = 
Firefly luciferase gene; hRLuc = Renilla luciferase gene, pA = poly Adenin signal; Sv40 and CMV = 
promoter sequences; pUC Ori = origin of replication; Kan/Neomycin = Resistence genes; 3’UTR 
CCL20 Mut = mutated untranslated region of CCL20 gene 
 
 
3.1.11.3 Control vector 
 
As a negative control vector the pEZX-MT01 vector form GeneCopoeiaTM was used 
which contain no 3’UTR dowstream of the Firefly-luciferase gene (Figure 8). Also in 
this vector a second firefly gene for the Renilla–firefly was available for expression 
and transfection normalization. A kanamycin/neomycin resistance gene served for 
vector cloning. 
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Figure 8 Luciferase Reporter Vector Control (without 3’UTR) 
hLuc = Firefly luciferase gene; hRLuc = Renilla luciferase gene, pA = poly Adenin signal; Sv40 and 
CMV = promoter sequences; pUC Ori = origin of replication; Kan/Neomycin = Resistence genes; 
3’UTR CCL20 Mut = mutated untranslated region of CCL20 gene 
 
 
3.1.12 Bacteria 
 
For amplification of vector DNA the competent Escherichia coli (E. coli) bacteria 
GC10 from Sigma-Aldrich® were used. 
During the mutagenesis procedure the ultracompetent bacteria XL10-Gold (contained 
in the QuikChange® II XL Site-Directed Mutagenesis Kit) were applied. 
 
 
3.2 Methods 
 
3.2.1 miRNA Target prediction programmes 
 
In order to identify miRNAs potentially interacting with the 3’UTR of CCL20 and 
therefore regulate its expression different online available target prediction 
programmes were applied using diverse input data (Table 4). 
 
 
 
 
Material and Methods 42 
Prediction Tool Input data 
TARGETSCANHUMAN 4.2 
(http://www.targetscan.org/vert_42) TargetGene Name 
MICRORNA.ORG 
(http://www.mircoRNA.org) TargetGene Name 
PICTAR 
(www./pictar.mdc-berlin.de/cgi-bin/PicTar_vertebrate.cgi) TargetGene Name 
EBI MICROCOSM TARGETS 
(http://www.ebi.ac.uk/enrightsrv/microcosm/htdocs/targets/v5) TargetGene Name 
MIRDB 
(http://mirdb.org/miRDB/) TargetGene Name 
PITA 
(http://genie.weizmann.ac.il/pubs/mir07/mir07_prediction.html) TargetGene AND microRNA Name 
RNA22 
(http://cbcsrv.watson.ibm.com/rna22.html) 
Target 3'UTR sequence AND microRNA 
sequence  
TAREF 
(http://scbb.ihbt.res.in/TAREF/index2.html) Target 3'UTR sequence 
MICROINSPECTOR 
(http://bioinfo.uni-plovdiv.bg/microinspector/) 
Target 3'UTR sequence AND microRNA 
sequence 
STARMIR 
(http://sfold.wadsworth.org/cgi-bin/starmir.pl) 
Target 3'UTR sequence AND microRNA 
sequence 
EIMMO 
(http://www.mirz.unibas.ch/ElMMo2/) 
TargetGene sequence AND microRNA 
Name 
TARGETRANK 
(http://genes.mit.edu/targetrank/) microRNA Name 
Table 4 Overview of the applied Target Prediction Programmes 
 
 
Input Data: 
 
Target Gene Name:  CCL20 
miRNA Name:  hsa-miR-21 or hsa-miR-145 
miRNA sequence:  5'_uagcuuaucagacugauguuga_3' (hsa-miR-21) 
    5'_guccaguuuucccaggaaucccu_3' (hsa-miR-145) 
Target 3’UTR sequence: CCL20: 
5’_AAACTGTGGCTTTTCTGGAATGGAATTGGACATAGCCCAAGAACAGAAAGAACCTTGCTG
GGGTTGGAGGTTTCACTTGCACATCATGGAGGGTTTAGTGCTTATCTAATTTGTGCCTCACT
GGACTTGTCCAATTAATGAAGTTGATTCATATTGCATCATAGTTTGCTTTGTTTAAGCATCA
CATTAAAGTTAAACTGTATTTTATGTTATTTATAGCTGTAGGTTTTCTGTGTTTAGCTATTT
AATACTAATTTTCCATAAGCTATTTTGGTTTAGTGCAAAGTATAAAATTATATTTGGGGGGG
AATAAGATTATATGGACTTTCTTGCAAGCAACAAGCTATTTTTTAAAAAAACTATTTAACAT
TCTTTTGTTTATATTGTTTTGTCTCCTAAATTGTTGTAATTGCATTATAAAATAAGAAAAAC
ATTAATAAGACAAATAT_3’ 
TargetGene sequence: NCBI Reference sequence NM_004591 
 
 
3.2.2 Quality of target prediction programmes 
 
The quality of the different target prediction programmes was assessed by comparing 
the number of correct predicted miRNA target gene interactions with the 
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combinations of features applied by the diverse programmes. 
 
 
3.2.3 Bacterial-Techniques 
 
3.2.3.1 Transformation and storage of bacteria 
 
For the amplification of plasmids competent E. coli GC10 bacteria were transformed 
with the according plasmid and cultivated. The applied vector plasmids were 
produced by GeneCopoeiaTM and provided dried on a “filter plate”. Dried vector DNA 
was resolved in 50 µl of TE-buffer pH 8.0 for 1 h. Afterwards 50 µl of GC10 
competent bacteria were thawn in 15 ml tubes on ice, 5 µl of vector DNA solution 
were added and incubated for 30 min on ice. Then competent bacteria were heat 
shocked for 45 sec at 42 °C in a water bath. Directly after the heat shock 450 µl of 
SOC-medium were added and the bacteria were aerobically incubated for 1 h at 37 
°C on an incubator shaker at 250 RPM. Accordingly the transformed bacteria were 
spread on two LB-Agarplates containing 50 µg/ml Kanamycin and incubated at 37°C 
over night. Transformation success was checked by optical assessment of the 
agarplates for colonies. For short-term storage of bacteria the agar plates were 
sealed with Parafilm® and retained at 4 °C in a refrigerator. 
 
 
3.2.3.2 Small-scale isolation of plasmid-DNA 
 
In order to analyze the DNA sequence of transformed plasmid-DNA small-scale 
isolation was performed using the QIAGEN Plasmid Mini Kit. The base for this kind of 
plasmid purification is the alkaline lysis followed by plasmid-DNA binding to anion-
exchange resin columns which bind plasmid-DNA under appropriate low-salt and pH 
conditions and thereby allows the detachment of proteins and other low molecular 
contaminants by different washing buffers (medium salt). At the end the plasmid-DNA 
is eluted with an elution buffer (high salt). 
For plasmid isolation 7 ml LB medium were inoculated with the desired bacterial 
clone and incubated at 37 °C on a shaker incubator over night. The next day 3 ml of 
the culture were transferred to two tubes and centrifuged at 6000 x g for 15 min. The 
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supernatants were discarded and the pellets were resuspended in 300 µl 
resuspension buffer P1 which contained RNAse A. The two resuspended pellets were 
mixed and 300 µl of lysis buffer P2 were added, mixed by inversion of the tube and 
then incubated for 5 min. Subsequently, 300 µl of precipitation buffer P3 were added 
and mixed thoroughly in order to precipitate cell debris, proteins and genomic DNA. 
The lysat was incubated for 5 min on ice and then centrifuged at 14000 RPM and 4 
°C for 10 min. During this step the QIAGEN-columns were equilibrated with 1 ml QBT 
buffer. After centrifugation the supernatant was loaded to the equilibrated column and 
due to the low salt concentration and pH-conditions the plasmid-DNA bound to the 
matrix. Following two wash steps with 800 µl of QC-buffer the plasmid-DNA was 
eluted with 800 µl of QF-buffer. Subsequently 560 µl of Isopropanol were added to 
precipitate the DNA and after mixing the sample was centrifuged at 14000 RPM at 
4°C for 30 min. Afterward the supernatant was discarded and the plasmid-DNA was 
washed with 1 ml of 70 % ethanol. The sample was centrifuged at 14000 RPM at RT 
for 10 min and the supernatant was discarded. After 5 to 10 min of drying the DNA 
pellet was resuspended in 20 µl of HPLC-H2O and the concentration was 
photometrically determined. Until further processing the plasmid-DNA was stored at -
20 °C. 
 
 
3.2.3.3 Large-scale isolation of plasmid-DNA 
 
In order to obtain a large amount of plasmid-DNA of high quality the GenEluteTM HP 
Plasmid Maxiprep Kit from Sigma-Aldrich® (Taufkirchen, Germany) was used. The 
base of this method is a lysis of the grown bacteria with a SDS containing alkaline 
buffer to set the plasmid-DNA free which is subsequently purified via a silica-
membrane. For bacterial culture 500 ml of LB media containing 100 µg/ml 
Kanamycin were inoculated with 1 ml of miniprep bacteria and incubated over night 
at 37 °C in an incubator shaker. The bacterial culture was centrifuged at 5000 x g for 
10 min and the supernatant was discarded. The bacterial pellet was resuspended by 
pipetting up and down in 12 ml of resuspension buffer which contained RNAse A and 
transferred to a 50 ml tube. After addition of 12 ml lysis buffer the mixture was 
agitated by inverting the tube several times and then incubated for 5 min at RT. The 
SDS in the buffer destroyed the bacterial cell membrane and thereby lysed the 
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bacterial cells and released cellular components including the vector DNA. 
Accordingly, 12 ml of neutralization buffer were added and carefully mixed by 
inverting the tube several times in order to precipitate proteins, lipids, chromosomal 
DNA and cell debries. After addition of 9 ml binding buffer the mixture was 
transferred into a filter syringe and incubated for 5 min. During this incubation step 12 
ml of column preparation solution were pipetted to the GenElute HP column and 
subsequently centrifuged for 2 min at 3000 x g. The flow through was discarded and 
one half of the bacterial lysate was added to the column through the filter syringe. 
After centrifugation for 2 min at 3000 x g the rest of the bacterial lysate was added 
and centrifuged in the same way. Due to the specific salt- and pH-conditions in the 
binding buffer the plasmid-DNA was bound to the matrix of the column whereas all 
other bacterial components passed the column. After two wash steps with wash 
buffer the plasmid-DNA was eluted with 3 ml of elution buffer pH 8.5 and 
centrifugation at 3000 x g for 5 min. The concentration of the isolated plasmid-DNA 
was determined photometrically at 260 nm. 
 
 
3.2.4 Cell culture techniques 
 
3.2.4.1 Cultivation of permanent adherent human cell lines 
 
Permanent human cell line cells were cultured in cell culture flasks (25 cm2) as 
monolayer. The morphology and viability of the cells was checked every day. The 
cultivation was performed under standard conditions in a humidified incubator at 37 
°C with 5 % CO2 or without CO2 supplementation dependent on used cell line. All 
cultivation steps were carried out under the laminar flow with sterile reagents. 
In the present thesis the permanent human cell lines HT29, Caco-2, SW480, SW620 
and 293T were used. 
 
 
3.2.4.1.1 HT29 cell line 
 
The CRC cell line HT29 was maintained in McCoy’s + GlutaMAX™ medium 
supplemented with 10 % (v/v) Fetal Bovine Serum and 1 % (v/v) 
Penicillin/Streptomycin. Cells were incubated at 37 °C and 5 % CO2 in a humidified 
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incubator. HT29 cells were splitted 1:6 two times a week. 
 
 
3.2.4.1.2 Caco-2 cell line 
 
The CRC cell line Caco-2 was cultivated in MEM + GlutaMAX™ medium comprising 
10 % (v/v) Fetal Bovine Serum and 1 % (v/v) Penicillin/Streptomycin and incubated at 
37 °C and 5 % CO2. Caco-2 cells were splitted 1:4 two times a week. 
 
 
3.2.4.1.3 SW480 and SW620 cell lines 
 
The CRC cell lines SW480 and SW620 were grown in Leibovitzs L-15, GlutaMAX™ 
medium comprising 10 % (v/v) Fetal Bovine Serum and 1 % (v/v) 
Penicillin/Streptomycin. Cell lines were incubated in a humdified incubator at 37 °C 
without CO2 supplementation. SW480 and SW620 were splitted 1:6 two times a 
week. 
 
 
3.2.4.1.4 293T cell line 
 
The human kidney epithelial cell line 293T was cultivated in DMEM + GlutaMAX™ 
medium comprising 10 % (v/v) Fetal Bovine Serum and 1 % (v/v) 
Penicillin/Streptomycin. Cells were incubated at 37 °C and 5 % CO2. 293T cells were 
splitted 1:10 two times a week. 
 
 
3.2.4.2 Thawing of adherent cell lines 
 
Stocks of the different cell lines were stored in a cryocontainer at -170 °C in liquid 
nitrogene. For thawing of cells 9 ml of prewarmed medium were pipetted into a round 
bottom tube and cells were taken from the liquid nitrogene container. Subsequently 
the cells were thawed in a waterbath transferred to the prewarmed medium and 
centrifuged for 5 min at 1000 RPM to get rid of the DMSO. After centrifugation the 
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supernatant was discarded and cells were resuspended in 1 ml medium. Cell 
suspension was transferred to a cell culture flask comprising 5 ml of medium. The 
medium was changed after 24 h of incubation. 
 
 
3.2.4.3 Splitting of adherent cells 
 
The splitting of the different cell lines was performed according to the proliferative 
and metabolistic condition of the cells. According to the confluency of the cells either 
the medium was renewed or the cells were splitted. Normally splitting was conducted 
when the confluence of the monolayer was around 80-90 %. Therefore the medium 
was detached and the cell monolayer was rinsed with 5 ml of PBS to remove 
remaining medium. Afterwards 1 ml Trypsin/EDTA was added to the cell layer and 
incubated for 5 min at 37 °C in order to detach the cells from the flask. Trypsin was 
inactivated by the addition of serum-containing medium and the cell suspension was 
transferred to a round bottom tube. After the cell suspension was centrifuged for 5 
min at 1000 RPM the supernatant was removed and the cell pellet was resuspended 
in 1 ml of medium. Subsequently, the cells were splitted in the according relation 
(HT29 1:6; Caco-2 1:4; SW480 1:6; SW620 1:6; 293T 1:10), transferred into a cell 
culture flask containing fresh medium and incubated at the according conditions. 
 
 
3.2.4.4 Counting of cells 
 
In order to determine the number of cells approximately 20 µl of cell suspension were 
applicted to a Neubauer counting chamber. Subsequently, the cells were counted 
under the microscope and the cell number was calculated. 
 
 
3.2.4.5 Transfection of eukaryotic cells 
 
The process of transfection is described as the insertion of exogeneous nucleic acids 
into eucaryotic cells analog to transformation in bacterial cells. There are different 
techiques for transfection but in the present thesis the transfection was performed by 
Material and Methods 48 
cationic lipids. For the lipofection synthetic cationic lipids were used that form 
unilamellar vesicles. These liposomes can aggregate spontaneously with negative 
charged phosphate groups in nucleic acids by ionic interactions with the positively 
charged parts of the cationic lipids. These aggregates have the potential to fuse with 
the cellular membrane of eucaryotic cells and thereby insert the bound nucleic acid 
into the cytoplasm of the cell [Felgner et al., 1987]. For optimization of liposome 
formation and membrane fusion the cationic lipids can be used either alone or with 
uncharged lipids [Chesnoy et al., 2000]. 
For the transfection of the cell lines applied in the present thesis the transfection 
reagents LipofectamineTM
 
(293T), DharmaFECT® (HT29 and Caco-2) and 
HiPerFect® (SW480 and SW620) were used. 
 
 
3.2.4.5.1 Co-transfection with LipofectamineTM 
 
The co-transfection with LipofectamineTM was performed in 24 well cell culture 
multiwell plates. One day before transfection cells were seeded (5 x 104 for 293T and 
8 x 104 for HT29) in 800 µl of medium per well and grown over night. For transfection 
50 pmoles (293T) or 75 pmoles (HT29) of Pre-miRTM miRNA Precursor (Ambion® 
Life Technologies) or Pre-miRTM Negative Control #1 (Ambion® Life Technologies) 
respectively and 50 ng of the luciferase reporter vector DNA were diluted in OPTI-
MEM® I Medium to a final volume of 50 µl. In another tube 1 µl (293T) or 2 µl (HT29) 
LipofectamineTM were diluted in OPTI-MEM® I Medium to a final volume of 50 µl. 
After incubation for 5 min the contents of the two tubes were mixed and incubated for 
further 20 min at RT. The medium on the cells was changed to 800 µl of medium 
without serum and Pen/strep and subsequently 100 µl of transfection mixture per well 
were added dropwise to the cells. The cells were cultivated at 37 °C and 5 % CO2 for 
48 h and then collected for Luciferase-reporter assay. 
 
 
3.2.4.5.2 Transfection with DharmaFECT® 
 
For transfection of the adherent growing cell lines HT29 and Caco-2 one day before 
transfection the cells were seeded. Per well of a 6 well plate 5 x 105 cells were 
adopted in 2.5 ml medium to reach a confluency of around 60 % at the day of 
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transfection. In the first tube 200 pmoles of Pre-miRTM miRNA Precursor were diluted 
in OPTI-MEM® I medium to a final volume of 200 µl. In another tube 6 µl of 
DharmaFECT® were also diluted in OPTI-MEM® I medium to a final volume of 200 
µl. The two tubes were incubated apart for 5 min and then mixed with each other by 
gentle vortexing. Afterwards the mixture was incubated for 20 min at RT and the 
medium on the cells was changed to 1.6 ml of medium without serum and Pen/Strep. 
Past incubation, per well 400 µl of the transfection mixture were dropwise added to 
the cells. The cells were incubated for 48 h at 37 °C and 5 % CO2 in an incubator and 
then prepared either for RNA isolation or protein isolation. 
 
 
3.2.4.5.3 Transfection with HiPerFect 
 
One day before transfection 5 x 105 cells per well of the adherent cell lines SW480 
and SW620 were seeded in a 6 well plate in order to reach a confluency of around 60 
% at the day of transfection. For transfection 100 pmoles of Pre-miRTM miRNA 
Precursor were mixed with OPTI-MEM® I medium before 12 µl of HiPerFect were 
added to a final volume of 400 µl. Subsequently, the samples were incubated for 10 
min to allow formation of transfection complexes. The growth medium on the cells 
was changed to 1.6 ml of medium without serum and Pen/Strep and accordingly 400 
µl transfection mixture per well were added dropwise to the cells. The cells were 
incubated at 37 °C and 5 % CO2 for further 48 h. 
 
 
3.2.4.6 Cryoconservation of cell lines 
 
Cells were cryoconserved according to a standard protocol. Thereby the cells were 
detached as done for splitting procedure and counted subsequently. After a 
centrifugation step the cells were resuspended in DMSO and transferred to 
cryotubes. The cells were kept at -80 °C over night and then transferred to -170 °C in 
liquid nitrogen for longterm storage.  
 
 
 
Material and Methods 50 
3.2.5 Luciferase-Assay 
 
The luciferase-assay is a kind of a reportergene-assay which enables investigations 
on the expression of a specific target gene as well as cellulare processes. Key 
feature of this assay is the capacity of the Firefly- and Renilla-luciferases to 
transubstantiate luciferin in the presence of oxygen, ATP and Mg2+ or 
Coelenterazine, respectively, to light. A quantitative evaluation of the luciferase 
reportergene-assay is possible because the emitted light is proportional to the 
amount of luciferase expressed. For investigations on miRNA-target gene 
interactions the 3’UTR of the target gene is cloned downstream of the Firefly-
luciferase gene so that the interaction of the according miRNAs with the 3’UTR 
influences Firefly-luciferase expression. 
The applied Dual-Luciferase® Reporter Assay from Promega allows the detection of 
Firefly-luciferase and Renilla-luciferase activity in one single assay. In the first step 
the activity of the Firefly-luciferase is detected using a substrate specific for this kind 
of luciferase: Luciferase Assay Reagent II (LARII). After measurement of the emitted 
light the activity of Firefly-luciferase is blocked and the activity of Renilla-luciferase is 
started by addition of the Stop & Glo® substrate. 
In the present thesis a reporter construct from GeneCopoeiaTM was used which 
contains the 3’UTR of CCL20. A reporter construct, which contains no 3’UTR 
(GeneCopoeiaTM), served as control. In the first step 5 x 104 293T cells per well or 8 x 
104 HT29 cells per well were seeded in 24 well plates. The following day the cells 
were co-transfected with the according reporter constructs and Pre-miRTM miRNA 
Precursor (as described 3.2.4.5.1). After 48 h the cells were lysed in 200 µl (293T) or 
100 µl (HT29) of 1 x passive lysis buffer (PLB) for 25 min on a shaker. For 
measurement of the 293T lysate the lysates were further pre-diluted 1:50 in 1 x PLB 
whereas the HT29 lysates kept undiluted. After 50 µl of LARII are dispensed in 
luminometer tubes 10 µl of cell lysate was added and the light emission was 
measured for 10 sec. Subsequently, 50 µl of Stop & Glo® substrate were added and 
the light emission was again detected for 10 sec. For evaluation, the activity of the 
Firefly-luciferase was normalized to the Renilla-luciferase activity of the same sample 
and the samples to be compared were related to each other. 
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3.2.6 Site-directed Mutagenesis 
 
For functional validation of the 3’UTR of CCL20 as a target of the investigated miRNA 
the predicted target sequence was mutated with the help of the QuikChange® II XL 
Site-Directed Mutagenesis Kit. This kit was optimized for the site-directed 
mutagenesis of sequences in big vector constructs (8-14 kb). The according mutation 
was introduced using specifically designed primers (as described 3.1.6). As central 
step the mutagenic replication of complementary plasmid-DNA strands was carried 
out with highest accuracy using the PfuUltra HF DNA polymerase. After replication of 
mutated plasmid-DNA the parental DNA was digested by Dpn1 (1 µl) for 1 h at 37 °C. 
The endonuclease Dpn1 is an enzyme which specifically digests methylated DNA 
molecules. Therefore the methylated parental plasmid-DNA becomes digested and 
the new amplificated, non-methylated mutated DNA-strands remain intact. The 
reaction mixture for the PCR is depicted in Table 5 and the according PCR 
programme is described in Table 6. 
 
Component Amount / volume 
10 x reaction buffer 5 µl 
dsDNA template 10 ng 
forward primer 125 ng 
reverse primer 125 ng 
dNTP mix 1 µl 
QuickSolution 3 µl 
ddH2O Adjust to final volume of 50 µl 
PfuUltra HF DNA Polymerase 1 µl 
Table 5 Pipetting scheme for Site-directed mutagenesis 
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Temperatur Time / Duration 
95 °C 1 min 
95 °C 50 sek 
60 °C 50 sek 
68 °C 8.5 min (1 min / kb) 
68 °C 7 min 
4 °C  
Table 6 Cycler programme for Site-directed mutagenesis 
 
After digestion of the PCR products with Dpn1 ultracompetent XL-Gold® cells were 
transformed with 2 µl of the DNA. Therefore the ultracompetent cells were thawed on 
ice and 45 µl of bacteria were dispensed in pre-chilled tubes. Afterwards 2 µl of ß-
Mercaptoethanol (ß-ME) were added to the cells and incubated on ice for 10 min. 
Subsequently, 2µl of the DNA were pipetted to the cells and the mixture was 
incubated on ice for 30 min. Then the cells were heat shocked in a waterbath at 42 
°C for 30 sec and incubated on ice for further 2 min. After addition of 500 µl 
preheated SOC medium (SOC Outgrowth Medium) cells were incubated at 37 °C on 
a shaker for 1 h. Then the cells were spread on LB-agar plates containing kanamycin 
and incubated in an incubator at 37 °C over night. A suspension culture was 
inoculated in 7 ml LB-medium containing kanamycin. 
As mutation control the QuikChange® II XL Site-Directed Mutagenesis Kit provided 
the control plasmid (pWhitescript plasmid with according Primers) and as 
transformation control the control plasmid (pUC18) was used. The mutation was 
validated by DNA sequencing by the company GATC (Konstanz, Germany). The 
interaction of the according miRNA with the mutated construct was investigated with 
the luciferase assay. 
 
 
3.2.7 RNA Technologies 
 
3.2.7.1 Isolation of total RNA from tissue samples 
 
For isolation of total RNA comprising miRNAs from human tissue samples of patients 
with CRC the mirVanaTM miRNA Isolations Kit from Ambion® Life Technologies was 
18 x 
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applied. The method is based on the organic extraction and immobilisation of RNA to 
glass-fiber filters in order to purify total RNA. In the first step 700 µl Lysis/Binding 
buffer is pre-dispensed in a round bottom tube. Afterwards 60 mg of tissue were 
weighed without thawing, added to the lysis buffer and homogenized using the Ultra-
Turrax ® T8. Subsequently, the homogenate was transferred to a 2 ml tube, 70 µl of 
Homogenate Additive were added and incubated on ice for 10 min. Adjacently, 700 µl 
of Acid-Phenol:Chloroform were pipetted to the homogenate and vortexed for 60 sec. 
For phase separation of the organic and aqueous phase the mixture was centrifuged 
for 20 min at 10000 x g at RT. The aqueous solution which contained the RNA was 
taken off, 1.25 volumes of 100 % Ethanol were added and mixed. Subsequently, 700 
µl of the mixture were applied to a filter column and centrifuged for 20 sec at 10000 x 
g. The flow-through was discarded and the last step was repeated until the whole 
lysate got loaded on the column. After the complete lysate was loaded three wash 
steps were done. Therefore 700 µl of Wash Solution 1 were added to the column, 
centrifuged for 20 sec at 10000 x g at RT and the flow-through was discarded. For 
the second and third wash step 500 µl of Wash Solution 2/3 were used followed by 
centrifugation. Another centrifugation step for 1 min at 10000 x g was done to get rid 
of remaining wash buffer. For the elution of the RNA from the filter the column was 
placed into a new 1.5 ml tube, 50 µl of 95 °C warm nuclease-free water were added 
and centrifuged for 30 sec at maximal speed. After elution the column was discarded 
and the concentration and purity of RNA was determined by photometric 
measurement. The isolated RNA was stored at -80 °C until further processing. 
 
 
3.2.7.2 Isolation of RNA from cultivated cells 
 
Isolation of RNA from cultivated cell lines was performed using the RNeasy® Mini Kit 
from Qiagen. The method is based on two technologies: the specific binding of RNA 
to a silica-membrane under specific buffer conditions and the microspin technology. 
In the first step 5 x 105 cells per well were seeded in 6 well plates. The following day 
cells were transfected with Pre-miRTM miRNA Precursor (described in 3.2.4.5.2 or 
3.2.4.5.3). After 48 h the cells were harvested and the RNA was isolated. Therefore 
the growth medium was removed and the cells were washed once with PBS. 
Subsequently, the cells were lysed with RLT buffer (part of the kit) which was 
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replenished with β-ME. β-ME irreversibly denaturates RNAses which are released 
during the lysis of cells. In combination with the Guanidiniumisothiocyanat contained 
in the RLT buffer all RNAses were completely inactivated. Past an incubation step of 
2 min, the lysate was pipetted to a 2 ml tube and 600 µl of 70 % ethanol were added 
and mixed. The addition of ethanol optimizes the binding condition for the RNA to the 
silica-membrane. Adjacently, the ethanol-lysate mixture was added to the filter-
column and centrifuged for 20 sec at 10000 RPM. The flow-through was discarded 
and in the following four wash steps proteins, salts and cell elements were removed. 
In the first wash step 700 µl of RW1-buffer were applied and centrifuged for 20 sec at 
10000 RPM. The next three wash steps were performed each with 500 µl of RPE-
buffer which was complemented with ethanol. After each wash step the column was 
centrifuged for 20 sec at 10000 RPM and the flow-through was discarded. An 
additional centrifugation step of 1 min at 14000 RPM was done after the last wash 
step to get rid of remaining wash buffer. Subsequently, the column was transferred to 
a new 1.5 ml tube and the RNA was eluted from the silica-membrane using 35 µl of 
RNAse-free HPLC-H2O. After incubation for 1 min the column was centrifuged for 1 
min at 10000 RPM to drain the column. The isolated RNA now resided in the tube. 
Quality and amount of RNA was analyzed using a photometer. Until further 
application the RNA was stored at -80 °C. 
 
 
3.2.8 Synthesis of cDNA 
 
In order to quantify the gene expression in a quantitative real-time PCR (qRT-PCR) 
the miRNA and RNA respectively have to be reverse transcribed to cDNA. The cDNA 
was either directly applied for further applications or stored at -20 °C. 
 
 
3.2.8.1 Synthesis of cDNA of specific miRNAs 
 
The reverse transcription of miRNAs was performed using the TaqMan® MicroRNA 
Reverse Transcription Kit and the 5 x Reverse Transcription-Primer of the according 
MicroRNA Assay (Applied Biosystems). For cDNA synthesis 10 ng of total RNA was 
applied. Therefore the concentration of RNA was measured after thawing, a dilution 
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of 1:100 was done and the volume containing 10 ng RNA was calculated. 
Subsequently, the Mastermix was prepared (Table 7) and 7 µl per reaction were pre-
dispensed in each PCR-tube. The amount of RNA which contains 10 ng was added 
and filled up with HPLC-H2O to a final volume of 12 µl. Last 3 µl of 5 x Reverse 
Transcription-Primer were pipetted to each tube and the reverse transcription was 
carried out in a thermocycler with the following programme (Table 8). 
 
Component Amount / volume 
dNTPs 0.15 µl 
Reverse Transkription buffer 1.50 µl 
Reverse Transkriptase 1.00 µl 
RNAse-Inhibitor 0.19 µl 
Nuklease free H2O 4.16 µl 
Table 7 Pipetting scheme for cDNA-synthesis of miRNAs 
 
Temperature Time / Duration 
16 °C 30 min 
45 °C 30 min 
85 °C 5 min 
  4 °C  
Table 8 Temperature scheme for cDNA-synthesis of miRNAs 
 
 
3.2.8.2 Synthesis of cDNA of mRNAs 
 
The synthesis of cDNA from mRNAs was performed using the High Capacity cDNA 
Reverse Transcription Kit. Thereby all mRNAs present in the RNA sample were 
reverse transcribed to cDNAs by the use of random primers. At first the concentration 
of the RNA was measured after thawing and the volume containing 1 µg of RNA was 
calculated. The calculated volume was pipetted into a PCR-tube and HPLC-H2O was 
added to a final volume of 17.5 µl. The Mastermix was combined according to Table 
9. In each tube 7.5 µl of Mastermix was added. In addition a negative control was 
performed containing no RNA in order to detect possible contaminations. The tubes 
were processed in a thermocycler according to the following programme (Table 10). 
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Component Amount / volume 
Reverse Transcription Buffer 2.5 µl 
dNTPs 1 µl 
Random Primer 2.5 µl 
Reverse Transkrictase 1.5 µl 
Table 9 Pipetting scheme for cDNA-synthesis of mRNAs 
 
Temperature Time / Duration 
25 °C 10 min 
37 °C 120 min 
85 °C 5 sek 
  4 °C  
Table 10 Temperature scheme for cDNA-synthesis of mRNAs 
 
After the PCR each sample contained a total volume of 25 µl with a concentration of 
40 ng/µl. For further application the samples were diluted 1:1 with HPLC-H2O to 
obtain a concentration of 20 ng/µl. 
 
 
3.2.9 Quantitative real-time-PCR 
 
The qRT-PCR is a technique to detect the expression levels of miRNAs and mRNAs, 
respectively. This method is based on a conventional PCR but in addition enables 
the quantification of the amplified cDNA in real time. After every PCR-cycle the 
fluorescence signal is measured which is equivalent to the cDNA quantity. In the 
present thesis TaqManTM-probes complementary to the sequence of the investigated 
cDNA were applied. These probes consist of oligonucleotides with a reporter-
fluorescence dye at one end and a fluorescence-quencher at the other end. In this 
state the probe does not emit fluorescence because of the adjacency of fluorescence 
dye and quencher. Thereby the fluorescence energy of the dye is transfered to the 
quencher which in turn emits light not measured (Figure 9 A). During the PCR cycles 
the probe hybridizes with the complementary DNA-strand. As the applied polymerase 
also have a 5’-3’ exonuclease activity the probe becomes abolished when the 
polymerase reaches the point where the probe has bound (Figure 9 A). 
Subsequently, the probe is degraded and the fluorescence dye becomes locally 
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separated from the quencher and measurable fluorescence is emitted (Figure 9 B 
and C). The fluorescence intensity increases proportional with the amount of 
amplificated PCR-product. This allows a precise quantification of gene expression 
[Bustin, 2000]. 
 
 
Figure 9 Theory of Taqman Assay. 
P = polmerase; R = Reporter dye; Q = quencher 
 
The quantified target genes were normalized to endogenous housekeeping genes 
during the gene expression analysis. These housekeeping genes are characterized 
by a relatively constant expression level in all tissue types and under all conditions 
investigated. Therefore in theory no significant change in expression should be 
visible between normal unaffected tissue and pathologically modified tissue. 
Nevertheless, in practice it was shown that certain expression variability is present. 
Rubie et al. indicated in a comparative study of different commonly used house 
keeping genes that the consistency of the expression of such house keeping genes 
could not be adopted in general among different tissue types or pathological 
modifications [Rubie et al., 2005]. According to the results of this study the 
housekeeping genes were chosen. 
The analysis of the qRT-PCR was done using either the absolute standard curve 
method or the ∆∆CT (Cycle Threshold)-method for the quantification of differences in 
expression levels between the samples. 
For the standard curve method the expression of the target gene was determined 
with a standard curve applied on the same plate. Therefore known concentrations of 
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the target gene in different concentrations were amplified on the same plate. The 
known concentrations of the standard points were plotted against the resulting CT -
values and in turn the concentrations of the investigated samples can be read from 
the slope of the standard curve [Holzapfel et al., 2007]. 
The ∆∆CT -method is used for relative quantification and gives no assertion on the 
copy number of the investigated cDNA. Such an assertion is sufficient when 
comparison of two groups (normal and cancerous) is performed. For this method the 
CT -values of the target gene and the constantly expressed housekeeping gene are 
substracted to get ∆CT -values and then the ∆CT -values of the two groups are 
substracted to get the ∆∆CT -value. In order to receive the expression disparity 
between the two groups the ∆∆CT -value is adopted to the formula 2 -∆∆CT. 
 
 
3.2.9.1 qRT-PCR for miRNA expression analysis 
 
In order to investigate the expression profiles of different miRNAs in samples of CRC 
patients in addition to the target-miRNAs the endogeneous control gene RNU48 was 
applied. RNU48 belong to the so called small nucleolar RNA (snoRNA) family and 
has a function in the 2’ O-Ribose methylation of its target RNAs [Galardi et al., 2002]. 
In a study performed by Applied Biosystems and other studies it was demonstrated 
that snoRNAs suits as endogeneous control gene for studies on the expression of 
miRNAs [Wong et al., 2007; Chang et al. 2010]. 
 
In the first step of qRT-PCR a Mastermix was prepared containing the miRNA 
specific TaqMan® Gene Expression Assay, TaqMan® Universal Master Mix II and 
HPLC-H2O (Table 11). Subsequently, 2.79 µl of the according miRNA-cDNA was pre-
dispensed in a tube and filled up with 39.21 µl of Mastermix to a final volume of 42 µl. 
The samples were vortexed, centrifuged and pipetted to MicroAmp® Optical 96-Well 
reaction plates in duplicates. Afterwards, the plate was sealed with MicroAmp® 96-
Well Optical Adhesive Film and run in a Sequence Detection System, 7900HT ABI 
PRISM with the cycling programme in Table 12. 
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Component Amount / Volume 
(per duplicate sample) 
TaqMan® Gene Expression Assay 2.1 µl 
TaqMan® Universal Master Mix II 21 µl 
HPLC-H2O 16.11 µl 
Table 11 Pipetting scheme of qRT-PCR Mastermix 
 
Enzym activation PCR 
Cycles (40 cycles) 
Step HOLD Denature Annealing / Elongation 
Temperature 95 °C 95 °C 60 °C 
Time / Duration 10 min 15 sec 60 sec 
Table 12 Temperature cycles of qRT-PCR 
 
 
3.2.9.2 qRT-PCR for CCL20 mRNA expression analysis 
 
For the investigations on expression profiles of the chemokine CCL20 in samples 
from CRC patients the housekeeping gene b2m was used as reference gene. For the 
CCL20 gene expression assay performed in tissue samples a standard curve was 
used. The Mastermix for the standard curve was pipetted as indicated (Table 13). 
 
Component Amount / volume 
(per duplicate sample) 
TaqMan® Gene Expression Assay 2.1 µl 
TaqMan® Universal Master Mix II 21 µl 
Table 13 Pipetting scheme for the standard curve Mastermix of qRT-PCR 
 
Subsequently, the appropriate amount of cDNA was pre-dispensed into a tube and 
HPLC-H2O was added to a final volume of 18.9 µl (Table 14). Then 23.1 µl of 
standard curve Mastermix was added.  
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 50 ng 20 ng 10 ng 1 ng 0.1 ng 
cDNA 5.25 µl 2.1 µl 1.05 µl 1.05 µl 1.05 µl  
Predilution X X X 1:10 1:100 
HPLC-H2O 13.65 µl 16.80 µl 17.85 µl 17.85 µl 17.85 µl 
Table 14 Pipetting scheme for cDNA dilutions of the standard curve 
 
In the next step the Mastermix for the investigated samples was prepared as follows 
(Table 15). For reaction preparation 2.1 µl of according cDNA was pre-dispensed in a 
tube und subsequently 39.9 µl of Mastermix were added to each tube to a final 
volume of 42 µl. The samples for the qRT-PCR were vortexed gently, centrifuged to 
bring down and then pipetted in duplicates to a MicroAmp® Optical 96-Well reaction 
plate. The plates were sealed with MicroAmp® 96-Well Optical Adhesive Film and 
the samples were processed in a 7900HT ABI PRISM with the same cycling 
programme used for miRNA expression analysis (Table 12). 
 
Component Amount / volume 
(per duplicate sample) 
TaqMan® Gene Expression Assay 2.1 µl 
TaqMan® Universal Master Mix II 21 µl 
HPLC-H2O 16.8 µl 
Table 15 Pipetting scheme for the qRT – PCR Mastermix of investigated samples 
 
 
3.2.10 Protein technologies 
 
3.2.10.1 Isolation of protein 
 
Protein lysates were isolated from colorectal tissue samples and cultivated cell lines 
using RIPA-buffer. RIPA-buffer is a highly denaturating lysis buffer due to its 
ingredients Sodium deoxycholate and Sodium dodecyl sulfate. This buffer therefore 
allows the extraction of cytoplasmic, nuclear and membrane proteins. 
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3.2.10.1.1 Isolation of proteins from tissue samples 
 
For isolation of proteins from tissue samples 60 mg of tissue were transferred to a 
round bottom tube containing 1 ml of RIPA-buffer (as described in 3.1.7.2). 
Subsequently, the tissue was homogenized with the help of the Ultra-Turrax ® T8. 
For the control of total homogeneity and further break up of cell structures the round 
bottom tube was taken to an ultrasonic bath for 30 sec. After total homogeneity was 
reached the samples were transferred to a 1.5 ml tube and centrifuged for 10 min at 
13000 RPM and 4 °C. After the centrifugation step the supernatant containing the 
protein was aliquoted in two new 1.5 ml tubes and the pellet containing cell debris 
was discarded. Until further processing the protein lysates were stored at -20 °C: 
 
 
3.2.10.1.2 Isolation of proteins from cultivated cell lines 
 
Also for isolation of proteins from cultivated cell lines the RIPA-buffer was applied. At 
first 5 x 105 cells per well were seeded in a 6 well plate. The following day the cells 
were transfected with Pre-miRTM miRNA Precursor (as described in 3.2.4.5.2 or 
3.2.4.5.3). After incubation for further 48 h the growth medium was removed and the 
adherent cells were washed once with PBS. Afterwards 1 ml of RIPA-buffer were 
added to the cells for 5 min. The lysed cells were pipetted to a 1.5 ml tube and 
centrifuged for 10 min at 13000 RPM and 4 °C. Then protein containing supernatant 
was aliquoted in two new 1.5 ml tubes and stored at -20 °C until further processing. 
 
 
3.2.10.2 Determination of protein concentration using the BCA-assay 
 
In order to determine the protein concentration of the protein extracts the 
bicinchoninic acid protein assay (BCA)-method was applied. This method is based on 
the reduction of Cu2+-ions to Cu+-ions through proteins in an alkaline environment. 
Thereby the amount of produced Cu+-ions is proportional to the amount of protein in 
the solution. These monovalent copper ions form a purple coloured complex together 
with bicinchoninic acid. This colour complex can be detected photometrically at a 
wavelength of 562 nm. The absorption is proportional to the protein concentration in 
the according sample [Smith et al., 1985]. The absolute protein concentration can be 
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determined using standard-dilution series with known concentrations of Bovine 
Serum Albumin (BSA) in the range of 0 to 2 mg/ml. 
 
In the first step protein lysates were diluted with dd H2O. The lysates from tissue 
samples were used in a dilution of 1:5 and 1:10 whereas the cell lysates were used 
undiluted and in a dilution of 1:2. Then the dilutions for the standard series were 
prepared with BSA (Table 16). Subsequently, 10 µl per well of the standard dilutions 
or the samples were pipetted to a 96 well plate. In order to start the quantifiable 
reaction, proportional to protein concentration, a reagent containing 50 parts BCA 
and 1 part 4 % Copper (II) sulfate was prepared and 200 µl of this solution were 
added to each well. The 96 well plate was shaken for 30 sec and afterwards 
incubated in an incubator at 37 °C for 30 min. Thereafter, the absorption at a 
wavelength of 562 nm was measured. The absolute protein concentration was 
calculated according to the standard curve. 
 
Concentration of BSA-solution Contents 
2 mg/ml undiluted 
1.5 mg/ml 25 µl Aqua dest. + 75 µl BSA (2 mg/ml) 
1 mg/ml 50 µl Aqua dest. + 50 µl BSA (2 mg/ml) 
0.75 mg/ml 50 µl Aqua dest. + 50 µl BSA (1.5 mg/ml) 
0.5 mg/ml 50 µl Aqua dest. + 50 µl BSA (1 mg/ml) 
0.25 mg/ml 50 µl Aqua dest. + 50 µl BSA (0.5 mg/ml) 
0.125 mg/ml 50 µl Aqua dest. + 50 µl BSA (0.25 mg/ml) 
0.025 mg/ml 90 µl Aqua dest. + 10 µl BSA (0.25 mg/ml) 
Table 16 Pipetting scheme of standard-dilution series of BCA assay 
 
 
3.2.10.3 Enzyme-linked Immunosorbent Assay (ELISA) 
 
The ELISA is a method to quantitatively detect specific proteins in protein lysates. In 
the present thesis the principal of Sandwich-type ELISA was applied. Thereby two 
target protein specific antibodies are required: (I) a so called “Capture antibody” and 
(II) a different “Detection antibody”. These two antibodies have to bind to different 
epitops on the antigen to avoid reciprocal inhibition. In the first step of the assay a 96 
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well ELISA-plate is coated with the “Capture antibody” which means that it is bound 
to the bottom of the plate. After an adequate incubation time a saturation buffer is 
applied which saturates all non-specific binding sites and avoids undesirable binding 
to uncoated areas. Subsequently, the samples are applied to the plate and the 
according antigen is bound to the “Capture antibody” at the recognized epitope. In 
order to remove unbound antigens a washing step is applied. In the next step a 
biotinylated “Detection antibody” is added which binds to a different epitope of the 
antigen and thereby accumulates to an antibody-antigen-antibody-complex which is 
the reason for the designation “Sandwich-type” ELISA. With the help of a further 
wash step excessive “Detection antibody” is removed. Subsequently, streptavidin 
which is conjugated to the enzyme horseradish-peroxidase (HRP) is added. 
Streptavidin shows an affinity binding to biotin and increases thereby the sensitivity 
for small protein amounts. The antigen can be quantified through the transformation 
of a chromogenic substrate (Tetramethylbenzidin) specific for the according enzyme. 
Thereby a colorimetric reaction occurs which is stopped by addition of 2 M sulphuric 
acid (H2SO4). The quantification is performed by measuring the absorption at a 
wavelength of 450 nm in a photometer. As reference the wavelength is measured at 
562 nm. With the help of a standard curve consisting of known protein concentrations 
the content of the specific protein in each sample can be calculated. 
For the detection of CCL20 in human colorectal tissue samples and protein lysates 
from cultivated cell lines a specific ELISA DuoSet® from R&D Systems® was used. 
In the first step the 96 well ELISA plates were coated with mouse anti-human MIP-
3α/CCL20 “Capture antibody”. Therefore the antibody was diluted with PBS to a final 
concentration of 1 µg/ml. In each well 100 µl of the antibody solution were pipetted. 
The plate was sealed with adhesive film and incubated at 4 °C over night. The 
following day the plate was washed three times with washing buffer and then 200 µl 
of saturation buffer were added per well. The saturated plates can be used after 
incubation at 37°C for 2 h or can be stored for up to one week at 4 °C. Prior to 
application of the samples under investigation every sample was diluted with PBS/0.1 
% BSA (50 ml PBS + 0.05 g BSA). Normally, tissue samples were diluted 1:5 and 
1:10 whereas cell lysates were diluted 1:2 and kept undiluted. For the standard curve 
the following dilution series was made with recombinant human CCL20 protein: 1000 
pg/ml, 500 pg/ml, 20 pg/ml, 125 pg/ml, 62.5 pg/ml, 31.25 pg/ml, 15.625 pg/ml and 0 
pg/ml (Blank). After sample preparation the ELISA-plate was washed three times with 
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washing buffer and 100 µl of sample or standard, respectively, were loaded in 
duplicates. Subsequently, the plate was sealed and incubated for 2 h at RT (or at 4 
°C over night). After incubation the plate was washed three times and then 100 µl of 
biotinylated goat anti-human MIP-3α/CCL20 “Detection antibody” (50 ng/ml) was 
added and incubated for 2 h at RT (or at 4 °C over night). Following incubation the 
plate was washed three times and then Streptavidin-HRP conjugate (1:200 in 
PBS/0.1 % BSA) was added. After incubating the plate for 30 min in the dark the 
plate was washed three times and accordingly 100 µl of substrate solution (1:1 
solution A : solution B) were added per well. Past a development time of 20 min the 
colorimetric reaction was stopped by the addition of 50 µl stopping solution (H2SO4). 
With the help of a plate reader the absorptions at the wavelengths 450 nm and 562 
nm were detected. 
 
 
3.2.11 Imaging technologies 
 
3.2.11.1 Immunohistochemistry (IHC) 
 
IHC methods are used for the detection of antigens (e.g. proteins) in tissue sections 
on cellular or even subcellular resolution. Thereby this method is widely used in 
diagnosis as well as basic research investigating localization of biomarkers. The IHC 
employs primary antibodies which specifically bind to the investigated antigen. As a 
detection system secondary antibodies are used which are conjugated to fluorescent 
dyes or enzymes (e.g. alkaline phosphatase) that have the potential to catalyze a 
colour generating reaction. These secondary antibodies were raised against the 
species the primary antibody was originated from and therefore specifically bind to 
the primary antibody. Therefore the fluorescent dyes or conjugated enzymes are 
located to the place where the investigated antigen is found. This in turn means that 
the fluorescence signal or coloured precipitate which appears after addition of an 
enzyme specific substrate indicates the cellular or subcellular location where the 
investigated antigen resides. Besides the system applying two antibodies there are 
also systems where the detection system is conjugated directly to the primary 
antibody but the system with two antibodies increases sensitivity because it allows an 
amplification of the signal as more than one secondary antibody can bind to the 
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primary antibody. The tissue sections stained with IHC subsequently can be analyzed 
using either a fluorescence microscope or a conventional light microcope. 
For investigation of tissue samples from colorectal cancer patients formalin-fixed, 
paraffinem-bedded (FFPE) tissue was used. Therefore, sections of 4 µm were cut 
using a microtome. Subsequently, the sections were incubated in a 37 °C water bath 
and then mounted on microscope slides. After drying the sections were stored at 37 
°C until further processing. 
For the staining procedure the sections had to be deparaffinized and rehydrated. The 
sections were deparaffinized and rehydrated by passaging them from xylene via 
different ethanol steps to TBS (Table 17). 
 
Step Solution Time / duration 
1 Xylene 10 min 
2 Xylene 10 min 
3 Xylene 10 min 
4 99.9 % ethanol immerse 10 x 
5 99.9 % ethanol immerse 10 x 
6 99.9 % ethanol 10 min 
7 96 % ethanol immerse 10 x 
8 96 % ethanol 10 min 
9 70 % ethanol immerse 10 x 
10 70 % ethanol 10 min 
11 Aqua dest. 5 min 
12 TBS 5 min 
Table 17 Deparaffinization and rehydration of tissue sections 
 
The rehydated tissue sections were transferred to a staining cuvette containing 1 x 
Target Retrieval buffer in order to unmask the antigens. The Target Retrieval Buffer 
containing the tissue sections was heated in a microwave to approximately 96 °C for 
20 min. Afterwards the solution was allowed to cool down at RT for 20 min. Then the 
sections were transferred to a new staining cuvette and washed two times with dd 
H2O for 3 min. Subsequently the endogenous peroxidases were blocked by 
incubating the sections in 3 % H2O2 for 10 min. After two washing steps with TBS for 
5 min unspecific binding sites were blocked by addition of rabbit serum diluted in PBS 
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(1 drop of serum + 3.33 ml PBS) for 20 min. Next, the serum was removed and the 
endogeneous biotin was blocked by addition of Avidin D-solution for 15 min followed 
by washing for 5 min in dd H2O and further incubation in Biotin-solution for 15 min. 
Afterward, the slides were washed 5 min in TBS and then the CCL20 specific primary 
antibody (PAK; goat anti human CCL20/MIP3α) diluted in antibody diluent (15 µg/ml) 
was applied to the sections and incubated in a humidity chamber at 4 °C over night. 
The next day the PAK was removed and the sections were washed two times with 
TBS for 5 min. Subsequently, the biotinylated secondary antibody (SAK; rabbit-anti 
goat) solution (3 drops serum + 10 ml PBS + 1 drop SAK) was added and incubated 
in a humidity chamber for 30 min at RT. At the beginning of the SAK incubation step 
the ABC-reagent was prepared (1 drop reagent A + 2.5 ml PBS + 1 drop reagent B) 
and incubated for 30 min. After SAK incubation the slides were washed two times for 
5 min in TBS and then the ABC-reagent was applied for 25 min. Subsequent two 
further 5 min wash steps with TBS the AEC-solution (5 ml Aqua dest. + 1 drop 
acetate buffer + 2 drops AEC concentrate + 2 drops 3 % H2O2) was added and left 
for 7 min. The colour reaction was stopped by rinsing the slides in dd H2O. In the next 
step the sections were counterstained by incubating them for 7 min in Mayers 
Hämatoxylin-solution. Subsequently, the slides were washed two times in dd H2O 
and then rinsed for 7 min with tap water. Accordingly, the slides were rinsed in dd 
H2O and finally aqueous embedded with two drops of Aquatex. 
 
 
3.2.11.2 In Situ hybridization (ISH) 
 
ISH is a method which allows an assignment on localization and distribution of 
nucleic acids in a portion or section of tissue (in situ). Thereby, the resolution of 
localization is relatively high and can distinguish between tissues, cells, cell 
compartments or even chromosomes. Since the ISH was first described in 1969 
[John et al., 1969; Gall et al., 1969] it became a routine method in diagnostics and is 
also applied for embryologic, cell biological, genetic or pathologic issues. 
The method of ISH applies RNA or DNA probes which are complementary to the 
nucleic acid sequence under investigation. This marks a major difference with 
respect to the method of IHC which detects proteins. The nucleic acid probes can be 
marked with radio-, fluorescent- or antigen-labelling. To date the probes for ISH with 
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emphasis on the detection of miRNAs are modified with LNA™ (Locked Nucleic Acid) 
a nucleic acid analogue which increases affinity, specificity and biostability of the 
probes. For the detection of mRNAs or miRNAs RNAse-free thin tissue sections are 
required. Thereby paraffin sections or frozen sections may be used. In the case of 
paraffin sections the first step in ISH is deparaffinization and rehydration followed by 
cell opening with proteinase K. Then the specific probe is applied under the 
according temperature pH- and salt-conditions [Jin et al., 1997]. With various wash 
steps at probe specific hybridization temperature non-specific interactions of the 
probe are removed. If radio- or fluorescent-labelling of the probe is used, the samples 
can be directly analyzed by autoradiography or fluorescence microscopy. When the 
probes were antigen labelled an immunohistochemical detection has to be performed 
before microscopic analysis of the sample. 
For the detection of miR-21 and miR-145 in tissue samples from CRC patients 6 µm 
thick sections were cut under RNAse-free conditions one day before ISH procedure. 
After stretching of the sections in a 37 °C DEPC water bath the sections were dried 
for 1 h at RT, heated to 60 °C for 40 min and then stored at 4 °C until use. The first 
step of the ISH protocol constitutes deparaffinization and rehydration of the sections. 
These steps were performed in the same way as described for IHC (Table 17) except 
that PBS was used instead of TBS. Following the PBS step the slides were placed in 
a humidified chamber and 300 µl of proteinase K (15 µg/ml) in proteinase K buffer 
were applied to the sections and incubated for 24 min at 37 °C. Afterwards, the slides 
were washed two times with PBS and then dehydrated applying increasing ethanol 
concentrations (Table 18). 
 
Solvent Time / Duration 
70 % Ethanol Immerse 10 times 
70 % Ethanol 1 min 
96 % Ethanol Immerse 10 times 
96 % Ethanol 1 min 
99.9 % Ethanol Immerse 10 times 
99.9 % Ethanol 1min 
Table 18 Dehydration procedure of In situ-hybridization 
 
After dehydration the slides were dried for 10 min at RT on a clean paper towel. 
During the drying phase the hybridization mixtures were prepared: For U6 snRNA 4 
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µl of probe stock (0.5 µM), for miR-21 and miR-145 12 µl of probe stock (25 µM), 
respectively, were transferred to different 2 ml tubes and heated at 90°C for 4 min. 
Hence, 2 ml of 1 x microRNA ISH buffer were added to each tube containing different 
probes. After the drying phase the slides were placed on a flat surface and 30 µl of 
the according hybridization mixture were pipetted on different sections. In the 
following step a sterile, RNAse-free cover glass was applied on each section to avoid 
air bubbles and the edges were sealed with Fixogum (rubber cement). The sealed 
slides were incubated for 1 h at the hybridization temperature of the respective probe 
(Table 19). 
 
Probe Hybridization temperature 
U6 snRNA 57 °C or 59°C 
miR-21 57 °C 
miR-145 59 °C 
Table 19 Hybridization temperature of applied probes 
 
After hybridization the Fixogum was removed using tweezers and the cover glasses 
were carefully detached to avoid damaging the tissue. Subsequently, the slides were 
incubated in a Coplin jar containing 5 x SSC at room temperature followed by several 
wash steps in different concentrations of SSC buffer (Table 20). 
 
Step Buffer Time / duration Temperature 
1 5 x SSC 5 min Hybr. Temp. 
2 1 x SSC 5 min Hybr. Temp. 
3 1 x SSC 5 min Hybr. Temp. 
4 0.2 x SSC 5 min Hybr. Temp. 
5 0.2 x SSC 5 min Hybr. Temp. 
6 0.2 x SSC 5 min RT 
Table 20 Stringency wash steps with different concentrations of SSC buffer 
 
After the washing procedure the slides were transferred to a Coplin jar with PBS and 
then placed in a humidifying chamber. The slides were dried with a clean towel 
around the section to create a hydrophobic barrier. Hence, 150 µl of blocking solution 
(10 x blocking solution diluted with 1 x Maleic acid to 1 x concentration) were added 
to each section and incubated for 15 min at RT. The blocking solution was removed 
and 50 µl of anti-DIG reagent (1 x blocking solution + 2 % sheep serum + 1:800 anti-
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DIG antibody) were applied to the tissue sections for 60 min at RT. After washing 
three times for 3 min in PBS-T the AP substrate was prepared. A NBT-BCIP tablet 
was solved in 10 ml dd H2O and levamisole was added to a final concentration of 0.2 
mM. Slides were taken to a humidifying chamber and dried around the sections prior 
to addition of 100 µl AP substrate. After incubating the AP substrate for 1 h at 30 °C 
the slides were transferred to a Coplin jar with KTBT-buffer and incubated two times 
for 5 min to stop the reaction. Subsequently, the slides were washed two times for 1 
min in dd H2O and then 200 µl of Nuclear Fast Red solution were added for 1 min to 
the sections. Accordingly, the slides were transferred to a Coplin jar with tap water 
and rinsed for 10 min with tap water. Afterwards the sections were dehydrated with 
different concentrations of Ethanol (Table 18) and then placed in Xylene. Finally, the 
slides were transferred to a clean paper towel and 1-2 drops of Eukitt mounting 
medium were added per section and a cover glass was applied. After over night 
settlement of the precipitate the sections were microscopically analysed. 
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4. Results 
 
4.1 Target prediction of miRNAs 
 
To predict miRNAs which potentially interact with the target gene CCL20 five online 
available target prediction programmes were applied (3.2.1). For continuative 
investigations only miRNAs were used which were predicted by two or more of the 
programmes (Table 21). Hence, four of the programmes predicted miR-21 to 
potentially interact with the 3’UTR of CCL20 whereas only two programmes predicted 
miR-145 to potentially be involved in CCL20 post-transcriptional regulation. For 
notice, target prediction programme PICTAR did not contain the sequence data of 
CCL20 and therefore a prediction was not possible. 
 
Prediction Tool hsa-miR-21 hsa-miR-145 
TARGETSCANHUMAN 4.2 X  
MICRORNA.ORG X X 
PICTAR   
EBI MICROCOSM TARGETS X X 
MIRDB X  
Table 21 Overview of miRNA target prediction based on CCL20 sequence 
Predicted interaction of the according miRNA with CCL20 is marked by X. 
 
In order to further investigate the feasibility for an interaction of the chosen miRNAs 
with the target gene CCL20 seven other target prediction programmes were applied 
which depend on sequence information of both the target gene and the respective 
miRNA (3.2.1 and Table 22). Thereby, four of these programmes confirmed an 
interaction of miR-21 with CCL20 and three of the programmes confirmed an 
interaction of miR-145 with CCL20. 
 
Prediction Tool hsa-miR-21 hsa-miR-145 
PITA X X 
RNA22 X X 
TAREF 
  
microinspector 
  
STARMIR X  
EIMMO X X 
TARGETRANK 
  
Table 22 Overview of miRNA target prediction based on CCL20 and miRNA sequence 
Predicted interaction of the according miRNA with CCL20 is marked by X. 
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According to most of the available target prediction programmes miR-21 has one 
binding site in the 3’UTR of CCL20 with a seed sequence located at position 261-268 
(Figure 10). In addition, two programmes predicted other binding sites: STARMIR 
(position 172-179) and RNA22 (position 189-195). In case of miR-145 four of five 
programmes predicted position 24-31 as the seed binding site whereas only PITA 
predicted an interaction at position 195-202. For further investigations only target 
sites predicted by the majority of the programmes were applied. 
 
Figure 10 Predicted miRNA binding sites in the 3’UTR of CCL20 (390 bp) 
Target sites indicated above the line were predicted by more than one programme. Target sites 
beneath the line were predicted by only one programme. 
 
The sequence alignments of the miRNAs with the 3’UTR of CCL20 are depicted for 
the binding site predicted by the majority of the respective target prediction 
programmes presented in Figure 11. 
 
 
 
Results 72 
 
Figure 11 Target site alignment  
Shown are the target positions predicted by most target prediction programmes under investigation. 
The alignment is adapted from the programme MICROCOSM TARGETS. Lines indicate base pairing 
between miRNA and target sequence, dots indicate wobble pairing and spaces indicate no pairing. 
 
 
4.2 Luciferase assay 
 
In order to validate the predicted interactions of the two miRNAs with the target gene 
CCL20 a luciferase assay was applied. In this assay, two luciferase reporter 
constructs manufactured by Gene CopoeiaTM were applied. The first construct 
contained the 3’UTR of the target gene CCL20 directly downstream of the firefly 
luciferase gene (Luc CCL20). The second construct served as a control vector and 
contained no 3’UTR downstream of the firefly luciferase gene (Luc No CCL20). The 
vector maps of the two constructs are depicted in Figure 6 and Figure 8. For 
normalization of transfection efficiency the constructs contain another luciferase gene 
(Renilla luciferase) under the control of a constitutive promoter. The luciferase assay 
was performed with the Dual-Luciferase® Reporter Assay from Promega (3.2.5). In 
case of a functional interaction between the 3’UTR of CCL20 and one of the 
investigated miRNAs a decreased expression of the firefly luciferase is expected and 
detectable by luminometric measurement. 
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4.2.1 Impact of miR-21 on CCL20-3’UTR dependent luciferase activity in 
293T cells 
 
Initially, luciferase assays were performed in cell line 293T which is commonly used 
for luciferase reporter assays. In this assay cells were co-transfected with the 
reporter vectors and pre-miR precursors of miR-21 or a negative control (NK) pre-
miR precursor, respectively, as described in chapter 3.2.4.5.1. In Figure 12 the mean 
values of luciferase activity after miR-21 pre-miR precursor co-transfection relative to 
NK pre-miR precursor transfected cells is shown. Data were obtained from five 
independent experiments with co-transfected 293T cells and presented with the 
according standard error of mean (SEM). 
Co-transfection of 293T cells with the reporter construct Luc CCL20 and the miR-21 
precursor resulted in a significant (P < 0.05) reduction of luciferase activity in relation 
to 293T cells which were co-transfected with Luc CCL20 and the NK pre-miR 
precursor. Co-transfection of 293T cells with Luc No CCL20 and miR-21 precursor 
resulted in no significant alteration of luciferase activity related to cells co-transfected 
with NK pre-miR precursors. Furthermore, a significant difference was observed (P < 
0.05) between 293T cells co-transfected with Luc CCL20 and miR-21 precursor and 
cells co-transfected with the Luc No CCL20 construct and the miR-21 precursor. 
Thus, our experiments demonstrate that miR-21 precursors regulate the expression 
of luciferase activity in a vector containing the 3’UTR of CCL20. Therefore, our 
results allow to draw the conclusion that miR-21 regulates the expression of the 
target gene CCL20 through a regulatory element present in the 3’UTR of CCL20 
mRNA. 
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Figure 12 Relative luciferase activity in miR-21 transfected 293T cells 
Luciferase activity in 293T cells co-transfected with Luc No CCL20 vector and Luc CCL20 vector, 
respectively, and miR-21 pre-miRNA precursor relative to cells co-transfected with negative control 
(NK) pre-miRNA precursor. Data are presented as mean +/- SEM (n=5). Only co-transfection of miR-
21 pre-miRNA precursor with Luc CCL20 vector resulted in a significantly decreased luciferase activity 
*(P < 0.05). Fold decrease below 1 indicates down-regulation of luciferase activity in miR-21 co-
transfected cells related to NK miR precursor transfected cells. 
 
 
4.2.2 Impact of miR-145 on CCL20-3’UTR dependent luciferase activity in 
293T cells 
 
In order to analyze the predicted interaction of miR-145 with the 3’UTR of CCL20 
also 293T cells were co-transfected with the according constructs and pre-miRNA 
precursors. Co-transfection of miR-145 precursor with the Luc CCL20 reporter 
construct did not result in decreased luciferase expression in relation to 293T cells 
co-transfected with NK miRNA precursors (Figure 13). Likewise, no difference in 
luciferase expression was observed with respect to the co-transfection of Luc No 
CCL20 and miR-145 precursors in relation to 293T cells co-transfected with NK 
miRNA precursors. Therefore, it may be concluded that there is no direct regulatory 
interaction between miR-145 and the 3’UTR of CCL20. 
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Figure 13 Relative luciferase activity in miR-145 transfected 293T cells 
Luciferase activity in 293T cells co-transfected with Luc No CCL20 vector and Luc CCL20 vector, 
respectively, and miR-145 pre-miRNA precursor relative to cells co-transfected with negative control 
(NK) pre-miRNA precursor. Data are presented as mean +/- SEM (n=5). Neither co-transfection of 
miR-145 precursor with Luc CCL20 nor with Luc No CCL20 resulted in altered luciferase expression in 
relation to co-transfection with NK miRNA. 
 
 
4.2.3 Impact of miR-21 on CCL20-3’UTR dependent luciferase activity in 
HT29 cells 
 
As cell lines are immortalized cells some cell lines exhibit alterations in their genome 
which can interfere with cellular regulatory mechanisms. To avoid a bias introduced 
by the choice of the applied cell line, luciferase assays were performed in an 
additional cell line. For this purpose HT29 was chosen as this cell line constitutes a 
CRC cell line leading to results which may be comparable to results obtained in 
cancerous tissue. 
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Figure 14 Relative luciferase activity in miR-21 transfected HT29 cells 
Luciferase activity in HT29 cells co-transfected with Luc No CCL20 vector and Luc CCL20 vector, 
respectively, and miR-21 pre-miRNA precursor relative to cells co-transfected with negative control 
(NK) pre-miRNA precursor. Data are presented as mean +/- SEM (n=5). Only co-transfection of miR-
21 pre-miRNA precursor together with the Luc CCL20 vector resulted in a significantly decreased 
luciferase activity *(P < 0.05). Fold decrease below 1 indicates down-regulation of luciferase activity in 
miR-21 co-transfected cells related to NK miR precursor transfected cells. 
 
The results obtained in cell line HT29 were similar to the results received in cell line 
293T. Co-transfection of Luc CCL20 with miR-21 pre-miRNA precursor resulted in 
significantly decreased luciferase activity related to cells co-transfected with the same 
reporter construct together with the NK pre-miRNA precursor (P < 0.05) (Figure 14). 
Co-transfection of Luc No CCL20 with miR-21 pre-miRNA precursor had no effect on 
luciferase activity compared to cells co-transfected with NK pre-miRNA precursor 
molecules. Likewise, a significant difference in relative luciferase activity was 
observed between HT29 cells co-transfected with miR-21 pre-miRNA precursors and 
Luc CCL20 and Luc No CCL20, respectively. These results support the conclusion 
that miR-21 regulates CCL20 gene expression by a miR-21 specific target site in the 
3’UTR. 
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4.2.4 Impact of miR-145 on CCL20-3’UTR dependent luciferase activity in 
HT29 cells 
 
The interaction of miR-145 with the 3’UTR of CCL20 was also tested in a luciferase 
assay performed in cell line HT29. Likewise, the results obtained in cell line HT29 
were very similar to the results received in cell line 293T. Neither co-transfection of 
miR-145 with either Luc No CCL20 nor the vector containing the 3’UTR of CCL20 
showed an alteration in luciferase activity related to cells co-transfected with the NK 
pre-miRNA precursor (Figure 15). Therefore, it may be concluded that miR-145 plays 
no role in direct regulation of CCL20 gene expression by direct interaction with the 
3’UTR of CCL20. 
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Figure 15 Relative luciferase activity in miR-145 transfected HT29 cells 
Luciferase activity in HT29 cells co-transfected with Luc No CCL20 vector and Luc CCL20 vector, 
respectively, and miR-145 pre-miRNA precursor relative to cells co-transfected with negative control 
(NK) pre-miRNA precursor. Data are presented as mean +/- SEM (n=5). Neither co-transfection of 
miR-145 precursor with Luc CCL20 nor with Luc No CCL20 resulted in altered luciferase expression in 
relation to co-transfection with NK miRNA. 
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4.3 Site directed mutagenesis of miR-21 binding site 
 
Applying the luciferase reporter gene assay it was demonstrated that miR-21 may 
reduce luciferase activity by binding to the 3’UTR of CCL20. To further investigate 
this interaction a site directed mutagenesis of the miR-21 binding site was performed. 
Target of the site directed mutagenesis approach was the region of the 3’UTR which 
was complementary to the seed sequence of the miR-21 target site predicted by 
most programmes. As the sequence complementary to the seed region of the 
according miRNA is the most important part for miRNA binding, two nucleotides in 
the sequence complementary to the seed sequence of the CCL20 3’UTR were 
mutated. The 3’UTR sequence ATAAGCTA was changed to GTGAGCTA by the use 
of primers containing mismatches at the according positions. The outcome of the 
mutations in the new construct (Luc CCL20 Mut) was confirmed by DNA sequencing 
of the mutated region performed by GATC (Figure 16). 
 
 
Figure 16 Mutated luciferase reporter construct 
Luciferase reporter construct containing two point mutations in the site complementary to the seed 
region of miR-21. 
 
 
4.4 Luciferase assay with mutated target site 
 
As miR-21 may reduce luciferase activity by binding to the 3’UTR of CCL20, a 
reporter construct with the mutated seed sequence of the CCL20 3’UTR was applied 
to investigate whether the observed regulatory effect is due to a direct interaction of 
miR-21 with the specific site in the 3’UTR of CCL20. Therefore, luciferase assays 
were repeated applying three constructs, Luc CCL20, Luc No CCL20 and the 
construct with the mutated, predicted target site of miR-21. Thus, it was aimed to 
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monitor if the introduced mutations may reduce or avert the miR-21 mediated 3’UTR 
dependent down-regulation of luciferase activity. 
 
 
4.4.1 Luciferase assay with mutated target site in 293T cells 
 
The mutated Luc CCL20 Mut construct was applied in a luciferase assay along with 
miR-21 pre-miR precursors in 293T cells. In samples co-transfected with the vector 
containing the mutated 3’UTR of CCL20 (Luc CCL20 Mut) in combination with miR-
21 pre-miR precursors a significantly decreased luciferase expression was observed 
with respect to samples co-transfected with NK pre-miR precursors (Figure 17). Also 
with respect to samples co-transfected with Luc No CCL20 and miR-21 pre-miR 
precursors a significantly decreased luciferase expression was observed in the Luc 
CCL20 Mut samples as presented in Figure 17. However, in comparison to Luc 
CCL20 samples co-transfected with miR-21 pre-miR precursors a significantly 
increased luciferase expression was observed in the Luc CCL20 Mut samples 
(Figure 17). Therefore, data resulting from luciferase assays with the mutated seed 
side of miR-21 indicate that mutating the predicted target site represses the inhibitory 
effect of miR-21 on CCL20 3’UTR dependent luciferase expression but they also 
show that this repression is not complete. 
 
Results 80 
0
0,2
0,4
0,6
0,8
1
1,2
Luc no CCL20 Luc CCL20 Luc CCL20 Mut
Reporter constructs
R
e
la
tiv
e
 
lu
ci
fe
ra
se
 
a
ct
iv
ity
 
in
 
m
iR
-
21
 
tra
n
sf
e
ct
e
d 
29
3T
 
ce
lls
*
*
*
*
*
R
e
la
tiv
e
 
lu
ci
fe
ra
se
 
a
ct
iv
ity
 
in
 
m
iR
-
21
 
tra
n
sf
e
ct
e
d 
29
3T
 
ce
lls
 
Figure 17 Luciferase assay with mutated target site in 293T cells 
Luciferase activity in 293T cells co-transfected with Luc No CCL20 vector, Luc CCL20 and Luc CCL20 
Mut vector, respectively, and miR-21 pre-miRNA precursors relative to cells co-transfected with 
negative control (NK) pre-miRNA precursors. Data are presented as mean +/- SEM (n=5). Co-
transfection of miR-21 pre-miRNA precursor / Luc CCL20 or miR-21 pre-miRNA precursor / Luc 
CCL20 Mut resulted in significantly decreased luciferase activities *(P < 0.05) related to co-
transfection of NK pre-miR precursors, respectively. Significant decreased luciferase activities were 
also found in miR-21 pre-miRNA precursor / Luc CCL20 and pre-miRNA precursor / Luc CCL20 Mut 
co-transfected cells compared to miR-21 pre-miRNA precursor / Luc no CCL20 cotransfected cells. 
Thereby, significant increased luciferase activities were observed in Luc CCL20 Mut / miR-21 pre-
miRNA precursor co-transfected cells in comparison to Luc CCL20 / miR-21 pre-miRNA precursor co-
transfected cells, respectively *(P < 0.05). 
 
 
4.4.2 Luciferase assay with mutated target site in HT29 cells 
 
Luciferase assays with the construct containing the mutated seed site of CCL20 were 
also perfomed in CRC cell line HT29. Also in this cell line co-transfection of miR-21 
pre-miR precursors with Luc CCL20 Mut resulted in a significant reduction of 
luciferase activity relative to the luciferase activity in cells co-transfected with NK pre-
miR precursors and Luc CCL20 Mut (P < 0.05) (Figure 18). Likewise, the reduction of 
luciferase activity in cells co-transfected with miR-21 pre-miR precursors and Luc 
CCL20 was significantly higher compared to cells co-transfected with miR-21 pre-miR 
precursors and Luc CCL20 Mut (P < 0.05). Relative luciferase activities of both Luc 
CCL20 and Luc CCL20 Mut were significantly lower compared to cells co-transfected 
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with the control vector Luc No CCL20 and miR-21 pre-miR precursors (Figure 18). As 
co-transfection of miR-21 pre-miR precursors with Luc No CCL20 showed no 
significant change in luciferase activity with respect to co-transfection of NK pre-miR 
precursors/Luc No CCL20, it was concluded that miR-21 does not interfere with 
luciferase activity if the 3’UTR of CCL20 is absent. Therefore, also results obtained in 
HT29 cells indicate that there is a 3’UTR dependent regulatory interaction between 
HT29 and luciferase or CCL20 expression, respectively. 
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Figure 18 Luciferase assay with mutated target site in HT29 cells 
Luciferase activities in HT29 cells co-transfected with Luc no CCL20, Luc CCL20 and Luc CCL20 Mut 
vector, respectively, and miR-21 pre-miR precursors relative to cells co-transfected with negative 
control (NK) pre-miRNA precursors. The data are presented as mean +/- SEM (n=5). Co-transfection 
of miR-21 pre-miRNA precursor / Luc CCL20 or miR-21 pre-miRNA precursor / Luc CCL20 Mut 
resulted in significantly decreased luciferase activities *(P < 0.05) related to co-transfection of NK pre-
miR precursors, respectively. Significant decreased luciferase activities were also found in miR-21 pre-
miRNA precursor / Luc CCL20 and pre-miRNA precursor / Luc CCL20 Mut co-transfected cells 
compared to miR-21 pre-miRNA precursor / Luc no CCL20 cotransfected cells. Thereby, significant 
increased luciferase activities were observed in Luc CCL20 Mut / miR-21 pre-miRNA precursor co-
transfected cells in comparison to Luc CCL20 / miR-21 pre-miRNA precursor co-transfected cells, 
respectively *(P < 0.05). 
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4.5 Quality of target prediction according to luciferase assay 
results 
 
With respect to data obtained from luciferase assays only one of the predicted 
miRNAs, namely miR-21, was successfully shown to regulate CCL20 gene 
expression by a miR-21 specific target site in the 3’UTR. Therefore, the quality of 
prediction was assessed. The target prediction tools TARGETSCANHUMAN 4.2, 
MICRORNA.ORG, MIRDB, PITA and STARMIR predicted a positive interaction for both 
miRNAs, miR-21 and miR-145 (Figure 19). The tools TAREF, TARGETRANK, EBI 
MICROCOSMTARGETS, EIMMO and RNA22 predicted correctly one of the miRNA 
target gene interactions whereas MICROINSPECTOR correctly predicted no interaction 
between the miRNAs and the respective target gene. PICTAR did not predict any 
interaction due to the absence of CCL20 in its database. Most of the target prediction 
tools applied “Seed complementarity” in combination with other features (Figure 19). 
The only exception constituted STARMIR which predicted miRNA target gene 
interaction according to thermodynamic features. The usage of further features for 
predicting miRNA target gene interactions seemed to be more efficient in most cases 
according to the results of the present thesis. 
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Figure 19 Target Prediction Tools Features and Quality. 
Number of correct predictions in accordance with the results of the luciferase assay (luciferase) ++ = 
correct predictions for both miRNAs, miR-21 and miR-145, + = correct prediction for one miRNA, - = 
no correct prediction, N.D. = no prediction was possible.  
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4.6 Transfection of eukaryotic cells with pre-miRNA mimics 
 
After demonstrating miR-21 interaction with the 3’UTR of CCL20 in luciferase assays, 
it was investigated if artificial over-expression of miRNAs in different CRC cell lines 
and the kidney cell line 293T may influence the expression of CCL20 on the mRNA 
and/or protein level. Therefore, four CRC cell lines, Caco-2, HT29, SW480 and 
SW620 as well as 293T were transfected with pre-miR precursor molecules of miR-
21, miR-145 and NK pre-miR precursor, respectively. After 48 h the expression of 
CCL20 was measured on the mRNA level by qRT-PCR and on the protein level using 
ELISA. 
 
 
4.6.1 Pre-miR-21 mimics 
 
In the previous sections a regulatory interaction of miR-21 with the 3’UTR of CCL20 
was shown and validated by the use of a luciferase assay. Thus, CCL20 expression 
was expected to be down-regulated after transfection of miR-21 pre-miR precursors 
into the CRC cell lines or the kidney cell line 293T. However, not all cell lines under 
investigation fulfilled this expectation. 
In cell line Caco-2 transfection with miR-21 pre-miR precursors showed no effect on 
CCL20 mRNA expression whereas on the protein level a significant 40 % down-
regulation of CCL20 protein expression was observed (P < 0.05). In contrast, artificial 
over-expression of miR-21 by transfecting cell line SW480 caused a significant down-
regulation of CCL20 expression both on the mRNA and the protein level (P < 0.05). 
As shown in Figure 20 A and B CCL20 mRNA expression was reduced to 
approximately 60 % and CCL20 protein expression was decreased to approximately 
40 % with respect to NK pre-miR precursor transfected cells. Likewise, CCL20 mRNA 
and protein expression were significantly reduced after transfection of cell line 
SW620 with miR-21 pre-miR precursor molecules. Here, CCL20 mRNA expression 
was significantly decreased to approximately 45 % and protein expression was 
significantly reduced to approximately 60 % related to cells transfected with NK pre-
miR precursors (P < 0.05) as shown in Figure 20 A and B. In contrast to the first 
three cell lines under investigation CRC cell line HT29 showed no significant 
alteration in CCL20 expression upon transfection with miR-21 pre-miR precursors 
Results 84 
neither on the mRNA nor on the protein level (Figure 20 A and B). However, in kidney 
cell line 293T CCL20 mRNA expression was also significantly down-regulated after 
artificial over-expression of miR-21 whereas CCL20 protein expression was not 
detectable at all, neither in NK transfected cells nor in miR-21 transfected cells. 
In summary, CCL20 mRNA expression was significantly down-regulated in two out of 
four CRC cell lines under investigation whereas CCL20 protein expression was 
significantly decreased in three CRC cell lines. Moreover, in kidney cell line 293T 
CCL20 mRNA expression was significantly down-regulated and CCL20 protein 
expression was not measurable. 
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Figure 20 CCL20 expression analysis in cell lines transfected with miR-21 pre-miR presursor 
(A) Expression of CCL20 mRNA in different cell lines after transfection with miR-21 pre-miR 
precursors or NK pre-miR precursors. Data are presented as mean +/-SEM (n=6). Fold decrease 
below 1 indicates down-regulation of CCL20 mRNA in the respective cell lines relative to NK 
transfected cells *(P < 0.05). (B) Expression of CCL20 protein in different cell lines after transfection 
with miR-21 pre-miR precursors or NK pre-miR precursors. Protein data are presented as mean +/- 
SEM (n=6). Fold decrease below 1 indicates down-regulation of CCL20 protein expression related to 
NK pre-miR precursor transfected cells *(P < 0.05). 
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4.6.2 Pre-miR-145 mimics 
 
Based on the luciferase assay no direct interaction between miR-145 and the 3’UTR 
of CCL20 has been indicated. However, in analogy to miR-21 transfection studies 
experiments with pre-miR precursor molecules of miR-145 were performed on CRC 
and 293T cells to test for an indirect regulatory effect of miR-145 on CCL20 mRNA 
and protein expression. As expected, no significant alteration in CCL20 mRNA or 
protein expression was observed in either cell line with respect to NK pre-miR 
precursor transfected cells (Figure 21). 
In summary, pre miR-145 transfection experiments have demonstrated that artificial 
increase of miR-145 has no effect on CCL20 expression, neither on the mRNA nor 
on the protein level. Therefore, miR-145 expression is not expected to influence 
CCL20 expression in a direct or indirect manner. 
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Figure 21 CCL20 expression analysis in cells transfected with miR-145 pre-miR precursors 
(A) Expression of CCL20 mRNA in different cell lines after transfection with miR-145 pre-miR 
precursors or NK pre-miR precursors. Data are presented as mean +/-SEM (n=6). Fold decrease 
below 1 indicates down-regulation of CCL20 mRNA expression in the respective cell lines relative to 
NK transfected cells. (B) Expression of CCL20 protein in different cell lines after transfection with miR-
145 pre-miR precursors or NK pre-miR precursors. Protein data are presented as mean +/- SEM 
(n=6). Fold decrease below 1 indicates down-regulation of CCL20 protein expression related to NK 
pre-miR precursor transfected cells. 
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4.7 Expression of the chemokine CCL20 in CRC tissue samples 
 
After demonstrating that artificial over-expression of miR-21 down-regulates CCL20 
expression in various CRC cell lines, the next set of experiments aimed to investigate 
CCL20 gene expression in CRC tissues. To study CCL20 gene expression on mRNA 
and protein level, tissue samples from patients with different clinicopathological 
features of CRC were analyzed using qRT-PCR and ELISA. 
 
 
4.7.1 CCL20 mRNA expression analyzed by qRT-PCR 
 
Investigating CCL20 mRNA expression in CRC tissues comprised samples from 46 
CRC patients. Quantification of mRNA levels was performed using qRT-PCR. Data 
were normalized to the housekeeping gene b2m. In Figure 22 the expression of 
CCL20 mRNA is depicted as n-fold expression relative to the corresponding normal 
colorectal tissue. The mean of all patients was calculated and the standard error of 
mean was indicated (Figure 22 A). In addition, the patients were grouped according 
to the characteristics of their tumour (Figure 22 B-C). With respect to corresponding 
normal tissue in tumourous tissue a significantly 14-fold increased expression of 
CCL20 mRNA was observed (P < 0.05) (Figure 22 A). This increase in expression 
was also observed when patients were grouped according to the T-stage of the 
tumour (P < 0.05) (Figure 22 B). Dividing the patients into subgroups according to 
clinical Staging indicated a nearly equal significant increase in CCL20 mRNA 
expression in both subgroups: Stage I+II and Stage III+IV (P < 0.05) (Figure 22 C). 
Also in patients of G1/G2 and G3/G4 a significantly increased CCL20 mRNA 
expression was observed related to the corresponding normal tissue (P < 0.05). 
(Figure 22 D). 
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Figure 22 CCL20 mRNA expression in CRC tissue 
CCL20 mRNA expression levels were analyzed by qRT-PCR and depicted as relative expression with 
respect to normal colorectal tissue. Data are presented as mean +/- SEM *(P < 0.05). (A) Mean data 
of all investigated patients. (B) Scoring of patient data according to T-stages. (C) Scoring of patient 
data according to clinical staging. (D) Scoring of patients according to G-stages. 
 
 
4.7.2 CCL20 protein expression analyzed by ELISA 
 
Investigations on CCL20 protein expression were carried out on tissue samples 
obtained from 36 patients with CRC. Quantification of protein levels was performed 
applying the ELISA technique. Data were normalized to the absolute protein content 
analyzed by a BCA-assay. In the total CRC cohort a significant increase in CCL20 
protein expression of CRC tissues was found compared to CCL20 protein expression 
in corresponding normal colorectal tissues (P < 0.05) (Figure 23 A). Likewise, 
significant CCL20 protein up-regulation was detected independently of T- and G– 
stages or clinical staging (P < 0.05) as presented in Figure 23 B-D 
 
Results 90 
0
9000
18000
27000
36000
1
CC
L2
0 
(pg
/m
l p
e
r 
m
g 
to
ta
l p
ro
te
in
)
 
in
 
to
ta
l C
R
C 
co
ho
rt
normal colorectal tissues CRC tissues
0
9000
18000
27000
36000
T1+T2 T3+T4
CC
L2
0 
(pg
/m
l p
e
r 
m
g 
to
ta
l p
ro
te
in
)
in
de
x
e
d 
by
 
T 
st
a
ge
s
normal colorectal tissues CRC tissues
0
9000
18000
27000
36000
G1+G2 G3+G4
CC
L2
0 
(pg
/m
l p
e
r 
m
g 
to
ta
l p
ro
te
in
)
in
de
x
e
d 
by
 
G
ra
di
n
g
normal colorectal tissues CRC tissues
0
9000
18000
27000
36000
Stage I+II Stage III+IV
CC
L2
0 
(pg
/m
l p
e
r 
m
g 
to
ta
l p
ro
te
in
)
 
in
de
x
e
d 
by
 
Cl
in
ic
a
l S
ta
gi
n
g
normal colorectal tissues CRC tissues
** *
** * *
B
D
A
C
CC
L2
0 
(pg
/m
l p
e
r 
m
g 
to
ta
l p
ro
te
in
)
 
in
 
to
ta
l C
R
C 
co
ho
rt
CC
L2
0 
(pg
/m
l p
e
r 
m
g 
to
ta
l p
ro
te
in
)
in
de
x
e
d 
by
 
T 
st
a
ge
s
CC
L2
0 
(pg
/m
l p
e
r 
m
g 
to
ta
l p
ro
te
in
)
in
de
x
e
d 
by
 
G
ra
di
n
g
CC
L2
0 
(pg
/m
l p
e
r 
m
g 
to
ta
l p
ro
te
in
)
 
in
de
x
e
d 
by
 
Cl
in
ic
a
l S
ta
gi
n
g
 
Figure 23 CCL20 protein expression in CRC tissue 
CCL20 protein expression levels were analyzed by ELISA analysis and depicted as absolute CCL20 
expression normalized to total protein expression. Data are presented as mean +/- SEM *(P < 0.05). 
(A) Absolute CCL20 expression in CRC tissues and corresponding normal colorectal tissues of all 
investigated patients. (B) Scoring of patient data according to T-stages. (C) Scoring of patient data 
according to clinical staging. (D) Scoring of patients according to G-stages. 
 
 
4.8 Expression of miRNAs in CRC tissue samples 
 
As miRNAs regulate the expression of their target genes by direct interaction with the 
3’UTR of these target genes, it may be concluded that miRNAs regulating CCL20 
gene expression are down-regulated in CRC samples. Therefore the expression 
levels of miR-21 and miR-145 were analysed in CRC tissue samples from 46 patients 
using qRT-PCR with special miRNA detection assays. The expression data obtained 
were normalized to the expression of RNU48, which is a housekeeping gene used for 
miRNA analysis, and relative miRNA expression in tumour samples was depicted as 
n-fold expression relative to corresponding normal colorectal tissue. 
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4.8.1 Analysis of miR-21 in CRC using qRT-PCR 
 
Mean miR-21 expression was significantly (P < 0.05) increased in the total cohort 
relative to corresponding non affected tissues (Figure 24 A). With respect to clinical 
features like T-stages, clinical staging or G-stages only late stages showed 
significantly up-regulated miR-21 expression (P < 0.05) (Figure 24 B-D). 
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Figure 24 Expression of miR-21 in CRC tissue samples 
The expression levels of miR-21 in samples from CRC patients were analyzed using qRT-PCR. miR-
21 expression was normalized to RNU48 and depicted as relative expression with respect to normal 
colorectal tissue Expression levels are presented as mean +/- SEM *(P < 0.05). (A) Expression of 
miR-21 in all investigated patient samples. (B) miR-21 expression according to T-stage of tumour. (C) 
Expression according to clinical staging. (D) Expression of miR-21 according to G-stage of tumour. 
 
 
4.8.2 Analysis of miR-145 in CRC using qRT-PCR 
 
Also gene expression of miR-145 was analyzed in CRC tissue samples by qRT-PCR 
resulting in significant down-regulation in the total CRC panel related to 
corresponding normal tissue (P < 0.05) (Figure 25 A). Subdivision of tumour samples 
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according to T-stages, clinical staging and grading resulted in significantly decreased 
miR-145 expression in all subgroups (P < 0.05) (Figure 25 B-D). 
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Figure 25 Expression of miR-145 in CRC tissue samples 
The expression levels of miR-145 in CRC tissue samples were analyzed using qRT-PCR. The 
expression of miR-145 was normalized to the endogenous control RNU48 and is presented relative to 
the expression in normal colorectal tissue. Data are presented as mean +/- SEM *(P < 0.05). (A) 
Relative expression of all analyzed patients. (B) Expression according to T-stage of tumour. (C) 
Expression according to Staging of tumour. (D) Expression for groups with different G-stage. 
 
 
4.9 Tissue localization of CCL20, miR-21 and miR-145 
expression 
 
If a functional interaction of a miRNA with a target gene takes place, an inverse 
expression correlation of the respective miRNA and target gene would be expected. 
With respect to previous results concerning functional miR-21/CCL20 interactions an 
antidromic expression pattern in CRC tissues was expected. However, gene 
expression analysis revealed that the expressions of miR-21 and the target gene 
CCL20 were both significantly up-regulated in CRC tissue samples. In contrast, 
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expression of miR-145 was shown to be significantly down-regulated. Thus, the next 
step aimed to investigate if the expressions of miR-21 and miR-145 as well as the 
target gene CCL20 were localized to the same cell type or even localized to the same 
cells within the CRC tissues. 
 
 
4.9.1 Localization of CCL20 expression using IHC 
 
Immunohistochemical presentation of normal colonic tissue samples of CRC patients 
(n=8) illustrated that CCL20 is primarily expressed in perinuclear regions of mucosal 
epithelial cells as shown in Figure 26 A. In addition, positive CCL20 signals were 
found in mesenchymal cells (Figure 26 A). In 7 out of 8 samples under investigation 
the tumour was negative for CCL20 reactivity. In these cases predominantly 
infiltrating immune cells like macrophages or lymphocytes in the microenvironment of 
the tumour showed CCL20 associated signalling (Figure 26 B). However, in one case 
a positive reactivity against CCL20 was also observed in adenocarcinoma cells of a 
CRC tumour sample (Figure 26 C). Also this specimen exhibited CCL20 associated 
signalling in infiltrating immune cells (Figure 26 C). Therefore, it may be speculated 
that in the majority of patients under investigation the significantly increased CCL20 
expression was due to an increase in mesenchymal cells associated with infiltration 
of immune cells like macrophages or lymphocytes to the site of the tumour. 
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Figure 26 Localization of 
CCL20 protein expression 
in CRC 
Representative specimens 
(thickness: ~4µm) of the 
regular mucosa as well as of 
adenocarcinomas of the 
colon and rectum, were 
probed with antibodies 
against CCL20 (15 µg/ml; 
ABC method). [A] 
Perinuclear regions of 
mucosal epithelial cells 
(arrowheads) and some 
mesenchymal cells (arrows) 
revealed immunoreactivity 
for CCL20. [B] Most CRC 
specimens displayed 
immunoreactive signals for 
CCL20 only in mesenchymal 
parts (arrows) while no anti-
CCL20 signals were 
observed in adenocarcinoma 
cells while one specimen [C] 
showed immunoreactivity for 
CCL20 in both 
adenocarcinoma cells (black 
asterisks) and mesenchymal 
elements (black arrows). 
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4.9.2 Localization of miRNA expression using In Situ hybridization 
 
For localizing miRNAs in CRC tissues ISH was employed on FFPE biopsies of 
approximately 1 mm diameter. As larger embedded tissue specimens (up to 1.5 cm) 
have shown positive in situ reactivity only in the outer layers of the sections and not 
in the center of the sections, only biopsies were applied for ISH experiments. Since 
this method has not been applied in our laboratory, ISH concerning miR-21 and miR-
145 has been established in the frame of this thesis. In the course of such 
establishing experiments subsequent optimization steps relating to changes in 
hybridization temperature and probe concentration were employed until an optimized 
hybridization result was achieved.  
A probe complementary to U6snRNA was used as a positive control and a scrambled 
probe not known as being complementary to any endogeneous miRNA was applied 
as a negative control. U6snRNA is a small nucleic acid present in abundancy in all 
cells and therefore easy to detect. As the scrambled probe is not complementary to 
any known nucleic acid in the cells this probe is not expected to produce any signal. 
Accordingly, no signal was detected in the negative controls (Figure 27 A), while ISH 
with the probe for U6snRNA resulted in a positive reactivity in nearly all nuclei without 
substantial background reactivity (Figure 27 B). 
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4.9.2.1 Localization of miR-21 expression in CRC samples 
 
As preliminary tests concerning thickness of sections revealed inferior results for 
sections with 4 µm, FFPE biopsy samples with a thickness of 6 µm were applied for 
all further experiments. Optimal performance of miR-21 probes was achieved at a 
hybridization temperature of 57°C and a probe concentration of 150 nM where 
positive colour reaction without substantial background reactivity was detected. 
Figure 27 In situ 
hybridisation controls 
Sections of formalin fixed 
paraffin embedded 
colorectal tissue were 
stained with [A] a 
scrambled probe (25 nM) 
as negative control and [B] 
a probe complementary to 
the U6snRNA (1 
nanoMolar) present in the 
nucleus of all cells. 
Hybridization temperature 
was 57°C in both cases. 
Both probes were double 
DIG labeled and colour 
reaction was performed by 
alkaline phosphatase. 
Tissue was counterstained 
with nuclear fast red. 
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Positive reactivity with miR-21 probes was restricted to mesenchymal areas in the 
microenvironment of CRC tissues (Figure 28 A). Therefore, predominantly fibroblasts 
exhibit a considerable amount of staining in their cytoplasmic compartments whereas 
lymphocytes and macrophages exhibit miR-21 staining to a minor extent (Figure 28 
B). However, tumour cells of CRC patients displayed no miR-21 reactivity indicating 
that miR-21 expression in tumour cells may be under the detection limit of the ISH 
experiments (Figure 28 A and B). Accordingly, miR-21 expression may be restricted 
to mesenchymal cells like tumour associated fibroblasts as well as macrophages or 
lymphocytes which are recruited to the site of tumour. 
 
 
Figure 28 
Localisation of miR-
21 expression in 
CRC biopsies 
In situ hybridization 
with a double DIG 
labelled probe to miR-
21 (150 nM) at a 
hybridization 
temperature of 57°C. 
Colour reaction was 
performed using 
alkaline phosphatase. 
Tissue was 
counterstained with 
nuclear fast red. 
Arrowheads indicate 
mesenchymal areas 
with positive miR-21 
associated signalling 
in the cytoplasm of 
stromal cells 
(fibroblasts, 
macrophages). 
Asterisks indicate 
tumour areas which 
are negative for miR-
21 staining. [A] low 
magnification [B] 
detail. 
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4.9.2.2 Localization of miR-145 expression in CRC samples 
 
Also for detecting miR-145 in CRC tissues, biopsies of 1mm diameter and 6 µm 
thickness were applied. ISH experiments were performed at an optimized 
temperature of 59°C and a probe concentration of 150 nM. ISH for miR-145 was 
performed at a higher temperature because lower hybridization temperatures 
resulted in increased background activity. Using the optimized hybridization 
conditions resulted in colour reactions with strong specific reactivity for miR-145 and 
low background. Positive reactivity for miR-145 probes was observed in 
mesenchymal areas in the microenvironment of CRC tumours including fibroblasts, 
macrophages or lymphocytes (Figure 29 A and B). In addition, smooth muscle fibres 
or myofibroblasts showed positive reactivity for miR-145 probes (Figure 29 A and B). 
In contrast, tumour cells were negative for miR-145 reactivity (Figure 29 A and B) 
implying that miR-145 signals detected by molecular biological methods were due to 
miR-145 expression in mesenchymal cells associated to the microenvironment of the 
tumour. It may be concluded that tumour cells do not contribute to miR-145 
expression in CRC tissues of the patients under investigation. 
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Figure 29 
Localization of 
miR-145 
expression in CRC 
biopsis 
In situ hybridization 
with a double DIG 
labelled probe to 
miR-145 (150 nM) at 
a hybridization 
temperature of 59°C. 
Colour reaction was 
performed using 
alkaline 
phosphatase. Tissue 
was counterstained 
with nuclear fast red. 
Arrowhaeds indicate 
mesenchymal areas 
with positive miR-
145 associated 
signalling in the 
cytoplasm and 
nucleus of stromal 
cells (fibroblasts, 
macrophages). In 
addition, smooth 
muscle fibres 
showed positive 
miR-145 staining 
(arrows). Asterisks 
indicate tumour 
areas which were 
negative for miR-145 
staining. [A] low 
magnification [B] 
detail 
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5. Discussion 
 
In the present thesis the functional interaction of miRNAs with chemokine CCL20 
gene expression was investigated. Chemokines gained in importance in 
investigations on proliferation and development of cancer. Also studies conducting 
anti-tumoural effects of malignant tumours due to their ability to attract tumour and 
immune cells contributed to the importance of chemokines in recent years. 
Chemokine CCL20 was formerly shown to be misregulated in different cancer entities 
like endometrial cancer or pancreatic cancer [Wallace et al., 2011; Rubie et al., 
2010]. Thereby, the role of CCL20 in cancer development is discussed 
controversially as there have been studies conducted indicating a proliferative role of 
CCL20 as well as anti-tumour effects [Wallace et al., 2011; Choi et al., 2010]. At the 
same time, designated miRNAs have gained in importance concerning the 
development and progression of cancer due to their altered expression in a wide 
variety of cancer types including pancreatic cancer [Bloomston et al., 2007], gastric 
cancer [Guo et al., 2009] as well as CRC [Arndt et al., 2009]. Accordingly, it was the 
first goal of this thesis to predict miRNAs that show an interaction with the expression 
of CCL20. After direct interactions have been investigated applying luciferase assays, 
precursors of the identified miRNAs were transfected in CRC cell lines in order to 
account for a functional effect on CCL20 gene expression in CRC cells. Furthermore, 
the expression of the identified miRNAs and CCL20 was analyzed in tissue samples 
from patients with CRC and the cellular localization of miRNAs and CCL20 
expression was investigated by IHC and in ISH. 
 
 
5.1 Prediction of miRNAs potentially interacting with CCL20 
 
To date, no easy and clear convention exists for procedures applied for the 
experimental identification of miRNAs targeting a specific gene of interest. Most 
commonly a combination of computational prediction followed by experimental 
validation is applied [Kuhn et al., 2008]. Thereby, computer assisted analysis 
estimated that miRNAs control approximately more than 60 % of human coding 
genes on the post-transcriptional level [Friedman et al., 2009]. Nevertheless, 
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presently only a small part of these regulatory interactions have been approved and 
therefore the need for tools able to predict and validate these interactions is very 
important for the understanding of miRNA biology. 
To date, a wide variety of strategies have been developed and used, both in in vivo 
and in vitro experiments, in order to identify functional targets of miRNAs for which no 
targets have been identified yet. Since bioinformatics provides the instruments to 
accumulate and handle large amounts of data and to merge diverse data sources, 
computer-assisted miRNA target gene interaction analysis is often applied. The 
theory behind those algorithms is dependent on the relative feasibility of in vitro 
experimentation as well as on the availability of statistical analysis. According to 
these basic principles diverse target prediction algorithms and data bases have been 
developed e.g. TargetScan [Grimson et al., 2007], PicTar [Krek et al., 2005], 
miRanda [Enright et al., 2003; Enright et al., 2005], PITA [Kertesz et al., 2007], 
RNA22 [Miranda et al., 2006] or DIANA-microT [Maragkakis et al., 2009]. These 
algorithms can be grouped into diverse categories according to the applied method: 
weighted dynamic programming algorithms, (e.g. miRanda) [Cormen et al., 1990], the 
usage of thermodynamic modelling, (e.g. TargetScan) [Zuker et al., 1981], Bayesian 
probabilistic algorithms, (e.g. PicTar) [Cooper et al., 1992], support vector machine 
based algorithms, (e.g. TAREF) [Shawe-Taylor et al., 2000], algorithms dealing with 
pattern recognition or string matching, (e.g. MICROINSPECTOR) [Rusinov et al., 2005] 
or systems that use the combination of diverse methods adapted from a retrieval 
engine and the use of a specific database structure, (e.g. MAGIA) [Raghavan, 1997]. 
All these target prediction tools have in common that they use various parameters, 
derived from the sequences of validated miRNA:target mRNA interactions or 
expression experiments as well as thermodynamic features, for the prediction of 
miRNA target sites in the 3’UTR of the mRNA under investigation. Thus, most target 
prediction tools used for predicting CCL20-miRNA interactions in this work, apply the 
following factors in different combinations and varying rating: conservation of target 
site, complementarity in the seed region of the miRNA, flanking sequence of the 
predicted target site, thermodynamic stability of the predicted interaction and the 
presence of compensatory 3’ end binding of the miRNA (Figure 19). In addition to 
these features also various other features are commonly used in order to refine 
prediction results [Sturm et al., 2010]. However, factors independent of binding sites 
may influence miRNA:target mRNA interactions and thereby influence the precise 
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prediction of these interactions negatively. Hence, prediction can be complicated by 
the impact of endogenously expressed miRNAs as well as by the mode of interplay 
between the miRNA and target mRNA with regard to target repression by mRNA 
degradation or inhibition of translation [Ruike et al., 2008]. Another factor that 
impedes prediction of regulatory miRNA interactions constitutes cooperative binding 
of different miRNAs to one mRNA which has an impact on inhibition of expression 
[Doench et al., 2004]. Such refinement of miRNA:target gene interactions is of great 
importance as all target prediction programmes relate to many false positive 
interactions and also miss true miRNA:target mRNA interactions [Mazière et al., 
2007]. 
To use the full spectrum of available methods and algorithms and to achieve the 
highest quality of prediction, in the present thesis 12 target prediction tools were 
applied. However, the results obtained were not consistent. Thus, eight of the applied 
target prediction tools identified miR-21 and five tools identified miR-145 as a 
potential regulator of CCL20 gene expression. Using combinations of features for 
their prediction of targets, may explain why not all of these programmes predict the 
same miRNAs. The features building the base of the prediction programmes include 
seed complementarity, compensatory 3’ end binding, site conservation, 
thermodynamic features and flanking sequences of the target site. The different 
programmes employ these features in different combinations and weighting which 
may explain the prediction of varying miRNA interactions predicted by the different 
programmes. Notably, target prediction programmes using no seed complementarity 
or not using seed complementarity as the primary feature for their predictions 
predicted different target sites with respect to programmes which apply seed 
complementarity as a primary feature. Therefore, application of programmes using 
seed complementarity not as the first step in prediction may advance the search for 
miRNA target gene interactions by the detection of additional miRNA target sites. 
 
 
5.2 Validation of direct miRNA:target gene interactions 
 
Due to the fact that the miRNA target prediction programmes do not work with high 
accuracy, predicted interactions have to be validated experimentally. To date, 
different experimental methods for the validation of regulatory interactions between 
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miRNAs and a potential target mRNA are available. These experimental methods 
comprise gene silencing [Meng et al., 2007], co-immunoprecipitation assays [Boll et 
al., 2012] and reporter gene assays, e.g. luciferase assays [Zhu et al., 2007]. The 
latter two assays are used to validate direct interactions between miRNAs and a 
potential target mRNA whereas gene silencing experiments also identify indirect 
interactions. As the luciferase assay is one of the most common methods for 
validating direct miRNA:target mRNA interactions, in the present thesis this assay 
was applied to identify direct interactions of the predicted miRNAs, miR-21 and miR-
145, respectively, with target gene CCL20. To identify a precise binding site for miR-
21 in the 3’UTR of CCL20, the luciferase assay was applied in combination with site 
directed mutagenesis of the predicted target site [Brennecke et al., 2005; Yang et al., 
2008]. 
As demonstrated in this thesis miR-21 regulates luciferase expression in a reporter 
construct containing the 3’UTR of CCL20 mRNA directly downstream of the 
luciferase gene. In contrast, miR-145 showed no effect on luciferase activity in this 
assay. These results were obtained in two different cell lines, 293T and HT29, 
respectively. However, down-regulation of luciferase upon miR-21 addition was more 
prominent in 293T cells compared to HT29 cells. This may be explained by the fact 
that the two cell lines express different sets of miRNAs. Thereby, the expression 
levels of miRNAs binding cooperatively with miR-21 to the 3’UTR of CCL20 may 
impact the luciferase expression level [Doench et al., 2004]. Therefore, the results 
indicate that miR-21 regulates CCL20 gene expression by an interaction with a 
regulatory binding site in the 3’UTR of CCL20. Validation of the precise binding site 
was achieved by mutation of the target site predicted by most of the prediction 
programmes. However, this mutation could not totally inhibit the regulatory effect of 
miR-21 on luciferase expression/activity as shown by luciferase assays performed 
with the mutated construct. These findings may be explained by additional binding 
sites predicted by individual target prediction programmes (STARMIR {172-179} and 
RNA22 {189-195}) or further miR-21 target sites not identified by any of the prediction 
programmes. Some studies report that mutating one of several binding sites does not 
result in a total reversion of miRNA mediated regulation of gene expression [Otsubo 
et al., 2011; Szczyrba et al., 2010]. Nevertheless, it is not clear if the target sites 
predicted by STARMIR and RNA22 are functional ones. Therefore, the mutation of all 
additional functional target sites of miR-21 in the 3’UTR of CCL20 mRNA would be 
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likely to completely inhibit miR-21 associated expression inhibition. Another 
explanation for the incomplete reversion of miR-21 down-regulation of CCL20 
expression suggests that the mutation of two nucleotides in the seed region in the 
3’UTR of CCL20 mRNA may be insufficient to totally circumvent the regulatory 
interaction of miR-21 with the 3’UTR. Nevertheless, some studies report that 
mutating 3-5 nucleotides in the seed region is sufficient to circumvent regulatory 
interactions of miRNA with target mRNAs [Yi et al., 2010]. Therefore, the mutation of 
more nucleotides in the binding region of miR-21 or total deletion of the binding 
region may result in complete inhibition of miRNA:target mRNA interactions and 
thereby impede miRNA mediated expression regulation. Such an effect was 
characterized for the interaction of miR-27b with the mRNA of PPARγ [Jennewein et 
al., 2010]. The aim of the present study was defined to identify functional, regulatory 
interactions between miRNAs and CCL20 mRNA and not to characterize miRNA 
binding sites. Thus, lack of complete reversion of repression by mutation is not an 
essential feature for the conclusion that only miR-21 may interact with CCL20. If miR-
21 interactions with CCL20 are aimed to be applied for cancer therapy, further 
studies will be needed for more accurate characterization of the respective interaction 
and binding sites. 
 
 
5.3 Quality of target prediction related to validated interactions 
 
The luciferase assay constitutes a common method for the validation of miRNA 
targets [Nicolas, 2011; Zhu et al., 2007]. Thus, the luciferase assay results presented 
in this thesis have shown that the features “flanking contribution” and 
“complementary 3’ end binding” performed best in target prediction. Nevertheless, 
this finding seemed to be due to the fact that these features were used more seldom 
than others and only in combination with other features. Therefore “flanking 
contribution” and “compensatory 3’ end binding” rather played a role in refinement of 
target prediction. In addition target prediction tools which applied the combination of 
more different features had a better performance than tools which applied less 
features. An exception of this observation is STARMIR which used only a single 
feature (thermodynamics) and resulted in correct prediction of both investigated 
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miRNAs in the present thesis. Besides the applied features also the difference in the 
prediction mechanism/algorithms used by the different tools could be a reason for 
prediction performance. 
Therefore, online available target prediction tools are to date only helpful to decrease 
the number of potential miRNAs which interact with CCL20 gene expression. 
However, these programmes also indicate false-positive as well as false-negative 
miRNA target gene interactions. Due to these limitations in computer miRNA target 
gene prediction, it is still essentially required to experimentally validate the predicted 
interactions. 
 
 
5.4 Transfection of eukaryotic cells with pre-miRNA precursors 
miR-21 or miR-145 
 
In CRC cell lines SW480, SW620 and kidney cell line 293T artificial over-expression 
of miR-21 by transfection of miR-21 precursor molecules resulted in significantly 
decreased expression of CCL20 on the mRNA level. In the other two CRC cell lines 
Caco-2 and HT29 no decrease in CCL20 expression was found on mRNA level. 
These results suggest that CCL20 expression is down-regulated by miR-21 due to 
degradation of the respective mRNA in two CRC cell lines and one kidney cell line. 
Degradation of mRNA is one common mechanism used by miRNAs to decrease 
target gene repression as reported by different studies [Kazenwadel et al., 2010; 
Jennewein et al., 2010]. However, another common regulatory mechanism applied by 
miRNAs is the inhibition of translation. Protein expression of the target gene 
constitutes a more suitable indication for functional interaction of miRNAs with the 
target mRNA [Borchert et al., 2011]. Upon transfection with miR-21 CCL20 
expression was significantly down-regulated in three of five cell lines, namely Caco-2, 
SW480 and SW620, on the protein level. Contrarily, in cell line HT29 CCL20 
expression was not altered on the protein level and in 293T cells the expression of 
CCL20 protein was not high enough to be measured in untransfected cells as well as 
in miRNA transfected cells. These findings may indicate that the repression 
mechanism which is responsible for down-regulation of CCL20 in the non-metastatic 
CRC cell line Caco-2 is different from the regulation mechanism in the metastatic 
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CRC cell lines SW480 and SW620. As miRNAs have the capability to inhibit the 
expression of their target genes either by mRNA degradation or translational 
repression, both mechanisms may contribute to decreased target protein expression. 
Thus, deciding which mechanism to apply depends on the degree of complementarity 
between the miRNA sequence and the target sequence in the 3’UTR of the target 
mRNA [Huntzinger et al., 2011]. A high degree of complementarity between the 
sequences results in degradation of the target mRNA [Hutvágner et al., 2002] 
whereas a low degree of complementarity leads to inhibition of target mRNA 
translation [Sun et al., 2010]. According to this correlation it may be assumed that a 
mutation in the target site for miR-21 in the 3’UTR of CCL20 mRNA has the potential 
to change the regulatory mechanism from mRNA degradation to repression of 
translation or totally avert a regulatory interaction. As cancer is characterized by 
genomic instability the feasibility for mutations is increased in cancer cell lines 
[Hoeijmakers, 2001] and mutations in the target sites of miRNAs were already shown 
to be associated with diseases [Hughes et al., 2011]. Therefore, such mutations may 
constitute a potential explanation for the fact that in Caco-2 cells CCL20 expression 
is down-regulated only on the protein level and not on the mRNA level in contrast to 
SW480 and SW620 cells and that no regulatory effect was visible in cell line HT29. 
To analyze possible causes for such differential regulatory interactions, the 3’UTR of 
CCL20 may be sequenced in different CRC cell lines so that putative mutations in the 
binding site of miR-21 may be detected. 
As expected, transfection of the various cell lines with precursors of miR-145 resulted 
in no alterations in CCL20 expression neither on mRNA level nor on protein level.  
Therefore, the transfection experiments confirmed the results obtained by the 
luciferase assays. However, functional interaction between miR-21 and CCL20 
expression was observed in the CRC cell lines and it may be speculated that the 
mode of interaction varies between certain cell lines 
 
 
5.5 Expression of CCL20 in CRC 
 
CCL20 expression is primarily found in mucosal-associated lymphoid tissues 
including liver, lung, peripheral lymph nodes, thymus, tonsils, colon and appendix. 
Also cells of the immune system like B-cells, dendritic cells, granulocytes, 
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macrophages or T-cells express and secrete CCL20 [Schutyser et al., 2000]. 
Chemokines were shown to be involved in different pro-tumour associated processes 
including tumour growth [Bandapalli et al., 2012; Owen et al., 1997], oncogenic 
transformation [Burger et al., 1999], angiogenesis [Gabellini et al., 1999] or 
metastasis [Müller et al., 2001] but also in contra-tumour associated processes like 
attraction of activated immune cells [Lavergne et al., 2004; Huang et al., 2004]. 
Therefore, the expression of chemokines in tumours and the microenvironment of 
tumours is important for the progression of cancerous lesions. Thus, CCL20 
expression was investigated in CRC by analyzing CCL20 expression patterns in 
tumour-free and tumour-infiltrated colorectal tissue samples on mRNA and protein 
level. The results of the expression analysis of the present thesis have shown that 
CCL20 gene expression is significantly increased in tumour-infiltrated colorectal 
tissues related to corresponding normal tumour-free tissue samples. Also a study by 
McLean et al. demonstrated CCL20 up-regulation in adenocarcinoma of the colonic 
mucosa compared to normal unaffected colonic mucosa. This up-regulation was also 
found in adenoma and proposed to be due to the inflammatory microenvironment of 
the tumour [McLean et al., 2011]. In contrast, Brand et al. demonstrated ambiguously 
expressed CCL20 expression in CRC based on the observation that CCL20 
expression was significantly down-regulated or lost in ~60 % of CRC samples 
indicated by semiquantitative IHC [Brand et al., 2006]. Nevertheless, the methods 
used in the present study are more sensitive for detecting differences in gene 
expression on the mRNA and protein level in contrast to the methods applied by 
Brand et al. Several other studies also reported significant up-regulation of CCL20 
expression in inflammatory diseases of the colon and rectum [Kwon et al., 2002] 
which also constitute risk factors for CRC. Therefore, it may be speculated if CCL20 
expression could be associated with the induction of CRC and correlated with early 
stages of CRC. In order to investigate such a correlation, patient samples were 
investigated according to T-stage and clinical staging. While no significant differences 
in CCL20 expression were found between tumours of different clinicopathological 
features, Brand et al. made the observation that tumours of higher TNM stage exhibit 
significantly lower CCL20 expression as measured by semiquantitative 
immunohistochemical analysis [Brand et al., 2006]. In addition sorting samples 
according to tumour grading showed no significant differences of CCL20 protein 
expression between tumours of low grade (G1+G2) and tumours of high grade 
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(G3+G4). This in turn indicates, that the differentiation state of the tumour does not 
influence the expression of CCL20 neither on the mRNA nor on the protein level. 
Since CCL20 was shown to be significantly over-expressed in CRC tissues 
compared to corresponding normal tissues, it would be a scientifically interesting 
question if this over-expression promotes or inhibits tumour growth and metastasis. 
To date, only few studies are available which investigated CCL20 expression in CRC 
and their results are contradictory. Thus, it was shown that CCL20 has the potential 
to induce ERK1/2 and SAPK/JNK kinases and the Akt pathway by signalling via 
CCR6 thereby stimulating proliferation and migration of CRC cells (SW480) [Brand et 
al., 2006]. Both mechanisms are also characteristic for tumour progression and 
metastasis. In addition, increased CCL20 levels in the microenvironment of CRC 
tumours were shown to be associated with recruitment of regulatory T-cells which 
results in an increase in tumour growth and a reduction of anti-tumour immunity [Liu 
et al., 2011a; Clarke et al., 2006]. In contrast, in a mouse model it was found that 
increased expression of CCL20 mediated by the therapeutic rofecoxib may increase 
immune response towards the tumour by attraction of dendritic cells, a mechanism 
known to be involved in the reduction of tumour immune escape [Walmesley et al., 
2007]. Besides these mechanisms which directly influence the primary tumour it was 
also reported that the CCL20/CCR6 axis is involved in organ specific (liver) 
metastasis of CRC [Rubie et al., 2006c; Ghadjar et al., 2006]. 
Significantly altered CCL20 gene expression was not only observed in CRC but also 
in various other cancer types. In HCC over-expression of CCL20 is associated with 
increased infiltration of regulatory T-cells which in turn are linked to worse prognosis 
[Chen et al., 2011]. Additionally, CCL20 induced growth of hepatocellular cell line 
Huh7 by signalling via the ERK1/2 pathway [Fujii et al., 2004]. Previous works of our 
group have demonstrated significant up-regulation of CCL20 in HCC tissues which 
correlate with tumour grade suggesting that the CCL20/CCR6 system may be 
involved in hepatocarcinogenesis [Rubie et al., 2006a]. Moreover, high level 
expression of CCL20 and CCR6 were also observed in CRLM with marked up-
regulation of CCL20 expression in CRLM in relation to HCC tissues [Rubie et al., 
2006b]. These results may indicate involvement of the CCL20/CCR6 axis in 
carcinogenesis and progression of hepatic malignancies. In addition, our group 
identified significant over-expression of CCL20 in pancreatic cancer [Rubie et al., 
2010]. Recently, endometrial cancers were shown to over-express CCL20 and CCR6 
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compared to unaffected endometrial tissues and CCL20 was demonstrated to induce 
proliferation in endometrial cancer cell lines [Wallace et al., 2011]. While CCL20 
expression was shown to be related to proliferation, some studies also associated 
CCL20 expression with invasion and migration in nasopharyngeal and pancreatic 
cancer [Chang et al., 2008; Kimsey et al., 2004]. In contrast, in renal cell carcinoma 
CCL20 was shown to be involved in recruitment of immature dendritic cells which can 
be activated by CCL19 in the tumour margin thereby mediating anti-tumour immunity 
[Middel et al., 2010]. 
Therefore, CCL20 over-expression observed in these experiments in CRC tissues 
was also detected in other studies as well as in investigations on tumours of different 
entities indicating that increased CCL20 expression is a common event in neoplasia. 
Nevertheless, functional investigations on CCL20 expression did not identify a clear 
pro- or anti-tumour activity of CCL20 as this molecule influences tumour cells as well 
as immune cells infiltrating the tumour thereby modulating the immune response to 
the tumour. 
 
 
5.6 Expression of miRNAs in CRC 
 
In recent years investigations on miRNA expression patterns were intensified and this 
in turn led to the identification of certain miRNA expression patterns associated with 
different kinds of diseases including cancer [Thai et al., 2010]. The first association 
between altered miRNA expression and cancer was shown by Calin et al. in 2002 
[Calin et al., 2002]. Since then several studies identified characteristic miRNA 
expression patterns associated with various kinds of cancer entities and different 
states of disease progression [Cohn et al., 2010; Vaksman et al., 2011]. In this 
respect, down-regulation as well as up-regulation of certain miRNAs was found to be 
involved in cancer associated processes and therefore miRNAs can act either as 
tumour suppressor miRNAs or as oncomiRs according to the set of targeted genes 
[Volinia et al., 2006]. Also in CRC some miRNAs were found to be up-regulated while 
others were shown to be down-regulated and correlated to tumour development, 
progression and metastasis [Schetter et al., 2008]. Based on these observations the 
expression profiles of miR-21 and miR-145 predicted to regulate the expression of 
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CCL20 were analyzed in tissue samples of patients with CRC. 
 
 
5.6.1 Expression of miR-21 in CRC 
 
First, miR-21 expression was analyzed in CRC using qRT-PCR specific for this 
miRNA. Expression patterns among the CRC patients under investigation were 
divergent. Most patients showed significant over-expression of miR-21 in tumour 
tissues but there were also a considerable number of patients showing no altered 
expression or even lower expression of miR-21. These results may indicate that miR-
21 over-expression is not essential for the development of CRC but may constitute a 
risk factor and could therefore play a role in the progression of CRC. Kulda et al. also 
observed increased miR-21 expression in CRC tissues compared to normal adjacent 
colon tissue. MiR-21 over-expression was also observed in CRLM samples, 
associated with shorter disease free survival and suspected to have oncogenic 
potential [Kulda et al., 2010]. Also another study observed miR-21 over-expression in 
CRC tissues compared to polyps and normal tissue. These authors also 
demonstrated down-regulation of the putative miR-21 target gene PDCD4 on mRNA 
level [Chang et al., 2011a]. In order to analyze, if miR-21 over-expression is 
dependent on the degree of local invasion of the investigated tumours, the samples 
were sorted into two groups according to the T-stage of the resected tumours. 
Analysis of the two groups resulted in a significant increase only in tumours of higher 
T-category. This may in turn indicate, that miR-21 expression is associated with 
increased local invasion of CRC. This is in contrast to a study by Slaby et al. which 
demonstrates significantly over-expressed miR-21 expression in all T-categories 
[Slaby et al., 2007]. Sorting patient samples by clinical stage indicated a significantly 
increased miR-21 expression compared to normal adjacent tissue only in the 
subgroup of tumours with higher clinical stages (III+IV). This is also in contrast to the 
study by Slaby et al. where significant over-expression of miR-21 was found in all 
clinical stages although tumours of higher clinical stages present highest miR-21 
expression levels compared to lower clinical stages [Slaby et al., 2007]. However, the 
number of investigated patients per clinical stage (3, 11, 6 and 9 respectively) was 
relatively low in the study by Slaby et al. The findings are also in line with a study by 
Vickers et al., which described that miR-21 expression was associated with clinical 
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progression of CRC [Vickers et al., 2012]. Nevertheless, the study by Vickers et al. 
predominantly compared samples of patients with metastasis with samples of 
patients without metastasis. As samples from patients with metastasis constitute 
stage IV, the results of this study are not directly comparable with stage III+IV 
tumours analyzed in the present thesis. Also Liu and colleagues found a significant 
over-expression of miR-21 in CRC tumour samples compared to normal adjacent 
tissue with elevated miR-21 expression in stage III compared to samples of stage II 
[Liu et al., 2011b]. In contrast to the present study Liu et al. only included tumours of 
stage II or III whereas the present study compares groups comprising stage I+II or 
stage III+IV. Moreover, the investigated tumours were divided by their differentiation 
state (G stage) to investigate their impact on miR-21 expression. Accordingly, a 
significantly increased expression was observed only in tumours with lower 
differentiation stages (G3+G4) indicating that increased miR-21 expression is 
potentially causative or a consequence of de-differentiation of CRC tumour cells. This 
result is well in line with other studies of Liu et al. investigating a difference in miR-21 
expression between well and moderately differentiated tumours and poorly 
differentiated tumours [Liu et al., 2011b]. Likewise, other studies observed an 
increase in miR-21 expression concurrently with decreased differentiation of the 
tumour [Slaby et al., 2007]. 
However, miR-21 up-regulation was not only reported in tissue samples of CRC 
patients but also in stool samples of CRC patients. As recent studies reported also 
significantly increased miR-21 levels in patients with adenoma but not in patients with 
polyps [Wu et al., 2012; Link et al., 2010], it was suggested that expression analysis 
of miR-21 may be used as a non-invasive screening tool for CRC. However, miR-21 
expression analysis in stool samples of CRC patients may not always lead to 
significant differences between CRC patients and healthy persons as Li et al. 
reported [Li et al., 2012a]. 
Corresponding to findings described in literature also the results obtained in the 
present thesis indicate miR-21 over-expression in CRC with higher expression levels 
in more progressive stages. Nevertheless, further studies are required to apply miR-
21 expression for a prognosis of CRC disease outcome. 
MiR-21 up-regulation was not only reported in CRC patients but also in tumours of 
other entities. Thus, in non-small cell lung cancer expression of miR-21 was shown to 
be up-regulated and high miR-21 expression was also correlated with various 
Discussion 112 
clinicopathological features including higher tumour stages, metastatic status, lymph 
node positivity and poor survival [Zhang et al., 2010; Gao et al., 2010]. Similarly, miR-
21 was reported to be up-regulated in breast cancer and correlated with advanced 
proliferation, higher clinical stage and lymph node positivity [Huang et al., 2009; Yan 
et al., 2008]. Likewise, in gastric cancer miR-21 over-expression was reported to be 
associated with the differentiation state and metastasis [Zhang et al., 2012]. 
As miR-21 is over-expressed in a wide variety of tumours it may be speculated that 
altered miR-21 expression is a common process in the malignant transformation of 
cells of different tumour entities. 
 
 
5.6.2 Expression of miR-145 in CRC 
 
Also the expression of miR-145 was analyzed in tumour tissues in relation to normal 
adjacent tissues using quantitative real-time PCR. As the results of this thesis have 
shown miR-145 expression is significantly down-regulated in tumour tissues 
compared to corresponding normal tissues. In contrast to miR-21 expression, 
significantly decreased expression of miR-145 was found in most patients under 
investigation. This may indicate that down-regulation of miR-145 is an early event in 
the development of CRC. In addition, decreased expression of miR-145 in CRC was 
found in two other studies which reported miR-145 down-regulation in CRC cell lines 
[Bandrés et al., 2006; Arndt et al., 2009]. Also in a microarray study on miRNA 
expression in CRC it was found that miR-145 is down-regulated in relation to normal 
tissue [Motoyama et al., 2009]. Sorting patient samples by T-category, clinical stage 
or grading into two groups, respectively, indicated that down-regulation of miR-145 is 
not changing during progression or dedifferentiation of CRC. Similar results were 
obtained by Wang et al. where miR-145 expression did not correlate with any of the 
investigated clinicopathological features [Wang et al., 2009a]. Therefore, it may be 
speculated that events leading to decreased miR-145 expression take place in early 
stages of CRC development. This theory is fortified by another study which 
demonstrated that miR-145 expression is also decreased in ulcerative colitis which in 
turn increases expression of K-RAS, API5 and MEK-2, molecules involved in cell 
regulatory processes as well as in apoptosis [Pekow et al., 2012]. Apart from a 
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decreased miR-145 expression in tumour tissues, reduced miR-145 expression was 
also detected in stool samples of CRC patients where it may be applied as a non-
invasive marker for colorectal neoplasia [Li et al., 2012a]. 
MiR-145 dysregulation is not only known to play a role in CRC pathogenesis, but also 
reported as a common mechanism that is involved in malignant neoplasia of different 
organs. Thus, in gastric cancer decreased miR-145 expression was observed by 
Takagi et al. [Takagi et al., 2009]. This study also reported that artificial increase of 
miR-145 in gastric cancer cells inhibits their proliferation. Also in prostate cancer 
down-regulated miR-145 expression was detected together with increased miR-145 
promotor methylation in prostate cancer cells which indicated epigenetic silencing of 
miR-145 [Zaman et al., 2010; Suh et al., 2011]. In addition other cancer entities like 
esophageal cell carcinoma [Kano et al., 2010], lung cancer [Yanaihara et al., 2006] 
and breast cancer [Iorio et al., 2005] were reported to exhibit down-regulation of miR-
145. In breast cancer cells it was also found that activation of miR-145 expression is 
dependent on p53 [Spizzo et al., 2010]. As p53 is a molecule regularly mutated and 
inactivated early in CRC development further studies will show if this pathway is 
responsible for miR-145 down-regulation. 
Recently it was reported that miR-145 is down-regulated in CRC as well as in most 
other solid cancers. In some cancer types down-regulation is associated with 
methylation of the promoter region of miR-145 or aberrant expression of p53. Hereby, 
it will be important to identify the specific causes for miR-145 down-regulation in CRC 
development. Investigating the causes of decreased miR-145 expression in cancer is 
of particular interest as miR-145 is known to act as a tumour suppressor and targets 
of miR-145 are established oncogenes. Among these the best established target is 
FSCN1 which is over-expressed e.g. in bladder cancer [Chiyomaru et al., 2010]. 
Restoration of miR-145 expression in bladder or prostate cancer cells was reported 
to result in higher FSCN1 expression and decreased cell viability, proliferation, 
migration and invasion [Chiyomaru et al., 2010; Fuse et al., 2011]. Another known 
oncogenic factor down-regulated by miR-145 is FLI1 and artificial expression 
restoration of this factor results in decreased CRC cell proliferation [Zhang et al., 
2011]. Further oncogenic molecules targeted by miR-145 in different cancer cell lines 
were SWAP70, p70S6K1, RTKN, JAM-A and fascin thus influencing oncogenic 
processes like tumour growth, invasiveness or apoptosis [Chiyomaru et al., 2011; Xu 
et al., 2012; Wang et al., 2009c; Götte et al., 2010]. 
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5.7 Expression of CCL20 in tumour microenvironment detected 
by IHC 
 
As tumours are heterogeneously composed, not only consisting of tumour cells but 
also of stromal and infiltrating immune cells, it is of great interest to detect the specific 
compartment where CCL20 is expressed. Hence, an antibody specific for CCL20 was 
used to detect CCL20 expression by IHC in CRC tissue samples as well as in 
unaffected colonic mucosa. In the present study it was found that CCL20 expression 
in CRC specimens is heterogeneously expressed with respect to tumour and 
microenvironment. In most colorectal tumours CCL20 expression was found in 
(mesenchymal) elements of the microenvironment comprising macrophages and 
lymphocytes. This is of particular interest as it was shown in a mouse model that 
over-expression of CCL20 by macrophages is involved in recruitment of CCR6 
positive regulatory T-cells and tumour development [Liu et al., 2011a]. In the present 
thesis it was also found that CCL20 is expressed in epithelial cells of normal 
colorectal mucosa whereas most colorectal tumour cells do not express CCL20. This 
is well in line with another study that investigated CCL20 and CCR6 expression in 
CRC demonstrating differential expression intensities of CCL20 with respect to 
colorectal tumours from different patients [Brand et al., 2006]. Thus, over-expression 
of CCL20 in colorectal tumour cells may only be characteristic for a specific subset of 
colorectal tumours. Nevertheless, no clinicopathological features were reported to 
correlate with the expression of CCL20 in CRC. Similarly, in various cancer entities 
like pancreatic cancer CCL20 expression was detected in cancer cells and also in 
tumour associated stromal cells [Rubie et al., 2010; Kimsey et al., 2004]. Anyway 
most pancreatic cancer specimens exhibit CCL20 expression in malignant cells 
[Campbell et al., 2005]. In addition, CCL20/CCR6 expression was also described in 
tumour cells of hepatocellular- and prostate cancer specimens [Ghadjar et al., 2008; 
Rubie et al., 2006a]. As in the present study it was shown that CCL20 is preferentially 
expressed in mesenchymal elements in the tumour microenvironment and CCR6 was 
formerly shown to be expressed in CRC cells it may be presumed that a paracrine 
pathway may account for CCL20/CCR6 mediated regulation in CRC. These 
considerations are well in line with studies reporting that exogeneous administration 
of CCL20 enforce colorectal tumour cell growth and migration [Brand et al., 2006]. 
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Therefore, expression of CCL20 in mesenchymal elements (e.g. macrophages) may 
impact CRC by two different mechanisms. The first one is recruitment of regulatory T-
cells which could mediate tumour immune escape and the second is direct promotion 
of cancer cell proliferation and migration. 
 
 
5.8 Expression of miRNAs in tumour microenvironment 
detected by ISH 
 
Detection of miRNAs using ISH brought up certain problems. Using slices from FFPE 
tissue samples resulted in positive staining only at the outer margin of the slices. The 
centres of the regions showed no staining. This may partly be due to fixing and 
embedding procedures of the tissue samples. Thus, the interfusion time of formalin 
during fixation is subject to the sample size. In case of larger samples the time till the 
fixation dye reaches the centre is relatively long and therefore RNAses could possibly 
degrade mRNA and miRNA in this area which may explain the loss of miRNA signal 
in the centre of the tissue samples. This theory is supported by the fact that using 
FFPE biopsies which are far smaller in diameter showed a continuous and consistent 
staining of the complete tissue slice. In addition to problems with fixation interfusion 
in a study based on mouse tissue it was shown that fixation of samples with 
formaldehyde leaded to loss of miRNAs in tissue sections [Pena et al., 2009]. Also 
another study reported negatively on formalin fixation for ISH experiments [Yan et al., 
2010]. Nevertheless, some studies based on FFPE tissue slices showed a uniformly 
and consistent staining [Hansen et al., 2012; Jørgensen et al., 2010]. Hence, 
appropriate fixation and embedding procedures are critical for the preservation of 
miRNAs in FFPE tissue samples. 
 
 
5.8.1 Expression of miR-21 in tumour microenvironment 
 
As tumours are heterogeneously composed and contain not only malignant but also 
stromal and other cells like infiltrating immune cells, in situ detection of miR-21 was 
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performed in order to examine the distribution of miR-21 expressing cells in CRC 
tissue sections. As reported in the present thesis miR-21 expression is primarily 
found in tumour associated mesenchymal/stromal compartments (e.g. fibroblast like 
cells) but not in tumour cells. This result is well in line with a recent study by Nielsen 
et al. which indicated that miR-21 expression is predominantly found in fibroblast-like 
cells in the stroma. In contrast to the present study only tumours of stage II were 
included in this study [Nielsen et al., 2011]. Nevertheless, it was also reported that 
miR-21 expression in CRC is found not only in the tumour associated fibroblasts in 
the stroma but also directly in tumour cells [Yamamichi et al., 2009]. However, 
recently miR-21 expression was reported to be exclusively expressed in colonic 
epithelial cells within the tumour of CRC patients [Schetter et al., 2008]. While various 
studies investigating the localization of miR-21 expression in CRC reported rather 
heterogeneous results, the findings of this thesis support miR-21 expression 
exclusively in the tumour microenvironment. Also studies in different tumour entities 
reported heterogeneous miR-21 localization. Whereas tumours within colon and 
breast exhibit miR-21 expression primarily in tumour-associated fibroblasts, tumours 
of pancreas, prostate and lung were shown to express miR-21 directly in tumour cells 
[Sempere et al., 2010]. Thus, pancreatic cancer cells, [Dillhoff et al., 2008; du Rieu et 
al., 2010] prostate cancer cells [Li et al., 2012c] as well as fibroblast expression in 
breast cancer [Rask et al., 2011] show a more homogeneous expression pattern of 
miR-21. 
 
 
5.8.2 Expression of miR-145 in tumour microenvironment 
 
Investigating the localization of miR-145 expression this study revealed primarily 
miR-145 expression in mesenchymal/stromal compartments of the tumour and 
smooth muscle cells whereas the tumour cells showed no detectable miR-145 
reactivity. In the literature miR-145 expression is described in normal colonic tissue 
primarily in colonocytes of the crypts. In contrast, CRC tissues are reported to 
express reduced miR-145 levels [Schepeler et al., 2008]. Recently another study 
demonstrated that miR-145 expression is also down-regulated in colonocytes of the 
crypts in ulcerative colitis [Pekow et al., 2012]. Thus, altered miR-145 expression 
might play a role in inflammation induced CRC development. As shown in the present 
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study, miR-145 is present in smooth muscle cells, whereas miR-145 expression 
analysis in lung cancer revealed significantly reduced miR-145 expression in smooth 
muscle cells, the main miR-145 expressing cells in normal lung tissue [Liu et al., 
2009]. In addition, other studies showed that in prostate and bladder cancer miR-145 
is down-regulated in tumours and microenvironment including epithelial cells, 
connective tissue and lymphocytes [Wach et al., 2012; Dyrskjøt et al., 2009]. 
Although probes against miR-145 only detect mature miRNAs which are found in the 
cytoplasm, the findings of this thesis report miR-145 expression not only in the 
cytoplasm of stromal cells but also perinuclearly and to a minor extent nuclearly. 
Nevertheless, these findings were also present in other studies which applied the 
same probe against miR-145 [Wach et al., 2012; Jørgensen et al., 2010]. It was 
proposed that this effect is due to the fact that this probe does not discriminate 
between the mature form and precursor forms of miR-145. Consequently, miR-145 
staining may be considered as a sum signal of mature and immature forms of miR-
145. 
 
 
5.9 Regulatory interactions of miRNAs with CCL20 in CRC 
 
In the present thesis it was demonstrated that both miR-21 and its functional target 
chemokine CCL20 exhibit significantly up-regulated expression in CRC tissue 
samples compared to normal non affected colorectal tissue. Initially, this result may 
be conflicting with the presumption that miRNAs and their target genes are 
expressed in an inverse manner, as reported in different studies [Xiao et al., 2012]. 
This conflict was elucidated by the finding that miR-21 as well as CCL20 is rarely 
expressed in CRC cells but predominantly in stromal compartments of colorectal 
tumours. In the stromal microenvironment miR-21 was predominantly found in 
fibroblast-like cells whereas CCL20 expression was primarily detected in infiltrating 
immune cells, like macrophages and lymphocytes. Hence, the main part of 
expression of miR-21 and CCL20 detected by molecular biological methods 
potentially does not exist in the same cells/cell types and therefore miR-21 and 
CCL20 in CRC do not interfere with each other. To further analyse this assumption, it 
would be recommendable to perform double staining experiments with miR-21 and 
Discussion 118 
CCL20 on the same section. However, in this thesis separate expression analyses 
were performed for miR-21 and CCL20. Thus, the observations presented in this 
thesis indicate that over-expression of a miRNA and its functional target gene in 
cancerous tissues is possibly due to expression of both molecules in different types 
of cells. However, tumour tissues consist not only of tumour cells but also of tumour 
stroma constituted of different cell types which may influence the outcome of 
molecular biological experiments. 
As it was demonstrated in the present thesis that miR-145 does not regulate the 
expression of CCL20 we expected that the expression patterns of miR-145 and 
CCL20 in CRC tissues are not associated with each other. Expression of miR-145 
was found predominantly in smooth muscle cells or myofibroblasts along with other 
cell types in the tumour microenvironment. It was previously shown that miR-145 is 
highly expressed in smooth muscle cells [Cheng et al., 2009]. Thus, miR-145 and 
CCL20 are likely to be expressed by different cell types. 
 
 
5.10 Conclusion and perspective 
 
The present thesis describes for the first time that the chemokine CCL20 is a target 
gene of miR-21 and artificial over-expression of miR-21 has the potential to suppress 
the expression of CCL20 in CRC cell lines [Vicinus et al., 2012]. Nevertheless this 
observation was not true for all investigated CRC cell lines which implicates the 
assumption that this interaction is fragile in CRC cell lines. Furthermore it was 
demonstrated that both CCL20 and miR-21 exhibit significant over-expression in 
CRC tissues whereas miR-145 exhibits significantly decreased expression in 
colorectal tumours compared to normal colorectal tissue. This in turn indicates that 
these molecules may be potentially involved in CRC associated processes. 
Thus, CCL20 and miR-145 showed significantly altered expression profiles in early 
as well as in late stages of CRC in comparison to corresponding normal tissues 
implicating a role in tumour development. The miRNA miR-21 was found to be 
primarily over-expressed in tumours of higher T-stages (T3+T4), higher clinical 
stages (III+IV) and lower differentiation stages (G3+G4) which implies that altered 
miR-21 expression may be causative for or a result of CRC progression. 
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Furthermore, it was shown for the first time that CCL20 is predominantly expressed in 
the tumour microenvironment but not in tumour cells. Over-expression of CCL20 as 
indicated by molecular biological experiments therefore may be due to CCL20 
expression in lymphocytes and macrophages infiltrating the tumour. Also for miR-21 
exclusive expression was found in the tumour microenvironment predominantly in 
tumour associated fibroblast-like cells. It may be speculated that miR-21 expression 
is induced in these cells by CRC cells or other cell types in the microenvironment. 
Expression of miR-145 was primarily found in smooth muscle cells in mesenchymal 
compartments of the tumour but not in tumour cells.  
Over-expression and involvement of CCL20 was shown in CRC as well as in different 
other cancer entities [Rubie et al., 2006b; Wallace et al., 2011; Chang et al., 2008; 
Kimsey et al., 2004]. Recently, it was demonstrated that down-regulation of other 
chemokines like CCL2 in prostate cancer cells reduced tumour progression and 
metastasis [Shi et al., 2011]. Furthermore down-regulation of the CXCL12/CXCR4 
pathway with an artificial miRNA resulted in lower invasion potential and metastasis 
of breast cancer cells [Liang et al., 2007b]. Hence, miR-21 mediated down-regulation 
of CCL20 in tumour tissues may be viewed as a potential future therapy option for 
CRC as well as for other CCL20 expressing cancer types. However, down-regulation 
of CCL20 directly in tumour cells only makes sense in tumours that express CCL20 in 
tumour cells. As the present thesis demonstrated that CCL20 is predominantly 
expressed in the microenvironment in CRC, down-regulation may be expected to 
take place in cells in the microenvironment. Nevertheless, miRNAs target a wide 
variety of genes and as long as not all regulated genes are identified, therapies which 
restore or block specific miRNAs are risky. Thus, mechanisms which identify miRNA-
target gene interactions in a fast and reliable way are required to use the therapeutic 
potential of miRNAs. 
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